



US012391722B2

(12) **United States Patent**
Dombrowski

(10) **Patent No.:** **US 12,391,722 B2**

(45) **Date of Patent:** ***Aug. 19, 2025**

(54) **STABILIZED NUCLEIC ACIDS ENCODING MESSENGER RIBONUCLEIC ACID (MRNA)**

(71) Applicant: **Intellia Therapeutics, Inc.**, Cambridge, MA (US)

(72) Inventor: **Christian Dombrowski**, Auburndale, MA (US)

(73) Assignee: **Intellia Therapeutics, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 114 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **18/310,298**

(22) Filed: **May 1, 2023**

(65) **Prior Publication Data**

US 2023/0271997 A1 Aug. 31, 2023

Related U.S. Application Data

(63) Continuation of application No. 16/791,076, filed on Feb. 14, 2020, now Pat. No. 11,673,911, which is a continuation of application No. PCT/US2018/046772, filed on Aug. 14, 2018.

(60) Provisional application No. 62/545,883, filed on Aug. 15, 2017.

(51) **Int. Cl.**

C12N 15/63 (2006.01)

C07H 21/02 (2006.01)

C12N 15/11 (2006.01)

C12N 15/70 (2006.01)

C07K 14/475 (2006.01)

C07K 14/52 (2006.01)

C12N 9/22 (2006.01)

(52) **U.S. Cl.**

CPC **C07H 21/02** (2013.01); **C12N 15/11** (2013.01); **C12N 15/63** (2013.01); **C07K 14/475** (2013.01); **C07K 14/521** (2013.01); **C12N 9/22** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

11,673,911 B2 * 6/2023 Dombrowski C07H 21/02 536/23.2

2016/0243258 A1 8/2016 Scharenberg et al.

2017/0166905 A1 6/2017 Eberle et al.

2018/0119213 A1 5/2018 Kim et al.

FOREIGN PATENT DOCUMENTS

KR 101786396 B1 11/2017

WO 2016115355 A1 7/2016

OTHER PUBLICATIONS

Chang, H. et al., "TAIL-seq: Genome-wide Determination of Poly(A) Tail Length and 3' End Modifications" Cell Press, vol. 53, Mar. 20, 2014 (Mar. 20, 2014) pp. 1044-1052.

International Search and Written Opinion issued for PCT/US2018/046772 on Dec. 4, 2018.

Jalkanen, A. et al., "Determinants and implications of mRNA poly(A) tail size—Does this protein make my tail look big?" Seminars in Cell and Developmental Biology, vol. 34, Oct. 1, 2014 (Oct. 1, 2014), pp. 24-32.

Lim, J. et al., "Mixed tailing by TENT4A and TENT4B shields mRNA from rapid deadenylation" Science, vol. 361, No. 6403, Jul. 19, 2018 (Jul. 19, 2018), pp. 701-704.

Lim, J. et al., "Uridylation by TUT4 and TUT7 Marks mRNA for Degradation" Cell, vol. 159, No. 6, Dec. 4, 2014 (Dec. 4, 2014), pp. 1365-1376.

Sergeeva, O.V. et al., "mRNA-Based Therapeutics—Advances and Perspectives" Biochemistry (Moscow) 81 (7):709-722 (2016).

* cited by examiner

Primary Examiner — Weihua Fan


(74) *Attorney, Agent, or Firm* — McNeill PLLC

(57) **ABSTRACT**

This disclosure relates to the field of poly-adenylated (poly-A) tails. In some embodiments, a DNA encodes a poly-A tail located 3' to nucleotides encoding a protein of interest, wherein the poly-A tail comprises one or more non-adenine nucleotide.

23 Claims, 7 Drawing Sheets

Specification includes a Sequence Listing.






Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

1

STABILIZED NUCLEIC ACIDS ENCODING MESSENGER RIBONUCLEIC ACID (MRNA)

This application is a Continuation of U.S. application Ser. No. 16/791,076, which was filed on Feb. 14, 2020, which is a Continuation of International Application No. PCT/US2018/046772, which was filed Aug. 14, 2018 and which claims the benefit of priority to U.S. Provisional Application No. 62/545,883, which was filed on Aug. 15, 2017, all of which are incorporated by reference in their entirety.

The patent application is filed with a sequence listing in electronic format. The Sequence Listing is provided as a file entitled "2023-04-27_01155-0019-01US_ST26," which was created on Apr. 27, 2023, and which is 95,864 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

This disclosure relates to the field of stabilized messenger ribonucleic acid (mRNA) and DNA encoding the stabilized mRNA.

BACKGROUND

Polyadenylation is the process of adding multiple adenine nucleotides to the 3' end of a messenger RNA (mRNA), forming a poly-A tail. The poly-A tail consists of multiple repeated adenine nucleotides, such as adenosine monophosphates, without other bases interrupting the sequence. The poly-A tail is critical for the nuclear export, translation, and stability of mRNA. In nature, as mRNA is produced from DNA, a terminal transferase adds adenine nucleotides to the 3' end of mRNA. This enzymatic process can be applied when producing mRNA *ex vivo*, but the process is difficult to control and results in poly-A tails of different lengths. By encoding a poly-A tail in the plasmid, it is possible to decrease the heterogeneity in the poly-A tail. However, it does not eliminate the heterogeneity, and has additional downsides such as potential instability of the plasmid.

The poly-A tail acts as the binding site for poly-A-binding protein. Poly-A-binding protein assists in exporting mRNA from the nucleus, translation, and inhibiting degradation of the mRNA. In the absence of export from the nucleus, mRNAs are typically degraded by the exosome. The poly-A-binding protein recruits proteins necessary for translation.

mRNA is now being used as a therapeutic molecule, for example, for the treatment of various diseases and disorders. mRNA is delivered to a subject in lieu of the protein so that the subject's cells produce the protein encoded by the mRNA within the cell. For these and other purposes, mRNA may be prepared via transcription from a DNA template, often contained in a plasmid. During mRNA production, the poly-A tail may be added to mRNA enzymatically after transcription from a plasmid or encoded on the plasmid itself. When the poly-A tail is encoded on a plasmid, the poly-A tail may become shorter (i.e., lose adenine nucleotides) over cycles of plasmid DNA replication, potentially leading to large variations in the resulting DNA and subsequent mRNA population. Thus, there exists a need in the art to design plasmids encoding poly-A tails that are stable and resistant to gradual loss of nucleotides encoding poly-A adenine nucleotides during DNA replication.

SUMMARY

Disclosed herein are DNA encoding, and mRNA comprising, poly-adenylated (poly-A) tails comprising consecutive adenine nucleotides located 3' to nucleotides encoding

2

a protein of interest, wherein the poly-A tail is stabilized by inserting non-adenine nucleotide "anchors."

As used herein, the term "poly-A tail" refers to a poly-A tail on an mRNA molecule, or a sequence encoding a poly-A tail within a DNA plasmid. A poly-A tail may be encoded by a complementary DNA sequence within a plasmid. A sequence of repeating thymine (T) nucleotides in a DNA sequence, e.g. a homopolymer T sequence, may encode a poly-A tail on an mRNA. Two or more consecutive adenosine (e.g. adenosine or deoxyadenosine), thymidine, or other nucleotides are called homopolymers. Naturally-occurring poly-A tails comprise long, uninterrupted homopolymer A sequences.

The non-adenine nucleotide anchors disclosed herein interrupt the poly-A tail at regular or irregularly spaced intervals and stabilize the DNA encoding the poly-A tail as well as the mRNA produced from the DNA. Exemplary non-adenine nucleotide anchors are provided in Table 4. An anchor sequence, for example, is adjacent to two adenine nucleotide homopolymer sequences within the poly-A tail.

In some embodiments, a DNA composition comprising nucleotides encoding a poly-adenylated (poly-A) tail located 3' to nucleotides encoding a protein of interest, wherein the poly-A tail comprises at least 8 consecutive adenine (A) nucleotides and one or more non-adenine (A) nucleotides is encompassed.

In some embodiments, the poly-A tail comprises at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 consecutive adenine nucleotides.

In some instances, the one or more non-adenine nucleotides prevent the loss of one or more adenine nucleotides during DNA replication as compared to the loss that occurs in a DNA comprising a 3' tail of a similar or same length that contains only adenine nucleotides.

In some embodiments, the one or more non-adenine nucleotides are positioned to interrupt the consecutive adenine nucleotides so that a poly(A) binding protein can bind to a stretch of consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises at least 50 total adenine nucleotides.

In some embodiments, the poly-A tail comprises 40-500 total adenine nucleotides.

In some instances, the poly-A tail comprises 95-100 total adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains 90, 91, 92, 93, 94, 95, 96, or 97 total adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains 96 or 97 total adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides.

In some embodiments, the non-adenine nucleotide(s) is located after at least 8, 9, 10, 11, or 12 consecutive adenine nucleotides.

In some instances, the one or more non-adenine nucleotides are located after at least 8-50 consecutive adenine nucleotides.

In some embodiments, the one or more non-adenine nucleotides are located after at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or

contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail has one or more non-adenine nucleotides or one or more consecutive stretches of 2-10 non-adenine nucleotides irregularly spaced anywhere along the length of the poly-A tail, wherein somewhere along the length of the poly-A tail there are at least 8 consecutive adenines. For example, a poly-A tail may be 70-1000 nucleotides in length, and have any number of non-adenines (either singly or grouped) irregularly spaced along the length, as long as there is one or more stretch of at least 8 consecutive adenines.

In some instances, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some instances, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 8-50 consecutive adenine nucleotides.

In some instances, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains more than one non-adenine nucleotide or more than one consecutive stretch of 2-10 nucleotides as interrupting sequences irregularly spaced within the poly-A tail.

In some embodiments, the poly-A tail comprises or contains more than one non-adenine nucleotide or more than one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides irregularly spaced within the poly-A tail.

In some instances, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 12 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 16 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 25 consecutive adenine nucleotides.

In some instances, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 30 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 39 consecutive adenine nucleotides.

In some embodiments, the non-adenine nucleotide is guanine, cytosine, or thymine. In some instances, the non-adenine nucleotide is a guanine nucleotide. In some embodi-

ments, the non-adenine nucleotide is a cytosine nucleotide. In some embodiments, the non-adenine nucleotide is a thymine nucleotide.

In some instances, where more than one non-adenine nucleotide is present, the non-adenine nucleotide may be selected from: a) guanine and thymine nucleotides; b) guanine and cytosine nucleotides; c) thymine and cytosine nucleotides; or d) guanine, thymine and cytosine nucleotides.

In some embodiments, the non-adenine nucleotide consists of one non-adenine nucleotide selected from guanine, cytosine, and thymine.

In some instances, the non-adenine nucleotides comprise two non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine.

In some embodiments, the non-adenine nucleotides comprise three non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine.

The adenine nucleotides may be adenosine monophosphate.

In some embodiments, the protein encoded by the mRNA is a therapeutic protein. In some instances, the protein is a cytokine, chemokine, growth factor, Cas9 or modified Cas9.

In some embodiments, mRNA encoded by any of the DNAs described herein is encompassed.

In some embodiments, the DNA is within a vector. The vector may be within a host cell, including insect, bacterial, or mammalian (e.g., human) cells.

In some embodiments, the one or more non-adenine nucleotide prevents loss of nucleotides encoding the poly-A tail within the vector during growth of the host cell as compared to the loss that occurs in a DNA comprising nucleotides encoding a poly-A tail of a similar or same length that contains only adenine nucleotides.

Methods of producing mRNA from any of the DNA vectors described herein are encompassed comprising: linearizing the vector downstream of the poly-A tail; denaturing the linearized vector; and contacting the denatured DNA with an RNA polymerase in the presence of guanine, cytosine, uracil, and adenine nucleotides.

In some embodiments, this disclosure includes a DNA comprising nucleotides encoding a poly-adenylated (poly-A) tail located 3' to nucleotides encoding a protein of interest, wherein the poly-A tail comprises a first homopolymer sequence of at least 8 consecutive adenine (A) nucleotides and an interrupting sequence comprising one or more non-adenine (A) nucleotides. In some such embodiments, the poly-A tail further comprises a second homopolymer sequence of at least consecutive adenine (A) nucleotides. In some embodiments, the poly-A tail comprises three or more homopolymer sequences of at least 8 consecutive adenine (A) nucleotides. In some embodiments, the first and/or subsequent homopolymer sequence comprises at least 10, 15, 20, 25, 30, 35, or 40 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide prevents the loss of one or more adenine nucleotide during DNA replication as compared to the loss that occurs in a DNA comprising a 3' tail of a similar or same length that contains only adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is positioned to interrupt the consecutive adenine nucleotides so that a poly(A) binding protein can bind to a stretch of consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises at least 50 total adenine nucleotides. In some embodiments, the poly-A tail comprises 40-1000, 40-900, 40-800, 40-700, 40-600, 40-500, 40-400, 40-300, 40-200, or 40-100 total adenine nucleotides. In some embodiments, the

5

poly-A tail comprises 95-100 total adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 90, 91, 92, 93, 94, 95, 96, or 97 total adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 96 or 97 total adenine nucleotides. In some embodiments, the one or more interrupting sequence comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides. In some embodiments, the one or more interrupting sequence comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides that includes two or more non-adenine nucleotides. In some embodiments, the non-adenine nucleotide(s) is located after at least 8, 9, 10, 11, or 12 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is located after at least 8-50 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is located after at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, as described in the preceding paragraph, the interrupting sequence is a trinucleotide, dinucleotide or mononucleotide interrupting sequence. In some such embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains more than one non-adenine nucleotide or more than one consecutive stretch of 2-10 non-adenine nucleotides. In some embodiments, the more than one non-adenine nucleotide or more than one consecutive stretch of 2-10 non-adenine nucleotides are irregularly spaced within the poly-A tail. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 12 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 16 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 25 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 30 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 39 consecutive adenine nucleotides. In some embodiments, the non-adenine nucleotide is guanine, cytosine, or thymine. In some embodiments, the non-adenine nucleotide is a guanine nucleotide. In some embodiments, the non-adenine nucleotide is a cytosine nucleotide. In some embodiments, the non-adenine nucleotide is a thymine nucleotide. In some embodiments, the DNA comprises more than one non-adenine nucleotide selected from: (a) guanine and thymine nucleotides; (b) guanine and cytosine nucleotides; (c) thymine and cytosine nucleotides; or (d) guanine, thymine and cytosine nucleotides. In some embodiments described above, the non-adenine nucleotide consists of one non-adenine nucleotide selected from guanine, cytosine, and thymine. In some embodiments, non-adenine nucleotides comprise two non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine. In some embodiments, non-adenine nucleotides comprise three non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine. In some embodiments, adenine nucleotides are adenosine monophosphate. In some embodiments, the protein is a therapeutic protein. In some embodiments, the protein is a cytokine or chemokine. In some embodiments, the protein is a growth factor. In some embodiments, the protein is Cas9 or modified Cas9.

6

This disclosure also encompasses an mRNA encoded by the DNA as described in the preceding paragraphs. In some embodiments, the DNA described in the preceding paragraphs may also be comprised within a vector. In some embodiments, the vector is comprised within a host cell. In some embodiments, where the DNA is within a vector, the one or more non-adenine nucleotide prevents loss of nucleotides encoding the poly-A tail within the vector during growth of the host cell as compared to the loss that occurs in a DNA comprising nucleotides encoding a poly-A tail of a similar or same length that contains only adenine nucleotides.

This disclosure also encompasses methods of producing mRNA from the DNA vectors described herein, comprising:

(a) linearizing the vector downstream of the poly-A tail; (b) denaturing the linearized vector; and (c) contacting the denatured DNA with an RNA polymerase in the presence of guanine, cytosine, uracil, and adenine nucleotides.

FIGURE LEGENDS

FIG. 1 shows a sequence encoding a poly-A tail that contains only adenosines decreasing in length over rounds of growth. Each clone refers to a DNA generated by successive rounds of growth/purification of host cells expressing plasmid encoding the clones.

FIG. 2 shows retention of size of a poly-A tail comprising non-adenine nucleotides over 2 growth passages.

FIG. 3 shows secreted embryonic alkaline phosphatase (SEAP) levels measured in a Cas9 mRNA assay using Cas9 mRNA with a poly-A tail containing only adenosines or Cas9 mRNA with a poly-A tail comprising non-adenine nucleotides and single guide RNA targeting SEAP (SEQ ID NO: 8).

FIG. 4 shows percent SEAP inhibition measured in a Cas9 mRNA assay using Cas9 mRNA with a poly-A tail containing only adenosines or Cas9 mRNA with a poly-A tail comprising non-adenine nucleotides and single guide RNA targeting SEAP (SEQ ID NO: 8) with a 24-hour incubation.

FIG. 5 shows percent SEAP inhibition measured in a Cas9 mRNA assay using Cas9 mRNA with a poly-A tail containing only adenosines or Cas9 mRNA with a poly-A tail comprising non-adenine nucleotides and single guide RNA targeting SEAP (SEQ ID NO: 8) with a 48-hour incubation.

FIG. 6 shows serum transthyretin (TTR) levels in mice 7 days after dosing of a control transformation and storage solution (TSS) buffer or dosing of liquid nanoparticles (LNP) formulated with the single guide RNA of SEQ ID

NO: 9 (targeting the mouse TTR gene) and either an mRNA encoded by SEQ ID NO: 6 (HiCas9 mRNA) or by SEQ ID NO: 7 (disrupted Poly-A mRNA).

FIG. 7 shows percent SEAP inhibition measured in a Cas9 mRNA assay using Cas9 mRNA with a poly-A tails containing only adenosines or Cas9 mRNA with a poly-A tails comprising non-adenine nucleotides and single guide RNA targeting SEAP (SEQ ID NO: 8) with a 48-hour incubation.

DETAILED DESCRIPTION

Disclosed herein are DNAs encoding a poly-adenylated tail located 3' to nucleotides encoding a protein of interest, wherein the poly-A tail comprises one or more non-adenine nucleotides. During DNA replication, DNA encoding a poly-A tail comprising one or more non-adenine nucleotide may show less gradual loss of adenine nucleotides within the poly-A tail compared with poly-A tails consisting only of adenine nucleotides. Thus, plasmids comprising DNA encoding a poly-A tail comprising one or more non-adenine nucleotide are provided. mRNA encoded by such DNA is also encompassed. Both the DNA and RNA may exhibit greater stability against processive loss of adenine nucleotides than similar molecules comprising non-interrupted poly-A tails.

The protein of interest may be any natural or non-natural protein. As used herein, "protein" refers to any sequence of consecutive amino acids. As such, a protein may refer to a protein that comprises the full amino acid sequence of a naturally occurring protein. In addition, a protein may refer to an amino acid sequence that comprises a fragment of a full-length protein. A protein may be a naturally-occurring sequence, a naturally-occurring sequence with one or more modifications, or an artificial sequence that does not occur in nature.

The protein of interest may be of therapeutic use in a subject, or this protein may be of use in a biochemical reaction. Therapeutic proteins include, for example, growth factors, antigens for vaccines or immuno-oncology, and enzymes, among others. Therapeutic proteins may be naturally occurring or modified. In certain circumstances, a modified protein may be a fusion protein.

In some embodiments, expression of a protein by an mRNA is for use as a treatment for a disease. In some embodiments, expression of a protein by an mRNA is for use as a cancer immunotherapy, vaccination against infectious disease, to induce tolerance to a type I allergy, as a replacement therapy, or as a regenerative medicine (see Sergeeva O V et al, *Biochemistry* (Moscow) 81(7):709-722 (2016)).

In some embodiments, autologous dendritic cells are transfected ex vivo with an mRNA encoding for prostate-specific antigen (PSA) to modulate the T-cell immune response in subjects with metastatic prostate cancer.

In some embodiments, an mRNA is a prophylactic vaccine. In some embodiments, an mRNA encodes for one or more antigenic proteins. In some embodiments, the antigenic protein(s) is a viral protein. In some embodiments, the mRNA causes cells of the body to produce and express an antigenic protein. In some embodiments, the mRNA causes expression of antigenic proteins without a danger or disease or spread between individuals. In some embodiments, expression of antigenic proteins causes the immune system of a subject to produce antibodies. In some embodiments, these antibodies can neutralize a virus and prevent future infection after exposure to the virus. In some embodiments, the mRNA is a prophylactic vaccine for an infectious disease. In some embodiments, the mRNA is prophylactic

vaccine against influenza, chikungunya, Zika, cytomegalovirus, human metapneumovirus (HMPV), or parainfluenza virus type 3 (PIV3). In some embodiments, the mRNA is a prophylactic vaccine against influenza H10 or H7 subtypes.

In some embodiments, an mRNA is a personalized cancer vaccine. In some embodiments, an mRNA primes the immune system of a subject with cancer to recognize cancer cells and mount a response. In some embodiments, this response is tailored to the individual patient's cancer or tumor. In some embodiments, an mRNA encodes a patient's specific neoantigens (unique proteins with mutations present in the patient's cancer or tumor). In some embodiments, an mRNA causes expression of a patient's specific neoantigens. In some embodiments, expression of neoantigens elicits a specific immune response in the patient to recognize and destroy cancer cells. In some embodiments, an mRNA is of use as a personalized cancer vaccine. In some embodiments, an mRNA is of use as a personalized cancer vaccine together with one or more checkpoint inhibitor antibodies, such as anti-PD-1 therapies.

In some embodiments, an mRNA is of use for intratumoral immuno-oncology. In some embodiments, injection of an mRNA into a tumor reduces off-target effects and/or may be more potent compared to systemic administration. In some embodiments, the mRNA causes expression of OX40L (CD252), the ligand for CD134. In some embodiments, the mRNA causes expression of cytokines such as interleukin 12 (IL-12).

In some embodiments, an mRNA causes expression of a protein for localized therapy. In some embodiments, an mRNA causes creation of more blood vessels and improved blood supply in a local tissue. In some embodiments, the mRNA causes expression of vascular endothelial growth factor A (VEGF-A). In some embodiments, expression of VEGF-A is local and transient. In some embodiments, local and transient expression of VEGF-A is of use for treatment of heart failure or after a heart attack, of diabetic wound healing, or of other ischemic vascular diseases.

In some embodiments, an mRNA causes expression of a protein for replacement therapy. In some embodiments, the protein is surfactant protein-B.

In some embodiments, an mRNA causes expression of an RNA-guided nuclease such as class 2 CRISPR-associated Cas endonuclease, e.g. Cas9/Csn1 (Cas9). An exemplary Cas9 sequence is UniProt Q99ZW2. In some embodiments, the protein is a modified Cas9 or a Cas9 protein fused to another functional protein or peptide. Modified versions of Cas9 having one catalytic domain, either RuvC or HNH, that is inactive are termed "nickases". In some embodiments, the compositions and methods comprise nickases. In some embodiments, the compositions and methods comprise a nickase Cas9 that induces a nick rather than a double strand break in the target DNA.

In some embodiments, the Cas protein may be modified to contain only one functional nuclease domain. For example, the Cas protein may be modified such that one of the nuclease domains is mutated or fully or partially deleted to reduce its nucleic acid cleavage activity. In some embodiments, a nickase Cas is used having a RuvC domain with reduced activity. In some embodiments, a nickase Cas is used having an inactive RuvC domain. In some embodiments, a nickase Cas is used having an HNH domain with reduced activity. In some embodiments, a nickase Cas is used having an inactive HNH domain.

In some embodiments, chimeric Cas proteins are encoded by the DNA, where one domain or region of the protein is replaced by a portion of a different protein. In some embodi-

ments, a Cas nuclease domain may be replaced with a domain from a different nuclease such as FokI. In some embodiments, a Cas protein may be a modified nuclease.

I. DNA Encoding Poly-A Tails Comprising Non-Adenine Nucleotides

As used herein, a “poly-A tail” refers to a sequence comprising adenosines or other adenine nucleotides at the 3' end of an mRNA. While natural poly-A tails may be comprised solely of adenine nucleotides, a “poly-A tail” of the present invention is stabilized by one or more non-adenine nucleotide “anchors”. In some embodiments, the poly-A tail comprises at least 8 consecutive adenine nucleotides and one or more interrupting sequence comprising a non-adenine nucleotide. In other words, the poly-A tails of the present invention comprise at least 8 consecutive adenines, but also comprise one or more non-adenine nucleotide within the interrupting or anchor sequences. The interrupting sequences disclosed herein interrupt the poly-A tail at regular or irregularly spaced intervals and stabilize the DNA encoding the poly-A tail as well as the mRNA produced from the DNA. Exemplary interrupting sequences are provided in Table 4.

As used herein, “non-adenine nucleotides” refer to any natural or non-natural nucleotides that do not comprise adenine. Guanine, thymine, and cytosine nucleotides are exemplary non-adenine nucleotides.

Native poly-A tails are added in a process of polyadenylation that begins after transcription of a DNA into mRNA. In molecular biology methods, however, poly-A tails are often encoded by a section of DNA within a plasmid that encodes a protein of interest. In this instance, the size of the poly-A tail (i.e., the number of adenine nucleotides comprised in the poly-A tail) is directly dependent on the number of DNA nucleotides in the plasmid that encode for these consecutive adenine nucleotides.

The number of DNA nucleotides encoding the poly-A tail may gradually decrease during DNA replication during, for example, growth of the plasmid in a host cell. When the number of consecutive adenine-encoding nucleotides in a plasmid reduces, the yield of plasmid encoding full-length poly-A tail is reduced, and the resulting mRNA having shorter poly-A tails may have decreased stability and/or increased degradation. For example, an mRNA with a poly-A tail of 40 consecutive adenine nucleotides might be expected to have lower stability than an mRNA with a poly-A tail of 90 or more nucleotides. By lower stability, it is meant that an mRNA may be degraded more quickly, and consequently expression of a target protein is decreased from an mRNA with a shorter poly-A tail. As such, maintaining the length of a poly-A tail within a DNA plasmid over multiple rounds of DNA replication within host cells is beneficial. In addition, the poly-A tail may be important for translation, and maintaining a longer poly-A tail may result in improved protein expression from the mRNA.

Inclusion of one or more non-adenine nucleotides in a poly-A tail located 3' to nucleotides encoding a protein of interest may prevent the loss of one or more adenine nucleotides during DNA replication as compared to the loss that occurs in a DNA comprising a 3' poly-A tail of a similar or same length that contains only adenine nucleotides. The presence of a longer poly-A tail may also improve the efficiency of protein translation from an mRNA.

A. Adenine Nucleotides

The number of consecutive adenine nucleotides in a poly-A tail of this invention is designed to allow the poly-A-binding protein to bind to the consecutive adenosines. As used herein, “poly-A binding protein,” “poly A binding

protein,” or “polyadenylate-binding protein” refers to a protein that binds to a poly-A tail of an mRNA. A poly-A binding protein may function to regulate translational initiation. By binding to poly-A tails, a poly-A binding protein may protect them from uridylation by ZCCHC6/ZCCHC11 and hence contribute to mRNA stability. A poly-A binding protein may be localized in cytoplasmic messenger ribonucleoprotein (mRNP) granules containing untranslated mRNAs that shuttle between the cytoplasm and the nucleus. An exemplary poly-A binding protein is PABPC1 (Uniprot Reference Number: P11940). DNA of the present invention may encode sufficient consecutive adenine nucleotides such that when transcribed into mRNA, one or more poly-A binding proteins retains ability to bind the poly-A tail. An interrupting non-adenine nucleotide anchor is placed after this functional number of consecutive adenine nucleotides.

In some embodiments, the one or more non-adenine nucleotide is positioned to interrupt the consecutive adenine nucleotides so that a poly-A binding protein can bind to a stretch of consecutive adenine nucleotides (i.e. an adenine nucleotide homopolymer or “homopolymer A”. In some embodiments, the poly-A tail comprises at least 8 consecutive adenine nucleotides. In some embodiments, the at least 8 consecutive adenine nucleotides are 8, 9, 10, 11, and/or 12 consecutive nucleotides. In some embodiments, the poly-A tail comprises at least 10, 15, 20, 25, 30, 35, and/or 40 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, and/or 90 consecutive adenine nucleotides. A homopolymer, for example in a poly-A RNA sequence, may comprise at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, or 40 consecutive adenosine nucleotides. A homopolymer, for example in a plasmid sequence encoding the poly-A tail, may comprise at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, or 40 consecutive thymidine nucleotides. In some embodiments, the poly-A tail comprises two or more homopolymer A sequences of different lengths, e.g. the interrupting sequences in the poly-A tail are irregularly spaced. In some embodiments, the poly-A tail comprises regularly spaced interrupting sequences and two or more homopolymers of the same length.

In some embodiments, the poly-A tail comprises a first homopolymer sequence of at least 8 consecutive adenine nucleotides, a second homopolymer sequence of at least 5 consecutive adenine nucleotides, and an anchor comprising one or more non-adenine nucleotides.

In some embodiments, the poly-A tail comprises one or more sets of 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises one or more sets of 8-100 consecutive adenine nucleotides. For poly-A tails with multiple sets of consecutive adenine nucleotides, i.e. multiple homopolymer sequences, each set of adenine nucleotides does not need to be the same length.

In addition to the number of consecutive adenine nucleotides, a poly-A tail may also be characterized by the number of total adenine nucleotides. The number of total adenine nucleotides is simply the sum of all adenine nucleotides in a poly-A tail. All adenine nucleotides in different groups of consecutive or non-consecutive groupings of adenine nucleotides would therefore be included in the number of total adenine nucleotides in a poly-A tail.

In some embodiments, the poly-A tail comprises 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-210, 210-220, 220-230, 230-240,

11

240-250, 250-260, 260-270, 270-280, 280-290, 290-300, 300-310, 310-320, 320-330, 330-340, 340-350, 350-360, 360-370, 370-380, 380-390, 390-400, 400-410, 410-420, 420-430, 430-440, 440-450, 450-460, 460-470, 470-480, 480-490, 490-500, 500-510, 510-520, 520-530, 530-540, 540-550, 550-560, 560-570, 570-580, 580-590, or 590-600 total adenine nucleotides. In some embodiments, the poly-A tail comprises one or more homopolymer A sequence of at least 8, 9, 10, 12, 25, 30, 50 nucleotides in length.

In some embodiments, the poly-A tail comprises 40-1000, 40-900, 40-800, 40-700, 40-600, 40-500, 40-400, 40-300, 40-200, or 40-100 total adenine nucleotides.

In some embodiments, the poly-A tail comprises at least 40 total adenine nucleotides. In some embodiments, the poly-A tail comprises at least 50 total adenine nucleotides. In some embodiments, the poly-A tail comprises at least 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 220, 240, 260, 280, or 300 adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains 90, 91, 92, 93, 94, 95, 96, or 97 total adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 96 or 97 total adenine nucleotides.

In some embodiments, the adenine nucleotides are adenosine monophosphate. The nucleotides may be modified.

B. Interrupting Sequences Comprising Non-Adenine Nucleotides

Non-adenine nucleotides of the present invention may comprise or consist of natural or non-natural nucleotides such as guanine, cytosine, or thymine. The nucleotides may be modified.

In some embodiments, a poly-A tail comprises one non-adenine nucleotide in a poly-A tail that otherwise consists only of adenine nucleotides. The one non-adenine nucleotide may interrupt a sequence of adenine nucleotides. The one non-adenine nucleotide may be selected from guanine, cytosine, and thymine. In some embodiments, the one non-adenine nucleotide is a guanine nucleotide. In some embodiments, the one non-adenine nucleotide is a cytosine nucleotide. In some embodiments, the one non-adenine nucleotide is a thymine nucleotide. The interrupting sequence may be a mononucleotide, dinucleotide, trinucleotide sequence. The interrupting sequence may comprise 1, 2, 3, 4, 5, or more non-adenine nucleotides and it may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotides in length.

In some embodiments, a single non-adenine nucleotide may interrupt sets or groups of consecutive adenine nucleotides. The one non-adenine nucleotide may be positioned to interrupt consecutive adenine nucleotides in such a way that a poly-A binding protein can bind to a stretch of consecutive adenine nucleotides.

In some embodiments, there are more than one non-adenine nucleotides in a poly-A tail. The more than one non-adenine nucleotide may be positioned to interrupt consecutive adenine nucleotides in such a way that a poly-A binding protein can bind to a stretch of consecutive adenine nucleotides. In some embodiments, non-adenine nucleotides are interspersed between more than one set of consecutive adenine nucleotides, with the number of adenine nucleotides in each series of consecutive adenine nucleotides being sufficient to allow binding of a poly-A binding protein.

The non-adenine nucleotides may be in stretches of more than one non-adenine nucleotide. The non-adenine nucleotides may be in stretches of 2-10 consecutive nucleotides that comprise one or more non-adenine nucleotides. The non-adenine nucleotides may be in interrupting sequences

12

that are interspersed between more than one set of consecutive adenine nucleotides, e.g., more than one homopolymer A sequence. In some embodiments, the number of consecutive non-adenine nucleotides may be one, two, three, four, or five. In some embodiments, there are consecutive stretches of 2-10 non-adenine nucleotides. In some embodiments, there are consecutive stretches of 2-10 nucleotides comprising at least two non-adenine nucleotides.

The consecutive non-adenine nucleotides may be more than one of the same nucleotide or the consecutive non-adenine nucleotides may be different from each other. For example, the non-adenine nucleotides may be more than one guanine, cytosine, or thymine nucleotides. The non-adenine nucleotides may also be guanine and thymine nucleotides; guanine and cytosine nucleotides; thymine and cytosine nucleotides; or guanine, thymine and cytosine nucleotides. The non-adenine nucleotides may comprise two non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine. The non-adenine nucleotide may comprise three non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine. The non-adenine nucleotide may comprise more than three non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine. The poly-A tail may comprise adenine nucleotides between non-adenine nucleotides at regular or irregular intervals. For example, one may view the poly-A tail as having a pattern, where the pattern is regular or irregular. The key to the pattern is the presence of one or more non-adenine nucleotide anywhere in the poly-A tail so long as there are at least 8 consecutive adenines anywhere along the length. In some embodiments, a poly-A may comprise a stretch of at least 8 consecutive adenine nucleotides anywhere along the length, where the adenine nucleotides are "interrupted" anywhere after 8 or more adenines with one or more non-adenine nucleotide. The interrupting sequence may be one non-adenine nucleotide, or 2 to 10 consecutive nucleotides, optionally comprising at least two non-adenine nucleotides. Each one or consecutive stretch of nucleotides comprising at least two non-adenine nucleotides may be followed by one or more adenines, optionally followed by one or more non-adenine nucleotides, optionally followed by one or more than one adenine nucleotides and so on until the end of the poly-A tail. This pattern of adenine nucleotides/non-adenine nucleotides may repeat at regular or irregular intervals. Alternatively, there may be no pattern, such as where there is only one or one consecutive stretch of 2-10 nucleotides, optionally comprising at least two non-adenine nucleotides along the entire length of poly-A.

II. Exemplary Patterns of Adenine and Non-Adenine Nucleotides in Poly-A Tails

Poly-A tails of this invention may comprise or consist of a number of different patterns of interrupting sequences such as consecutive adenine nucleotides and one or more non-adenine nucleotide.

A poly-A tail may begin with one or a series of consecutive adenine nucleotides followed by a non-adenine nucleotide. A poly-A tail that begins with a series of adenine nucleotides means that the 5' end of the poly-A tail consists of one or a series of consecutive adenine nucleotides with one or more non-adenine nucleotide coming after the consecutive adenine nucleotides. "After," means that the non-adenine nucleotides are 3' to a series of consecutive adenine nucleotides.

In some embodiments, the 5' end of the poly-A tail may consist of a series of consecutive adenine nucleotides followed by one or more non-adenine nucleotide(s). In some embodiments, one or more non-adenine nucleotide(s) is

13

located after at least 8, 9, 10, 11, or 12 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is located after at least 8-50 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is located after at least 8-100 consecutive adenine nucleotides. In some embodiments, the non-adenine nucleotide is after one, two, three, four, five, six, or seven adenine nucleotides and is followed by at least 8 consecutive adenine nucleotides.

In some embodiments, the 5' end of the poly A tail consists of one to eight adenine nucleotides followed by one or more non-adenine nucleotide(s). In such embodiments, the non-adenine nucleotide(s) are followed by more adenine nucleotides. The adenine nucleotides that follow the one or more non-adenine nucleotide comprise at least 8 adenines nucleotides before another non-adenine nucleotide.

The range of size of a group of consecutive adenine nucleotides that begins the poly-A tail may vary. In some embodiments, the 5' end of the poly-A tail consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 consecutive adenine nucleotides. Where the first non-adenine nucleotide falls after 1-7 adenine nucleotides, the poly-A tail further comprises a stretch of at least 8 adenine nucleotides after the non-adenine nucleotide.

In some embodiments, the one or more non-adenine nucleotide is located after at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

The poly-A tail may end with a stretch of non-adenine nucleotides at the 3' end. The number of non-adenine nucleotides at the 3' end of the poly-A tail may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 non-adenine nucleotides. Alternatively, the 3' end of the poly-A tail may consist of one or more adenine nucleotides.

The poly-A tail of the present invention may comprise one sequence of consecutive adenine nucleotides followed by one or more non-adenine nucleotides, optionally followed by additional adenine nucleotides. The poly-A tail of the present invention may also comprise more than one sequence of consecutive adenine nucleotides interrupted by one or more non-adenine nucleotides. The sequence of consecutive adenine nucleotides may be at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides. The number of non-adenine nucleotides in an interrupting sequence may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 non-adenine nucleotides.

A poly-A tail of the invention may also comprise more than one series of consecutive adenine nucleotides that are interrupted or interspersed with non-adenine nucleotides. The length of the interrupting sequence may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. The length of the interrupting sequence may be 1-3, 1-5, 1-10, 2-10, 2-8, 2-6, or 2-5 nucleotides. The poly-A tails of the invention may comprise more than one set of consecutive adenine nucleotides and an interrupting sequence comprising one non-adenine nucleotide or more than one consecutive stretch of 2-10 non-adenine nucleotides between each set of consecutive adenine nucleotides. The poly-A tails of the invention may comprise more than one set of consecutive adenine nucleotides and

14

one non-adenine nucleotide or more than one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides between each set of consecutive adenine nucleotides. The poly-A tails of the invention may comprise more than one set of consecutive adenine nucleotides and one or more interrupting sequences, each comprising one or more non-adenine nucleotide. The sets may each comprise the same or different number of adenine nucleotides. In embodiments with multiple sets of consecutive adenine nucleotides, each set of consecutive adenine nucleotides may be sufficient in length to allow binding of a poly-A binding protein.

In some embodiments, one or more non-adenine nucleotide is an interrupting sequence located at regular intervals with the poly-A tail. By regular intervals, it is meant that a set number of consecutive adenine nucleotides is followed by non-adenine nucleotides in a repeated fashion.

In some embodiments, one or more non-adenine nucleotide is located at irregular intervals with the poly-A tail. By irregular intervals, it is meant that a set number of consecutive adenine nucleotides is followed by non-adenine nucleotides followed by another set of consecutive adenine nucleotides that comprise a different number of adenines than the first set.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides every 8-100 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides every 8-100 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8-50 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8-100 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8-100 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising a non-adenine nucleotide every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 nucleotides comprising at least two non-adenine nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,

15

36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, number of non-adenine nucleotides may be 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides. In some embodiments, the number of consecutive adenine nucleotides may be 8-50 adenine nucleotides. In some embodiment embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

The numbers of consecutive adenine nucleotides in a poly-A tail may be 12, 16, 25, 30, or 39. The number of consecutive adenine nucleotides may also be greater than 39. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 12 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 16 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 25 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 30 consecutive adenine nucleotides. In some embodiments, the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 39 consecutive adenine nucleotides. The number of consecutive non-adenine nucleotides may also be greater than 5.

Exemplary trinucleotide interrupting sequences include GCG, CCG, GTG, TGG, CGG, GGT, TAT, CAT, CGT, CTC, GAT, CCT, TGT, TGC, CAC, TGC, TCG, TCT, CCC, GAC, TAG, GTT, CTG, and TTT. There are 63 possible trinucleotide interrupting sequences, and 36 trinucleotide interrupting sequences that omit a terminal A. In some embodiments, the poly-A tail comprises one or more trinucleotide interrupting sequences chosen from TGG, CGG, GGT, TAT, CAT, CGT, CTC, GAT, CCT, TGT, CGC, CAC, TGC, TCG, TCT, CCC, GAC, TAG, GTT, CTG, and TTT. In some embodiments, the poly-A tail comprises multiple interrupting sequences designed to minimize hybridization and annealing between 3 or more nucleotides within the sequence encoding the poly-A tail or within the poly-A tail. In certain embodiments, the interrupting sequences that minimize annealing between 3 or more nucleotides are chosen from the 34 trinucleotide interrupting sequences that omit a terminal A. In some embodiments, the interrupting sequences that minimize annealing between 3 or more nucleotides are chosen from TGG, CGG, GGT, TAT, CAT, CGT, CTC, GAT, CCT, TGT, CGC, CAC, TGC, TCG, TCT, CCC, GAC, TAG, GTT, CTG, and TTT. In some embodiments, e.g. SEQ ID NO: 18, the poly-A tail comprises di- and/or tri-nucleotide interrupting sequences chosen from TGG, CGG, GGT, TAT, CAT, CGT, CTC, GAT, CCT, TGT, CGC, CAC, TGC, TCG, TCT, CCC, GAC, TAG, GTT, CTG, and TTT. In some embodiments, the poly-A tail comprises trinucleotide interrupting sequences chosen from GCG, CCG, and GTG. Exemplary dinucleotide interrupting sequences include CG, GC, CC, GG, TT, CT, TC, GT, and TG. There are 15 possible dinucleotide interrupting sequences, and 9 dinucleotide sequences that do not include a terminal A. Mononucleotide interrupting sequences can be C, G, and T. Note that, with respect to any nucleotide sequence above, when referring to an RNA sequence (such as an mRNA), as opposed to a DNA sequence, T is replaced by U.

16

One skilled in the art would be able to design a number of different patterns of DNA encoding poly-A tails with consecutive adenine nucleotides and one or more non-adenine nucleotide. Some exemplary poly-A tails comprising at least 8 consecutive adenine nucleotides and one or more adenine-nucleotide are presented, for example, in SEQ ID Nos: 1-5, 10, 11, and 18.

III. Methods of Use

The DNA of this invention may be used for production of mRNA encoded by the DNA. In some embodiments, an mRNA is encoded by the DNA of the invention.

In some embodiments, the DNA of the invention is prepared for production of mRNA. In some embodiments, the DNA is within a vector. In some embodiments, the vector is within a host cell. In some embodiments, an mRNA encoded by the DNA of this invention is used for translating the protein of interest encoded by the DNA.

In some embodiments, the one or more non-adenine nucleotide prevents the loss of one or more adenine nucleotides during DNA replication as compared to the loss that occurs in a DNA comprising a 3' tail of a similar or same length that contains only adenine nucleotides. DNA replication is a necessary step in growth of plasmid for DNA purification. As such, a plasmid comprising the DNA of this invention encoding a poly-A tail comprising at least 8 consecutive adenine nucleotides and one or more non-adenine nucleotide may show improved stability over one more rounds of growth and purification of the plasmid, as compared to a plasmid encoding a poly-A tail consisting only of adenine nucleotides.

A plasmid comprising the DNA of this invention comprising a sequence encoding a poly-A tail comprising at least 8 consecutive adenine nucleotides and one or more non-adenine nucleotide may have greater stability when grown in a host cell compared to a plasmid comprising a DNA comprising a sequence encoding a poly-A tail consisting only of consecutive adenine nucleotides. During growth of the host cell expressing a plasmid with a DNA sequence, a DNA sequence encoding a poly-A tail that comprises consecutive adenine nucleotides and one or more non-adenine nucleotide may be resistant to a decrease in length of the DNA encoding the poly-A tail compared to a poly-A tail consisting only of adenine nucleotides. In some embodiments, a plasmid comprising a DNA encoding a poly-A tail comprising one or more non-adenine nucleotide prevents loss of adenines during growth of a host cell as compared to a plasmid comprising a DNA encoding a poly-A tail comprising only adenine nucleotides.

Any means of growing and purifying a vector known to one skilled in the art may be used for growth of a host cell encoding a plasmid. The process of growth and purification of a vector may also be referred to as plasmid preparation. Standard steps of plasmid purification include growth of a bacterial culture, harvesting and lysis of the bacteria, and purification of plasmid DNA. Many kits are available from various manufacturers to purify plasmid DNA. The step of plasmid preparation may be miniprep (with expected yield of 20 to 40 µg or 50 to 100 µg of plasmid DNA), midiprep (with expected yield of 100 to 350 µg of plasmid DNA), maxiprep (with expected yield of 500-850 µg of plasmid DNA), megaprep (with expected yield of 1.5-2.5 mg of plasmid DNA), or gigaprep (with expected yield of 7.5-10 mg of plasmid DNA). For therapeutic mRNA production, plasmids may be produced at scales of 100 mg, 1 g, 10 g, or more. The increased stability and replication efficiency of plasmids encoding poly-A tails with non-adenine nucleotides as

17

described herein may improve the consistency and efficiency of plasmids made at such scales.

In some embodiments, a method of producing mRNA from a DNA vector of the present invention is encompassed. In some embodiments, the method of producing mRNA from the DNA vector comprises linearizing the vector downstream of the poly-A tail; denaturing the linearized vector; and contacting the denaturized DNA with an RNA polymerase in the presence of RNA nucleotides such as guanine, cytosine, uracil, adenine, or chemically modified version of such nucleotides such as pseudouridine, N-1-methyl pseudouridine, methoxyuridine, among others. Modified residues, such as base, sugar, and backbone modifications of nucleotide residues can be used in the mRNAs, polynucleotides, and methods described herein.

This description and exemplary embodiments should not be taken as limiting. For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing quantities, percentages, or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term "about," to the extent they are not already so modified. Accordingly, unless indicated to the contrary, the numerical

18

parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

It is noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the," and any singular use of any word, include plural referents unless expressly and unequivocally limited to one referent. As used herein, the term "include" and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.

Description of Sequences

This table provides a listing of certain sequences referenced herein. Note again that, when referring to the RNA version of a DNA sequence in the table below, T is replaced by U. When referring to a DNA version of an RNA sequence in the table below, U is replaced by T.

TABLE 1

Description	Sequence	SEQ ID No
sequence of an exemplary poly-A tail comprising non-adenine nucleotides with 30, 30, and 39 consecutive adenosines and ending with non-adenine nucleotides	AAAAAAAAA AAAAAAAAAA AAAAAAAAAA GCGAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAACCGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA AAAAACCC	1
30PA-sequence of an exemplary poly-A tail comprising non-adenine nucleotides with 30, 30, and 39 consecutive adenosines	AAAAAAAAA AAAAAAAAAA AAAAAAAAAA GCGAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAACCGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA AAAA	2
25PA-sequence of an exemplary poly-A tail comprising non-adenine nucleotides with four sets of 25 consecutive adenosines	AAAAAAAAA AAAAAAAAAA AAAAAGCGAA AAAAAAAAA AAAAAAAAAA AAACCGAAAA AAAAAAAAA AAAAAAAAAA AGTGAAAAA AAAAAAAAA AAAAAAAAAA	3
16PA-sequence of an exemplary poly-A tail comprising non-adenine nucleotides with six sets of 16 consecutive adenosines	AAAAAAAAA AAAAAGAAA AAAAAAAAAA AAACAAAAA AAAAAAAAAA TAAAAAAA AAAAAATAA AAAAAAAAAA AAACAAAAA AAAAAAAAA A	4
16PA long-sequence of an exemplary poly-A tail comprising non-adenine nucleotides with six sets of 16 consecutive adenosines and 63 consecutive adenosines	AAAAAAAAA AAAAAGAAA AAAAAAAAAA AAACAAAAA AAAAAAAAAA TAAAAAAA AAAAAATAA AAAAAAAAAA AAACAAAAA AAAAAAAAA ACAAAAAAA AAAAAAAAAA AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA AAAA	5
Cas9 mRNA with a poly-A tail consisting of 97 adenosines	TAATACGACTCACTATAGGGTCCCGCAGTCGGCGTCCAGC GGCTCTGCTTGTTGTCGTGTGTGTCGTGTCAGGCCTTATT CGGATCCATGGATAAGAAGTACTCAATCGGGCTGGATATC GGAAC TAATTCCGTGGGTTGGGCAGTGATCACGGATGAAT ACAAAGTGCCGTCCAAGAAGTTCAAGGTCCTGGGGAACAC CGATAGACACAGCATCAAGAAAAATCTCATCGGAGCCCTG CTGTTTGACTCCGGCGAAACCGCAGAACGACCCGGCTCA AACGTACCGCGAGGCGACGCTACACCCGGCGGAAGAATCG	6

TABLE 1-continued

Description	Sequence	SEQ ID No
	CATCTGCTATCTGCAAGAGATCTTTTCGAACGAAATGGCA AAGGTCGACGACAGCTTCTTCCACCGCCTGGAAGAATCTT TCCTGGTGGAGGAGGACAAGAAGCATGAACGGCATCCTAT CTTTGGAAACATCGTCGACGAAGTGGCGTACCACGAAAAG TACCCGACCATCTACCATCTGCGGAAGAAGTTGGTTGACT CAACTGACAAGGCCGACCTCAGATTGATCTACTTGGCCCT CGCCCATATGATCAAATTCGCGGACACTTCCTGATCGAA GGCGATCTGAACCTGATAACTCCGACGTGGATAAGCTTT TCATTCAACTGGTGCAGACCTACAACCAACTGTTGGAAGA AAACCAATCAATGCTAGCGGCGTCGATGCCAAGGCCATC CTGTCCGCCCGGCTGTGCAAGTCGCGGCGCTCGAAAACC TGATCGCACAGCTGCCGGGAGAGAAAAGAACGGACTTTT CGGCAACTTGATCGCTCTCTCACTGGGACTCACTCCCAAT TTCAAGTCCAATTTTGACCTGGCCGAGGACGCGAAGCTGC AACTCTCAAAGGACACCTACGACGACGACTTGGACAAATTT GCTGGCACAATTTGGCGATCAGTACGCGGATCTGTTCTT GCCGCTAAGAACCTTTTCGGACGCAATCTTGCTGTCGATA TCCTGCGCGTGAAACACCGAAATAACCAAAGCGCGCTTAG CGCCTCGATGATTAAGCGGTACGACGAGCATCACAGGAT CTCACGCTGCTCAAAGCGCTCGTGAGACAGCAACTGCCTG AAAAGTACAAGGAGATCTTCTTCGACCAGTCCAAGAATGG GTACGCAAGGTACATCGATGGAGGCGCTAGCCAGGAAGAG TTCTATAAGTTCATCAAGCCAATCCTGAAAAGATGGACG GAACCGAAGAACTGCTGGTCAAGCTGAACAGGGAGGATCT GCTCCGGAACAGAGAACCTTTGACAACGGATCCATTCCC CACCAGATCCATCTGGGTGAGCTGCACGCCATCTTGCGGC GCCAGGAGGACTTTTACCCATTCTCAAGGACACCGGGA AAAGATCGAGAAAATTCTGACGTTCCGCATCCCGTATTAC GTGGGCCCACTGGCGCGCGCAATTCGCGCTTCGCGTGGA TGACTAGAAAATCAGAGGAAACCATCACTCTTGGAATTT CGAGGAAGTTGTGGATAAGGAGCTTCGGCACAAAGCTTC ATCGAACGAATGACCAACTTCGACAAGAATCTCCCAAACG AGAAGGTGCTTCCTAAGCACAGCCTCCTTTACGAATACTT CACTGTCTACAACGAAGTACTAAAGTGAATACGTTACT GAAGGAATGAGGAAGCCGGCCTTTCTGTCCGGAGAACAGA AGAAAGCAATTGTGATCTGCTGTTCAAGACCAACCGCAA GGTGACCGTCAAGCAGCTTAAAGAGGACTACTTCAAGAAG ATCGAGTGTTCGACTCAGTGAATCAGCGGGGTGGAGG ACAGATTCAACGCTTCGCTGGGAACCTATCATGATCTCCT GAAGATCATCAAGGACAAGGACTTCCTTGACAACGAGGAG AACGAGGACATCCTGGAAGATATCGTCTTGACCTTGACCC TTTTCGAGGATCGCGAGATGATCGAGGAGAGGCTTAAGAC CTACGCTCATCTCTTCGACGATAAGGTCATGAACAACCTC AAGCGCCGCGGTACACTGGTTGGGGCCGCTCTCCCGCA AGCTGATCAACGGTATTTCGCGATAAACAGAGCGGTAAC TATCCTGGATTCTCTCAAATCGGATGGCTTCGCTAATCGT AACTTCATGCAATGATCCACGACGACAGCCTGACCTTTA AGGAGGACATCCAAAAGCACAAAGTGTCGCGACAGGAGA CTCACTCCATGAACACATCGCGAATCTGGCCGGTTCCGCCG GCGATTAAAGAGGAATTCGCAAACTGTGAAGGTGGTCG ACGAGCTGGTGAAAGTCAAGGACGGCACAAACCGGAGAA TATCGTGATTGAAATGGCCCGAGAAAACGAGACTACCCAG AAGGGCCAGAAAACCTCCCGCAAAGGATGAAGCGGATCG AAGAAGGAATCAAGGAGCTGGGACGCCAGATCTTGAAAGA GCACCCGGTGGAAAACACGACGCTGCAGAACGAGAAGCTC TACCTGTACTATTGCAAAATGGACGGGACATGTACGTGG ACCAAGAGCTGGACATCAATCGGTTGCTGATTACGACGT GGACCACATCGTTCCACAGTCTTTCTGAAGGATGACTCG ATCGATAACAAGGTGTTGACTCGCAGCGACAAGAACAGAG GGAAGTCAGATAATGTGCCATCGGAGGAGTCTGTAAGAA GATGAAGAATTACTGGCGGAGCTCTGAATGCGAAGCTG ATTACCCAGAGAAAGTTTGACAATCTCACTAAAGCCGAGC GCGCGGACTCTCAGAGCTGGATAAGGCTGGATTCACTAA ACGGCAGCTGGTCGAGACTCGGCAGATTACCAAGCAGCTG GCGCAGATCTTGACTCCCGCATGAACACTAAATACGACG AGAACGATAAGCTCATCCGGGAAGTGAAGGTGATTACCT GAAAAGCAAACCTTGTGCGACTTTTCGGAAGGACTTTAG TTTTACAAAGTGAGAGAAATCAACAACTACCATCACGCGC ATGACGCATACCTCAACGCTGTGGTTCGTACCGCCCTGAT CAAAAGTACCTAACTTGAATCGAGTTTGTGTACGGA GACTACAAGGTCTACGACGTGAGGAAGATGATAGCCAAGT CCGAACAGGAAATCGGGAAGCAACTGCGAAATACCTCTT TTAATCAACATCATGAACCTTTTCAAGACTGAAATTACG CTGGCCAATGGAGAAATCAGGAAGAGGCCACTGATCGAAA CTAACGGAGAAACGGCGCAATCGTGTGGGACAGGGCAG GGACTTCGCAACTGTTCCGCAAGTGCTCTCTATGCCGCAA	

TABLE 1-continued

Description	Sequence	SEQ ID No
	GTCAATATTGTGAAGAAAACCGAAGTGCAAAACCGGCGGAT TTTCAAAGGAATCGATCCTCCCAAAGAGAAATAGCGACAA GCTCATTGCACGCAAGAAAGACTGGGACCCGAAAGATAC GGAGGATTTCGATTGCGCGACTGTGCGATACTCCGTCTCTG TGGTGGCCAAGGTGGAGAAGGAAAGAGCAAAAAGCTCAA ATCCGTCAAAGAGCTGCTGGGATTACCATCATGGAACGA TCCTCGTTCGAGAAGAACCCGATTGATTCTCTCGAGGCGA AGGGTTACAAGGAGGTGAAGAAGGATCTGATCATCAAAC CCCCAAGTACTCACTGTTGAACTGGAAAATGGTCGGAAG CGCATGTGCGCTTCGGCCGGAAGTCCAAAAAGGAAATG AGCTGGCCTTGCCCTAGCAAGTACGTCAACTTCTCTATCT TGCTTCGCACTACGAAAAACTCAAAGGGTCACCGGAAGAT AACGAACAGAAGCAGCTTTTCGTGGAGCAGCACAAGCATT ATCTGGATGAAATCATCGAACAATCTCCGAGTTTTCAAA GCGCGTGATCCTCGCCGACGCCAACCTCGACAAAGTCCTG TCGGCTTACAATAAGCATAGAGATAAGCCGATCAGAGAAC AGGCCGAGAACATTATCCACTTGTTCACCCGTGACTAACCT GGGAGCCCCAGCCGCTTCAAGTACTTCGATACTACTATC GATCGCAAAAGATACACGTCCACCAAGGAAGTTCTGGACG CGACCCGTGATCCCAAAAGCATCACTGGACTCTACGAAAC TAGGATCGATCTGTGCGAGCTGGGTGGCGATGGCGGTGGA TCTCCGAAAAAGAGAAAGGTGTAATGAGCTAGCCATC ACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAA AGAAAAATGAAGATCAATAGCTTATTCATCTCTTTTCTTT TTCGTTGGTGTAAGCCAACCCCTGTCTAAAAACATAA ATTTCTTTAATCATTTTGCCCTCTTTCTCTGTGCTTCAAT TAATAAAAAATGGAAAGAACCTCGAGAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAA	
T7 promoter and Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 1	TAATACGACT CACTATAGGG TCCCGCAGTC GGCGTCCAGC GGCTCTGCTT GTTCGTGTGT GTGTCTGTGC AGGCCTTATC CGGATCTGCC ACCATGGATA AGAAGTACTC GATCGGGCTG GATATCGGAA CTAATTCCGT GGGTTGGGCA GTGATCACGG ATGAATACAA AGTGCCGTCC AAGAAGTTCA AGGTCTCTGG GAACACCGAT AGACACAGCA TCAAGAAGAA TCTCATCGGA GCCCTGCTGT TTGACTCCGG CGAAACCGCA GAAGCGACCC GGCTCAAACG TACCGCGAGG CGACGCTACA CCGCGCGGAA GAATCGCATC TGCTATCTGC AAGAAATCTT TTCGAACGAA ATGGCAAAGG TGGACGACAG CTCTTCCAC CGCCTGGAAG AATCTTTCTT GGTGGAGGAG GACAAGAAGC ATGAACGGCA TCCTATCTTT GGAAACATCG TGGACGAAGT GGCGTACCAC GAAAAGTACC CGACCATCTA CCATCTGCGG AAGAAGTTGG TTGACTCAAC TGACAAGGCC GACCTCAGAT TGATCTACTT GGCCCTCGCC CATATGATCA AATTCCGCGG ACACCTCCTG ATCGAAGGCG ATCTGAACCC TGATAACTCC GACGTGGATA AGCTGTTTCA TCAACTGGTG CAGACCTACA ACCAACTGTT CGAAGAAAAC CCAATCAATG CCAGCGGCGT CGATGCCAAG GCCATCCTGT CCGCCCGGCT GTCGAAGTCG CGGCGCCTCG AAAACCTGAT CGCACAGCTG CCGGGAGAGA AGAAGAACGG ACTTTTCGGC AACTTGATCG CTCTCTCACT GGGACTCACT CCCAATTTC AATCCCAATT TGACCTGGCC GAGGACGCGA AGCTGCAACT CTCAAAGGAC ACCTACGACG ACGACTTGGA CAATTGCTG GCACAAATTG GCGATCAGTA CGCGGATCTG TTCCTTGCCG CTAAGAACCT TTCGACGCA ATCTTGCTGT CCGATATCCT GCGCGTGAA ACCGAAATAA CCAAGCGCC GCTTAGCGCC TCGATGATTA AGCGGTACGA CGAGCATCAC CAGGATCTCA CGCTGCTCAA AGCGCTCGTG AGACAGCAAC TGCTGAAAA GTACAAGGAG ATTTTCTTCG ACCAGTCCAA GAATGGGTAC GCAGGGTACA TCGATGGAGG CGCCAGGCCAG GAAGAGTTCT ATAAGTTTCA CAAGCCAATC CTGGAAAAGA TGGACGGAAC CGAAGAACTG CTGGTCAAGC TGAACAGGGA GGATCTGCTC CGCAACAGAG GAACCTTTGA CAACGGAAGC ATCCACACC AGATCCATCT GGGTGAGCTG	7

TABLE 1-continued

Description	Sequence	SEQ ID No
	CACGCCATCT TCGGCGCCCA GGAGGACTTT	
	TACCCATTCC TCAAGGACAA CCGGAAAAAG	
	ATCGAGAAAA TTCTGACGTT CCGCATCCCG	
	TATTACGTGG GCCACTGGC GCGCGGCAAT	
	TCGCGCTTCG CGTGGATGAC TAGAAAAATCA	
	GAGGAAACCA TCACTCCTTG GAATTTCGAG	
	GAAGTTGTGG ATAAGGGAGC TTCGCACAA	
	TCCTTCATCG AACGAATGAC CAACTTCGAC	
	AAGAATCTCC CAAACGAGAA GGTGCTTCCT	
	AAGCACAGCC TCCTTACGA ATACTTCACT	
	GTCTACAACG AACTGACTAA AGTGAATATAC	
	GTTACTGAAG GAATGAGGAA GCCGGCCTTT	
	CTGAGCGGAG AACAGAAGAA AGCGATTGTC	
	GATCTGCTGT TCAAGACCAA CCGCAAGGTG	
	ACCGTCAAGC AGCTTAAAGA GGACTACTTC	
	AAGAAGATCG AGTGTTTCGA CTCAGTGGAA	
	ATCAGCGGAG TGGAGGACAG ATTC AACGCT	
	TCGCTGGGAA CCTATCATGA TCTCTGAAG	
	ATCATCAAGG ACAAGGACTT CTTGACAAC	
	GAGGAGAACG AGGACATCCT GGAAGATATC	
	GTCTGACCT TGACCCCTTT CGAGGATCGC	
	GAGATGATCG AGGAGAGGCT TAAGACCTAC	
	GCTCATCTCT TCGACGATAA GGTGATGAAA	
	CAACTCAAGC GCCGCCGTA CACTGGTTGG	
	GGCCGCCTCT CCGCAAGCT GATCAACGGT	
	ATTTCGCGATA AACAGAGCGG TAAAACTATC	
	CTGGATTTC TCAAAATCGGA TGGCTTCGCT	
	AATCGTAACT TCATGCAGTT GATCCACGAC	
	GACAGCCTGA CCTTTAAGGA GGACATCCAG	
	AAAGCACAAG TGAGCGGACA GGGAGACTCA	
	CTCCATGAAC ACATCGCGAA TCTGGCCGGT	
	TCGCCGCGCA TTAAGAAGGG AATCTGCAA	
	ACTGTGAAGG TGGTGGACGA GCTGGTGAAG	
	GTCTATGGAC GGCACAAACC GGAGAATATC	
	GTGATTGAAA TGGCCCGAGA AAACCAGACT	
	ACCCAGAAGG GCCAGAAGAA CTCCCGCGAA	
	AGGATGAAGC GGATCGAAGA AGGAATCAAG	
	GAGCTGGGCA GCCAGATCCT GAAAGAGCAC	
	CCGGTGGAAA ACACGCAGCT GCAGAACGAG	
	AAGCTCTACC TGTAATTATT GCAAATGGA	
	CGGGACATGT ACGTGGACCA AGAGCTGGAC	
	ATCAATCGGT TGTCTGATTA CGACGTGGAC	
	CACATCGTTC CACAGTCCTT TCTGAAGGAT	
	GACTCCATCG ATAACAAGGT GTTGACTCGC	
	AGCGACAAGA ACAGAGGGAA GTCAGATAAT	
	GTGCCATCGG AGGAGGTCGT GAAGAAGATG	
	AAGAATTACT GCGCGCAGCT CCTGAATGCG	
	AAGCTGATTA CCCAGAGAAA GTTTGACAAT	
	CTCACTAAAG CCGAGCGCGG CGGACTCTCA	
	GAGCTGGATA AGGCTGGATT CATCAAACGG	
	CAGCTGGTCG AGACTCGGCA GATTACCAAG	
	CACGTGGCGC AGATCCTGGA CTCCCGCATG	
	AACACTAAAT ACGACGAGAA CGATAAGCTC	
	ATCCGGGAAG TGAAGGTGAT TACCCTGAAA	
	AGCAAACCTG TGTCCGACTT TCGGAAGGAC	
	TTTCAGTTTT ACAAAAGTGAG AGAAATCAAC	
	AACTACCATC ACGCGCATGA CGCATACCTC	
	AACGCTGTGG TCGGCACCGC CCTGATCAAG	
	AAGTACCCTA AACTTGAATC GGAGTTTGTG	
	TACGGAGACT ACAAGGTCTA CGACGTGAGG	
	AAGATGATAG CCAAGTCCGA ACAGGAAATC	
	GGGAAAGCAA CTGCGAAATA CTTCTTTTAC	
	TCAAACATCA TGAACCTCTT CAAGACTGAA	
	ATTACGCTGG CCAATGGAGA AATCAGGAAG	
	AGGCCACTGA TCGAAACTAA CGGAGAAACG	
	GGCGAAATCG TGTGGGACAA GGGCAGGGAC	
	TTCGCAACTG TTCGCAAAGT GCTCTCTATG	
	CCGCAAGTCA ATATTGTGAA GAAAACCGAA	
	GTGCAAACCG GCGGATTTTC AAAGGAATCG	
	ATCCTCCCAA AGAGAAATAG CGACAAGCTC	
	ATTGCACGCA AGAAAGACTG GGACCCGAAG	
	AAGTACGGAG GATTGATTC GCCGACTGTC	
	GCATACTCCG TCCTCGTGGT GGCCAAGGTG	
	GAGAAGGGAA AGAGCAAGAA GCTCAAATCC	
	GTCAAAGAGC TGCTGGGGAT TACCATCATG	
	GAACGATCCT CGTTCGAGAA GAACCCGATT	

TABLE 1-continued

Description	Sequence	SEQ ID No
	GATTTCCTGG AGGCGAAGGG TTACAAGGAG GTGAAGAAGG ATCTGATCAT CAAACTGCCC AAGTACTCAC TGTTGGAACG GGAAAATGGT CGGAAGCGCA TGCTGGCTTC GGCCGGAGAA CTCCAGAAAG GAAATGAGCT GGCCTTGCCCT AGCAAGTACG TCAACTTCCT CTATCTTGCT TCGCACTACG AGAACTCAA AGGGTCACCG GAAGATAACG AACAGAAGCA GCTTTTCGTG GAGCAGCACA AGCATTATCT GGATGAAATC ATCGAACAAA TCTCCGAGTT TTCAAAGCGC GTGATCCTCG CCGACGCCAA CCTCGACAAA GTCCTGTCTGG CCTACAATAA GCATAGAGAT AAGCCGATCA GAGAACAGGC CGAGAACATT ATCCACTTGT TCACCTGAC TAACCTGGGA GCTCCAGCCG CCTTCAAGTA CTTGATACT ACTATCGACC GCAAAAGATA CACGTCCACC AAGGAAGTTC TGGACGCGAC CCTGATCCAC CAAAGCATCA CTGGACTCTA CGAAACTAGG ATCGATCTGT CGCAGCTGGG TGGCGATGGT GGCGGTGGAT CCTACCCATA CGACGTGCCT GACTACGCCT CCGGAGGTGG TGGCCCCAAG AAGAAACGGA AGGTGTGATA GCTAGCCATC ACATTTAAAA GCATCTCAGC CTACCATGAG AATAAGAGAA AGAAAATGAA GATCAATAGC TTATTCATCT CTTTTTCTTT TTCGTGGTG TAAAGCCAAC ACCCTGTCTA AAAAAATATA ATTTCTTTAA TCATTTTGCC TCTTTCTCT GTGCTTCAAT TAATAAAAAA TGGAAGAAGC CTCGAGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAGCGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAC CGAAAAAA AAAAAAAAAA AAAAAAA AAAAAAAAAA A	
Single guide RNA targeting SEAP	mC*mU*mC*C CUGAUGGAGA UGACAGGUUU UAGAmGmCmU mAmGmAmAmA mUmAmGmCAA GUUAAAAUAA GGCUAGUCCG UUAUCAmAmC mUmUmGmAmA mAmAmAmGmU mGmGmCmAmC mCmGmAmGmU mCmGmGmUmG mCmUmUmU *mU	8
Single guide RNA targeting mouse TTR	mU*mU*mA*CAGCCACGUCUACAGCAGUUUAGAmGmCmU mAmGmAmAm AmUmAmGmCAAGUUAAAAUAGGCUGUCCGUUAUCAmAm CmUmUmGm AmAmAmAmAmGmUmGmGmCmAmCmCmAmGmUmCmGmGm UmGmCmU* mUmUmU	9
12PA-sequence of an exemplary poly-A tail comprising non-adenine nucleotides with nine sets of 12 consecutive adenosines and mononucleotide interrupting sequences	AAAAAAAAAAATAAAAAAAAAAATAAAAAAAAAAACA AAAAAAAAAAATAAAAAAAAAAACAAAAAAAAAAGAA AAAAAAAAAACAAAAAAAAAATAAAAAAAAAA	10
8PA-sequence of an exemplary poly-A tail comprising non-adenine nucleotides with twelve sets of 8 consecutive adenosines and mononucleotide interrupting sequences	AAAAAAAAAAATAAAAAAAAAAACAAAAAAAAA AAAGAAAAAAAAATAAAAAAACAAAAAACAAAAAAT AAAAAAAGAAAAAACAAAAAATAAAAAA	11
PolyA-1 BclIIa primer annealing sites flanking sequence comprising five interrupting sequences separating six repeats of 12 consecutive adenosines	TCTTCCTTCAGTCTGTAAACCTCAGCTCGAGAAAAA AAATGGAAAAAAAAAACGGAAAAAAAAAAGGTAAAA AAAAAAATATAAAAAAAAAAACATAAAAAAAAAAACG TTCATATCGGTTCTAGACCACACTTCTTACTGAGGTCCC	12

TABLE 1-continued

Description	Sequence	SEQ ID No
PolyA-2 BclIIa primer annealing sites flanking sequence comprising five interrupting sequences separating six sets of 12 consecutive adenosines	TCTTCCTTCAGTCTGTAAACCTCAGAATTCATCTAGCTCG AGAAAAAATTCGAAAAAAAAAAAAACGTAAAAAAAAAAAAAC TCAAAAAAAAAAAGATAAAAAAAAAAACCTAAAAAAAAA AAAAATGTAAAAAAAAAAGGGAAGTCTTCCATATCGGT TCTAGACCACACTTCTTACTGAGGTCCC	13
PolyA-3 BclIIa primer annealing sites flanking sequence comprising five interrupting sequences separating six sets of 12 consecutive adenosines	TCTTCCTTCAGTCTGTAAACCTCAGCTCGAGGAAGACAAG GGAAAAAAAAAACGCAAAAAAAAAAACACAAAAAAAAA AAAAATGCAAAAAAAAAAATCGAAAAAAAAAATCTAAA AAAAAAAAACGTTTATATCGGTTCTAGACCACACTTCTTA CTGAGGTCCC	14
PolyA-4 BclIIa primer annealing sites flanking sequence comprising six interrupting sequences separating seven sets of 12 consecutive adenosines	TCTTCCTTCAGTCTGTAAACCTCAGCTCGAGAAAAATTC GAAAAAAAAAAAAACCAAAAAAAAAAAGCAAAAAAAAAA AAATAGAAAAAAAAAAGTTAAAAAAAAAACTGAAAA AAAAAAATTTAAAAAAAAAAATCTAGACCACACTTCTT ACTGAGGTCCC	15
PolyA 1-2 BclIIa primer annealing sites flanking sequence comprising 11 interrupting sequences separating 12 sets of 12 consecutive adenosines	TCTTCCTTCAGTCTGTAAACCTCAGAATTCATCTAGCTCG AGAAAAAAAAAATGGAAAAAAAAAACGAAAAAAAAA AAAAGGTAAAAAAAAAATATAAAAAAAAAAACATAAA AAAAAAAAACGAAAAAAAAAACGTAAAAAAAAAACT CAAAAAAAAAAAGATAAAAAAAAAAACCTAAAAAAAAA AAATGTAAAAAAAAAAGGGAAGTCTTCCATATCGGTT CTAGACCACACTTCTTACTGAGGTCCC	16
PolyA 3-4 BclIIa primer annealing sites flanking sequence comprising 12 interrupting sequences separating 13 sets of 12 consecutive adenosines	TCTTCCTTCAGTCTGTAAACCTCAGCTCGAGGAAGACAAG GGAAAAAAAAAACGCAAAAAAAAAAACACAAAAAAAAA AAAAATGCAAAAAAAAAAATCGAAAAAAAAAATCTAAA AAAAAAAAACGAAAAAAAAAACCAAAAAAAAAAAGA CAAAAAAAAAAATAGAAAAAAAAAAGTTAAAAAAAAA AAACTGAAAAAAAAAATTTAAAAAAAAAAATCTAGAC CACACTTCTTACTGAGGTCCC	17
300PA sequence of an exemplary poly-A tail comprising 24 interrupting sequences separating 13 repeats of 12 consecutive adenosines	AAAAAAAAAATGGAAAAAAAAAACGAAAAAAAAA AAGGTAAAAAAAAAATATAAAAAAAAAAACATAAAAA AAAAAACGAAAAAAAAAACGTAAAAAAAAAACTCA AAAAAAAAAAGATAAAAAAAAAAACCTAAAAAAAAA ATGTAAAAAAAAAAGGGAAGAAAAAAAAACGCAAAAA AAAAACACAAAAAAAAAATGCAAAAAAAAAAATCGA AAAAAAAAAATCTAAAAAAAAAACGAAAAAAAAA CCCAAAAAAAAAAAGCAAAAAAAAAAATAGAAAAAA AAAAAGTTAAAAAAAAAACTGAAAAAAAAAATTTAA AAAAAAAAA	18
100PA-sequence of an exemplary poly-A tail comprising 97 adenine nucleotide homopolymer	AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAA	19
pUC-M seq2 forward primer	GGGTATTGTCTCATGAGCG	20
pUC-M seq reverse primer	TTTTGTGATGCTCGTCAGGG	21
RN-Ballla for	TCTTCCTTCAGTCTGTAAACCTCAG	22
RN-Bollla rev	GGGACCTCAGTAAGAAGTGTGG	23
Liv-Udepleted: Cas9 mRNA with a poly-A tail consisting of 98 consecutive adenosines	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAAACAGCGT CGGATGGGCAGTCATCACAGACGAATACAAGGTCCCGAGC AAGAAGTTCAGGTCTCTGGGAACACAGACAGACACAGCA TCAAGAAGAACCTGATCGGAGCACTGCTGTTCGACAGCGG AGAAACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAGAAGAACAGAACTGCTACCTGC AGGAAATCTTCAGCAACGAATGGCAAGGTTCGACGACAG CTTCTTCCACAGACTGGAAGAAAGCTTCTCGTTCGAAGAA GACAAGAAGCACGAAGACCCCGATCTTCGGAAACATCG TCGACGAAGTCGCATACCACGAAAGTACCCGACAATCTA	24

TABLE 1-continued

Description	Sequence	SEQ ID No
	CCACCTGAGAAAGAAGCTGGTCGACAGCACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCC GGACAACAGCGACGTCGACAAGCTGTTTCATCCAGCTGGTC CAGACATACAACCAGCTGTTTGAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCCTGAGCGCAAGACT GAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAGCTG CCGGGAGAAAAGAAGACGGACTGTTTCGGAACCTGATCG CACTGAGCCTGGGACTGACACCGAAGCTCAAGAGCAACTT CGACCTGGCAGAAGACGCAAGCTGCGAGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTGCTGGCAGATCG GAGACCGGTACGCGAGACCTGTTCTGCCAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCTGAGAGTCAAC ACAGAAATCACAAGGACCCGCTGAGCGCAAGCATGATCA AGAGATACGACGAAACACCAAGGACCTGACACTGCTGAA GGCACTGGTCAGACAGCAGCTGCCGAAAAGTACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGCAAGGATACA TCGACGGAGGAGCAAGCAGGAAAGAACTTCAAGATTCTAT CAAGCCGATCTTGAAAAGATGGACGGAACAGAAAGAACTG CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAAGCAGA GAACATTCGACAACGGAAGCATCCCGCAGCAGATCCACCT GGGAGAACTGCACCAATCTGAGAAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAACAGAGAAAAGATCGAAAAGA TCCTGACATTCAGAATCCCGTACTACGTGCGACCGCTGGC AAGAGGAAACAGCAGATTCGCATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGGAACTTCGAAGAAGTCGTCG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAGAATGAC AAATTCGACAAGAACCTGCCGAACGAAAAGGTCTGCCG AAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTACAGAAAGGAATGAGAAA GCCGGCATCTCTGAGCGGAGAACAGAAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCGTCGAATCAGCGGAGTCGAAGACAGATTCAACGCA AGCTGGGAACATACCACGACCTGCTGAAGATCATCAAGG ACAAGGACTTCCTGGACAACGAAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT TCGACGCAAGGTATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAATCTGGACTTCC TGAAGAGCGACGGATTTCGCAACAGAAACTTCATGCACT GATCCACGACGACAGCCTGACATTCGAAGGAAGACATCCAG AAGGCACAGGTCAAGCGACAGGAGACAGCCTGCACGAAC ACATCGCAAACCTGGCAGGAAGCCCGCAATCAAGAAGGG AATCTTCGACAGCTCAAGGTCGTCGACGAAGTGGTCAAG GTCATGGGAAGACACAAGCCGAAAACATCGTTCATCGAAA TCGCAAGAGAAAAACACACAACAGAAAGGACAGAAAGAA CAGCAGAGAAGAAATGAAGAGAATCGAAGAAGGAATCAAG GAACTGGGAAGCCAGATCCTGAAGGAACCCCGGTGCAAAA ACACACAGCTGCGAAGCAAGAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTGACACAGGAAGTGGAC ATCAACAGACTGAGCGACTACGACGTGACCCACATCGTCC CGCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAAC GTCCCGAGCGAAGAAGTCTCAAGAAGATGAAGAACTACT GGAGACAGCTGCTGAACGCAAGCTGATCACACAGAGAAA GTTCGACAACCTGACAAGGCGAGAGAGGAGGACTGAGC GAACTGGACAAGGCGAGATTATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAGCAAGTCGCACAGATCCTGGA CAGCAGAAATGAACACAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTATCACACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCAGTTCTACAAGGTGAG AGAAATCAACAATACCACACGACACGACGATACCTTG AACGAGTCTGCGAAGACGACTGATCAAGAAGTACCCGA AGCTGGAAAGCGAATTCGTCTACGAGACTACAAGGTCTA CGACGTGAGAAAGATGATCGCAAGAGCGAACGGAATC GGAAAGGCAACAGCAAAGTACTTCTTACAGCAACATCA TGAATCTCTCAAGACAGAAATCACACTGGCAACCGGAGA AATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCGTCTGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCTGAGCATGCCGAGGTCAACATCGTCAA GAAGACAGAAGTCCAGACAGGAGGATTGAGCAAGGAAAGC ATCTTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAA AGAAGGACTGGGACCGAAGAAGTACGAGGAGATTGACAG CCCGACAGTCGCATACAGCGTCTGGTCTGCGCAAGGTC	

TABLE 1-continued

Description	Sequence	SEQ ID No
	GAAAAGGGAAAGAGCAAGAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCCTGGAAGCAAAGGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCAAGTACAGCC TGTTCGAAGTGGAAAAACGGAAGAAGAGAATGCTGGCAAG CGCAGGAGAACTGCAGAAGGGAACGAACTGGCACTGCCG AGCAAGTACGTCAACTTCCTGTACCTGGCAAGCCACTACG AAAAGCTGAAGGGAAGCCCGGAAGACAACGAAACAGAAGCA GCTGTTCTGTGAAACAGCACAAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTACGCAAGAGAGTATCCTGG CAGACGCAAACTGGACAAGTCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAAACATC ATCCACCTGTTTACACTGACAACCTGGGAGCACCAGCAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCACAGGACTGTACGAACACAAGATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGAA GAGAAAAGTCTAGCTAGCCATCACATTAAAAGCATCTCA GCCTACCATGAGAATAAGAGAAGAAAATGAAGATCAATA GCTTATTCATCTCTTTTCTTTTCTGTTGGTGTAAAGCCA ACACCTGTCTAAAAAACATAAATTTCTTTAATCATTGTG CCTCTTTCTCTGTGCTTCAATTAAATAAAATGGAAAGA ACCTCGAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAA AAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAA AAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAA	
Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 3	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTCTGTGACGGCTTATTTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCEGAACAAACAGCGT CGGATGGGCAGTCAACAGAGCAATACAAGGTCCCGAGC AAGAAGTTCAGGTCTGGGAAACACAGACAGACACAGCA TCAAGAAGAACCTGATCGGAGCACTGCTGTTTCGACAGCGG AGAAACAGCAGAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAAGAAAGACAGAAATCTGTACCTGC AGGAAATCTTCAGCAACGAAATGGCAAAGGTGACGACAG CTTCTTCCACAGACTGGAAGAAAGCTTCCTGGTCTGAAGAA GACAAGAAGCACGAAAGACCCGATCTTCGGAACATCG TCGACGAAGTCGCATACCACGAAAGTACCCGACAATCTA CCACCTGAGAAAGAGCTGGTTCAGACGACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCC GGACAACAGCGACGTGACAAAGCTGTTTCATCCAGCTGGTC CAGACATACAACAGCTGTTCTGAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCTGAGCGCAAGACT GAGCAAGAGCAGAAAGACTGGAACCTGATCGCACAGCTG CCGGGAGAAAAGAAAGACGCACTGTTTCGAAACCTGATCG CACTGAGCCTGGGACTGACACCGAATTCAGAGCAACTT CGACCTGGCAGAAAGACGCAAGCTGACGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTGCTGGCACAGATCG GAGACCAGTACGACAGCTGTTCTGGCAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCCTGAGAGTCAAC ACAGAAATCACAAAGGCAACCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCACGAGACCTGACACTECTGAA GGCCTGGTCAGACAGCAGCTGCCGAAAAGTACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGCAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAATTCTACAAGTTTCAT CAAGCCGATCCTGGAAAAGATGGACGGAACAGAAAGACTG CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAGCAGA GAACATTCCACAACGGAAGCATCCCGACCCAGATCCACCT GGGAGAACTGCACGCAATCCTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAAACAGAGAAAGATCGAAAAGA TCCTGACATTTCAGAAATCCCGTACTACGTCCGACCGCTGGC AAGAGGAAAACAGCAGATTTCGATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGAAGCTTCGAAGAAGTCGTCTG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAATGAC AAATTCGACAAGAACCTGCCGAAACGAAAAGGTCCTGCCG AAGCACAGCTGCTGTACGAATACTTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAA GCCGGCATTCTGAGCGGAGAAACAGAAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCTCGAATCAGCGGAGTCGAAGACAGATTCAACGCA AGCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGG ACAAGGACTTCCTGGACAACGAGAAAACGAAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT	25

TABLE 1-continued

Description	Sequence	SEQ ID No
	TCGACGACAAGGTCATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAATCCTGGACTTCC TGAAGAGCGACGGATTTCGCAAAACAGAACTTCATCCAGCT GATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAG AAGGCACAGGTCAGCGGACAGGGAGACAGCCTGCACGAAC ACATCGCAAACTGGCAGGAAGCCCGCAATCAAGAAGGG AATCCTGCAGACAGTCAAGGTCGTCGACGAACCTGGTCAAG GTCATGGGAAGACACAAGCCGGAACATCGTCATCGAAA TGGCAAGAGAAAACAGACACACAGAAGGGACAGAAGAA CAGCAGAGAAAAGATGAAGAGAATCGAAGAAGGAATCAAG GAAC TGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAAA ACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTCGACAGGAACCTGGAC ATCAACAGACTGAGCGACTACGACGTCGACCACATCGTCC CGCAGAGCTTCTCTGAAGGACGACAGCATCGACACAAAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGCAAC GTCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAATACT GGAGACAGCTGCTGAACGCAAGCTGATCAGACAGAGAAA GTTTCGACAACCTGACAAGGACAGAGAGGAGGACTGAGC GAAC TGGACAAGGCAGGATT CATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAAGCAGCTCGCACAGATCCTGGA CAGCAGAATGAACACAAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTCATCACACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCTAG AGAAATCAACAATACCAACACGACACGACGATACCTTG AACGCAGTCGTGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAGCGAATTCGTCTACGGAGACTACAAGGTCTA CGACGT CAGAAAGATGATCGCAAGAGCGAACAGGAAATC GGAAAGGCAACAGCAAAAGTACTTCTTACAGCAACATCA TGAACTTCTTCAAGACAGAAATCACACTGGCAACCGAGA AATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCCTGAGCATGCCGAGETCAACATCGTCAA GAAGACAGAAGTCCAGACAGGAGGATT CAGCAAGGAAAGC ATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAA AGAAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAG CCCGACAGTCGCATACAGCGTCTGTGTCGCAAGGTC GAAAAGGGAAGAGCAAGAAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCTGGAAGCAAAGGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCC TCTTCGAAC TGGAAAACGGAAGAAAGAGAATGCTGGCAAG CGCAGGAGAATGCAGAAAGGGAACGAACTGGCACTGCCG AGCAAGTACGTCAACTTCTGTACTTGGCAAGCACTACG AAAAGCTGAAGGGAAGCCCGAAGACAAACGACAGAAGCA GCTGTTCTGTCGAACAGCACAAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTCAGCAAGAGAGTCATCCTGG CAGACGCAAACTGGACAAGGTCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAACATC ATCCACCTETTCACACTGACAAACCTGGGAGCACCCGCGAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCAGGACTGTACGAAACAGAATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCGAAGAAGAA GAGAAAGGTCTAGCTAGCCATCACATTTAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATA GCTTATTCTCTCTTTTCTTTTCTGTTGGTGTAAAGCCA ACACCCCTGTCTAAAAACATAAAATTTCTTAATCATTTTG CCTCTTTTCTCTGTGCTCAATTAATAAAAAATGGAAAGA ACCAAAAAAAAAAAAAAAAAAAAAAAAAAGCGAAAAAAAAAA AAAAAAAAAAAAAAAAAACCGAAAAAAAAAAAAAAAAAAAAA AAAAGTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	
Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 4	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTCGTTTCAGGCTTATTTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAAACAGCGT CGGATGGGCAGTCATCAGACGAATACAAGGTCCCGAGC AAGAAGTTCAGGTCCTGGGAAACACAGACAGACACAGCA TCAAGAAGAACCTGATCGGAGCACTGCTGTCGACAGCGG AGAAACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAGAAGAACAGAATCTGCTACCTGC AGGAAATCTTCAGCAACGAATGGCAAGGTTCGACAGCAG CTTCTTCCACAGACTGGAAGAAGCTTCTGCTCGAAGAA GACAAGAAGCACGAAGACACCCGATCTTCGGAACATCG TCGACGAAGTCGATACCAAGCAAGTACCCGACAATCTA	26

TABLE 1-continued

Description	Sequence	SEQ ID No
	CCACCTGAGAAAGAAGCTGGTCGACAGCACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCC GGACAACAGCGACCTCGACAAGCTGTTTCATCCAGCTGGTC CAGACATACAACCAGCTGTTTCGAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCCTGAGCGCAAGACT GAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAGCTG CCGGGAGAAAAGAAGACGGACTGTTTCGGAACCTGATCG CACTGAGCCTGGGACTGACACCGAAGCTCAAGAGCAACTT CGACCTGGCAGAAGACGCAAGCTGCAGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTGCTGGCACAGATCG GAGACCAAGTACGACAGACCTGTTCTEGCAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCCTGAGAGTCAAC ACAGAAATCACAAGGACCCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCACAGGACCTGACACTECTGAA GGCACTGGTCAGACAGAGCTGCCGAAAAGTACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGCAAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAAATCTACAAGTTTCA CAAGCCGATCCTGGAAAAGATGGACGGAACAGAAAGAACTG CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAAGCAGA GAACATTCGACAACGGAAGCATCCCCACCAAGATCCACCT GGGAGAACTGCACCAATCTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAACAGAGAAAAGATCGAAAAGA TCCTGACATTCAGAATCCCGTACTACGTGCGACCGCTGGC AAGAGGAAACAGCAGATTCGCATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGGAACTTCGAAGAAGTCGTG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAGAAGTGAC AAATTCGACAAGAACCTGCCGAACGAAAAGGTCTGCCG AAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTACAGAAGGAATGAGAAA GCCGGCATTCTGAGCGGAGAACAGAAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCGTCGAATCAGCGGAGTCGAAGACAGATTCAACGCA AGCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGG ACAAGGACTTCCTGGACAACGAAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT TCGACGCAAGGTATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAATCCTGGACTTCC TGAAGAGCGACGGATTTCGCAACAGAAACTTCATGCACT GATCCACGACGACAGCCTGACATTCGAAGGAAGACATCCAG AAGGCACAGGTCAAGCGACAGGAGACAGCCTGCACGAAC ACATCGCAAACCTGGCAGGAAGCCCGCAATCAAGAAGGG AATCCTGCAGACAGTCAAGGTCGTGACGAAGTGGTCAAG GTCATGGGAAGACACAAGCCGGAACATCGTTCATCGAAA TGGCAAGAGAAAAACAGACAAACAGAAAGGACAGAAAGAA CAGCAGAGAAGAAATGAAGAGAATCGAAGAAGGAATCAAG GAACTGGGAAGCCAGATCCTGAAGGAACCCCGGTGCAAAA ACACACAGCTGCGAAGACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTGACACAGGAAGTGGAC ATCAACAGACTGAGCGACTACGACGTGACCCACATCGTCC CCCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAAC GTCCCGAGCGAAGAAGTCTCAAGAAGATGAAGAACTACT GGAGACAGCTGCTGAACGCAAGCTGATCACACAGAGAAA GTTCGACAACCTGACAAGGCAGAGAGAGGAGGACTGAGC GAACTGGACAAGGCAGGATTATCAAGAGACAGCTGGTTCG AAACAAGACAGATCACAAGCAAGTCGCACAGATCCTGGA CAGCAGAAATGAACACAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTATCACACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCAGTTCTACAAGGTGAG AGAAATCAACAATACCACCACGACACGACGCATACCTG AACGCACTCGTTCGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAAGCGAATTCGTCTACGAGACTACAAGGTCTA CGACGTGAGAAAGATGATCGCAAGAGCGAACAGGAAATC GGAAAGGCAACAGCAAAGTACTTCTTACAGCAACATCA TGAATCTCTCAAGACAGAAATCACACTGGCAACCGGAGA AATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCGTCTGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCTGAGCATGCCGAGGTCAACATCGTCAA GAAGACAGAAGTCCAGACAGGAGGATTGAGCAAGGAAAGC ATCTTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAA AGAAGGACTGGGACCGAAGAAGTACGAGGAGATTGACAG CCCGACAGTCGCATACAGCGTCTGGTCTGCGCAAGGTTC	

TABLE 1-continued

Description	Sequence	SEQ ID No
	GAAAAGGGAAAGAGCAAGAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCCTGGAAGCAAAGGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCAAGTACAGCC TGTTCGAACTGGAACCGGAAGAAGAGAATGCTGGCAAG CGCAGGAGAACTGCAGAAGGGAACGAACTGGCACTGCCG AGCAAGTACETCAACTTCCTGTACCTGGCAAGCCACTACG AAAAGCTGAAGGGAAGCCCGGAAGACAACGAAACAGAAGCA GCTGTTCTGTCGAACAGCACAAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTCAAGCAAGAGAGTATCCTGG CAGACGCAAACTGGACAAGTCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAAACATC ATCCACCTGTTCACTAGACAACCTGGGAGCACCAGCAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCAGAGACTGTACGAACACAAGATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGAA GAGAAAGGTCTAGCTAGCCATCACATTAAAAGCATCTCA GCCTACCATGAGAATAAGAGAAGAAAATGAAGATCAATA GCTTATTCATCTCTTTTCTTTTCTTTTCTTTTGGTGTAAAGCCA ACACCTGTCTAAAAAACATAAATTTCTTTAATCATTGTG CCTCTTTCTCTGTGCTTCAATTAAATAAAATGGAAGA ACCAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAACAAAAAAAAAAAAAAAAAAAA	
Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 5	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTCTGTGTCAGGCCTTATTTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAAACAGCGT CGGATGGGCAGTCATCACAGACGAATACAAGGTCCCGAGC AAGAAGTTCAGGTCTGGGAAACACAGACAGACACAGCA TCAAGAAGAACCTGATCGGAGCACTGCTGTTTCGACAGCGG AGAAACAGCAGAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAGAAAGACAGAATCTGTACCTGC AGGAAATCTTCAGCAACGAAATGGCAAAGGTGACGACAG CTTCTTCCACAGACTGGAAGAAAGCTTCCTGGTCTGAAGAA GACAAGAAGCACGAAAGACCCGATCTTCGGAACATCG TCGACGAAGTCGCATACCACGAAAAGTACCCGACAATCTA CCACCTGAGAAAGAGCTGGTTCAGCAGCAGACAGCAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCC GGACAACAGCGACGTGACAAAGCTGTTTCATCCAGCTGGTC CAGACATACAACAGCTGTTCTGAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCTGAGCGCAAGACT GAGCAAGAGCAGAAAGACTGGAACCTGATCGCACAGCTG CCGGGAGAAAAGAAAGACGGAAGTTCGGAACCTGATCG CACTGAGCCTGGGACTGACACCGAATTCAGAGCAACTT CGACCTGGCAGAAAGACGCAAGCTGACGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTGCTGGCACAGATCG GAGACCAGTACGACAGCTGTTCTGCGAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCCTGAGAGTCAAC ACAGAAATCACAAAGGCACCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCACAGGACCTGACACTGCTGAA GGCCTGGTCAGACAGCAGCTGCCGAAAAGTACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGCAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAATTCTACAAGTTCAT CAAGCCGATCCTGGAAAAGATGGACGGAACAGAAGAACTG CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAGCAGA GAACATTCGACAACCGGAAGCATCCCGACCCAGATCCACCT GGGAGAACTGCACGCAATCCTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAAACAGAGAAAAGATCGAAAAGA TCCTGACATTGCAATCCCGTACTACGTCCGACCGCTGGC AAGAGGAAAACAGCAGATTCCCATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGAAGCTTCGAAGAAGTCGTCTG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAATGAC AAATTCGACAAGAACCTGCCGAAACGAAAAGGTCTGCCG AAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAA GCCGGCATTCCTGAGCGGAGAAACAGAAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCTCGAATCAGCGGAGTCGAAGACAGATTCAACGCA AGCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGG ACAAGGACTTCCTGGACAACGAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT	27

TABLE 1-continued

Description	Sequence	SEQ ID No
	TCGACGACAAGGTCATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAATCCTGGACTTCC TGAAGAGCGACGGATTTCGCAAAACAGAACTTCATGCAGCT GATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAG AAGGCACAGGTCAGCGGACAGGGAGACAGCCTGCACGAAC ACATCGCAAACTGGCAGGAAGCCCGCAATCAAGAAGGG AATCCTGCAGACAGTCAAGGTCGTCGACGAACCTGGTCAAG GTCATGGGAAGACACAAGCCGGAACATCGTCATCGAAA TGGCAAGAGAAAACAGACACACAGAAGGGACAGAAGAA CAGCAGAGAAAAGATGAAGAGAATCGAAGAAGGAATCAAG GAAC TGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAAA ACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTCGACAGGAACCTGGAC ATCAACAGACTGAGCGACTACGACGTCGACCACATCGTCC CCCAGAGCTTCTTGAAGGACGACAGCATCGACACAAAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGCAAC GTCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAATACT GGAGACAGCTGCTGAACGCAAGCTGATCAGACAGAGAAA GTTTCGACAACCTGACAAGGACAGAGAGGAGGACTGAGC GAAC TGGACAAGGCAGGATT CATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAAGCAGCTCGCACAGATCCTGGA CAGCAGAATGAACACAAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTCATCACACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCAG AGAAATCAACAATACCACCACGACACGACGATACCTTG AACGCAGTCGTGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAGCGAATTCGTCTACGGAGACTACAAGGCTCA CGACGTGAGAAAGATGATCGCAAGAGCGAACAGGAAATC GGAAAGGCAACAGCAAGTACTTCTTACAGCAACATCA TGAACTTCTTCAAGACAGAAATCACACTGGCAACCGAGA AATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCETCTGGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCCTGAGCATGCCGAGGTCAACATCETCAA GAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAGC ATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAA AGAAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAG CCCGACAGTCGCATACAGCGTCTGGTCGTCGCAAGGTC GAAAAGGGAAGAGCAAGAAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCTGGAAGCAAAGGGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCC TGTTTCAACTGGAACCGGAAGAAAGAGAAATGCTGGCAAG CGCAGGAGAACTGCAGAAGGGAACGAACTGGCACTGCCG AGCAAGTACGTCAACTTCTGTACTGGCAAGCCTACG AAAAGCTGAAGGGAAAGCCCGAAGACAAACGACAGAAGCA GCTGTTCTGTCGAACAGCACAAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTCAGCAAGAGAGTCATCCTGG CAGACGCAAACTGGACAAGGTCCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAACATC ATCCACCTGTTCACTGACAAACCTGGGAGCACCCGCGAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCAGAGACTGTACGAAACAGAATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCGGAAGAAGAA GAGAAAGGTCTAGCTAGCCATCACATTTAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATA GCTTATTCTCTCTTTTCTTTTTCGTTGGTGTAAAGCCA ACACCCCTGTCTAAAAACATAAATTTCTTTAATCATTTTG CCTCTTTTCTCTGTGCTCAATTAATAAAAAATGGAAGA ACCAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAAAAAA AA AA AAAAAAAA	
Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 10	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAACACAGCGT CGGATGGGAGTCTACACAGACGAATACAAGGTCCCGAGC AAGAAGTTCAAGGTCCTGGGAAACACAGACAGACACAGCA TCAAGAAGAACCCTGATCGGAGCACTGCTGTTTCAGACGCG AGAAACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAGAAAGAACAGAAATCTGCTACCTGC AGGAAATCTTCAGCAACGAATGGCAAGGTCGACGACAG CTTCTTCCACAGACTGGAAGAAGCTTCTGGTTCGAAGAA	28

TABLE 1-continued

Description	Sequence	SEQ ID No
	GACAAGAAGCACGAAAGACACCCGATCTTCGGAAACATCG TCGACGAAGTCGCATACCACGAAAAGTACCCGACAACTCA CCACCTGAGAAAGAAGCTGGTCGACGACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTCAGAGGACACTTCTGTATCGAAGGAGACCTGAACCC GGACAACAGCGACGTGACAAAGCTGTTTCATCCAGCTGGTC CAGACATACAAACAGCTGTTTGAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAAGGCAATCTGAGCGCAAGACT GAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAGCTG CCGGGAGAAAAGAAACGGACTGTTTCGGAACCTGATCG CACTGAGCCTGGGACTGACACCGAAGTTCAAGAGCAACTT CGACCTGGCAGAAGACGCAAGCTGACGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTECTGGCACAGATCG GAGACCAAGTACGACAGACCTGTTCTGGCAGCAAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCTTGAGAGTCAAC ACAGAAATCACAAAGGCACCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCCAGGACCTGACACTGTGTGAA GGCACTGGTCAGACAGCAGCTGCCGGAAGTACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGCAAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAACTTACAAGTTTCAT CAAGCCGATCTTGGAAAAGATGGACGGAACAGAAGAACTG CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAGCAGA GAACATTCGACAAACGGAAGCATCCCGCACCAGATCCACCT GGGAGAACTGCACGCAATCTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAAAGAGAAAAGATCGAAAAGA TCCTGACATTCAGAATCCCGTACTACGTCGGACCGCTGGC AAGAGGAAAACAGCAGATTTCGATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGGAACTTCGAAGAAGTCGTCG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAAATGAC AAACTTCGACAAGAACCTGCCGAACGAAAAGGTCTTCCCG AAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTACAGAAAGGAATGAGAAA GCCGGCATTCTTGAGCGGAGAAAGAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAAAGAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCGTCGAAATCAGCGGAGTCAAGACAGATTCAACGCA AGCCTGGGAACATACACGACCTGCTGAAGATCATCAAGG ACAAGGACTTCTTGGACAACGAAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGACACCTGT TCGACGACAAGGTTCATGAAGCAGTGAAGAGAAGAGATA CACAGGATGGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAGACAACTCTGGACTTCC TGAAGAGCGACGGATTTCGAAAACGAAACTTCATCCAGCT GATCCACGACGACAGCCTGACATTCAGGAAGACATCCAG AAGGCAACAGGTGAGCGGACAGGGAGACAGCTGCACGAAC ACATCGCAAACTTGGCAGGAAGCCCGCAATCAAGAAGGG AATCCTGCAGACAGTCAAGGTGTCGACGAAGTGGTCAAG GTCTGGAAGACACAAGCCGGAACATCGTTCATCGAAA TCGCAAGAGAAAAACGACAAACAGAAAGGACAGAAGAA CAGCAGAGAAGAAATGAAGAGAACTCGAAGAAAGGAATCAAG GAATGGGAAGCCAGATCTTGAAGGAACACCCGTCGAAA ACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTGACCGAAGAACTGGAC ATCAACAGACTGAGCGACTACGACGTGACCCACATCGTCC CGCAGAGCTTCTTGAAGGACGACAGCATCGACAACAGGT CCTGACAAGAAAGCAGCAAGAACAGAGGAAAGAGCGACAAC GTCCCGAGCGAAGAGTCTGTAAGAAGATGAAGAACTACT GGAGACAGCTGCTGAACGCAAGCTGATCACACAGAGAAA GTTTCGACAACCTGACAAAGGCAGAGAGAGGAGGACTGAGC GAATGGACAAGGCAGGATTTCATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAAGCAGTCGACACAGATCCTGGA CAGCAGAATGAACACAAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTTCATCACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTTCAG AGAAATCAACAACCTACCACACGACACGACGATACCTG AACGCAGTCTGTCGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAAGCGCAATTCGTCTACGGAGACTACAAGGTCTA CGACGTGAGAAAGATGATCGCAAGAGCGAAGAGGAAATC GGAAAGGCAACAGCAAAGTACTTCTTACAGCAACATCA TGAATTTCTTCAAGACAGAAATCACACTGGCAACCGGAGA AATCAGAAAGAGACCGCTGATCGAAAACAAACGGAGAAACA GGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCTGAGCATGCCGAGGTCAACATCGTCAA GAAGACAGAAGTTCAGACAGGAGGATTACGCAAGGAAAGC ATCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAA	

TABLE 1-continued

Description	Sequence	SEQ ID No
	AGAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAG CCCGACAGTCGCATACAGCGTCTGGTCTGCGCAAAGGTC GAAAAGGGAAGAGCAAGAAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACATCATGGAAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCTTGAAGCAAAGGGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCC TGTTCGAACTGGAACGGAAGAAGAGAATGCTGGCAAG CGCAGGAGAACTGCAGAAGGGAACGAAC'TGGCACTGCCG AGCAAGTACGTCAACTTCTGTACTTGGCAAGCCACTACG AAAAGCTGAAGGGAGCCCGAAGACAAACGAACAGAAGCA GCTGTTCTGTCGACAGCACAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTGAGCAAGAGAGTATCCTGG CAGACGCAAACTGGACAAGGTCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAAATC ATCCACCTGTTCACTGACAACTGGGAGCACCCGCAG CATTCAAGTACTTCGACACACATTCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCACAGGACTGTACGAACAGAATCGACCTGA GCCAGCTGGGAGGAGACGGAGGGAAGCCCGAAGAGAA GAGAAAGGTCTAGCTAGCCATCACATTTAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAATGAAGATCAATA GCTTATTCATCTCTTTTCTTTTCTGTTGGTGAAGCCA ACACCCCTGTCTAAAAACATAAATTTCTTTAATCATTTTG CCTTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAGA ACCAAAAAATAAATAAATAAATAAATAAATAAATAA ACAAAAAAATAAATAAATAAATAAATAAATAAATAA GAAAAAATAAATAAATAAATAAATAAATAAATAA	
Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 11	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTGTTGCAAGGCTTATTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAACAGCGT CGGATGGGAGTCATCACAGACGAATACAAGTCCCAGAGC AAGAAGTTCAGGTCTGGGAAACACAGACAGACACAGCA TCAAGAAGAACCTGATCGGAGCACTGCTGTTGACAGCGG AGAAACAGCAGAAGCAACAAGACTGAAGAGAACASCAAGA AGAAGATACACAAGAAGAAAGAACAGAATCTGCTACCTGC AGGAAATCTTCAGCAACGAATGGCAAAGTTCGACGACAG CTTCTTCCACAGACTGGAAGAAAGCTTCTGGTCAAGAA GACAAGAAGCACGAAGACACCCGATCTTCGGAACATCG TCGACGAAGTCGCATACCACGAAAGTACCCGACAATCTA CCACCTGAGAAAGAGCTGGTTCGACAGCACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTCAAGGACACTTCTGATCGAAGGAGACCTGAACCC GGACAACAGCGACGTCGACAAGCTGTTTCATCCAGCTGGTC CAGACATACAACCAGCTGTTTCAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCCTGAGCGCAAGACT GAGCAAGAGCAGAAGACTGGAACAACTGATCGCACAGCTG CCGGGAGAAAAGAAAGACGGACTGTTTGGAAACCTGATCG CACTGAGCTGGGACTGACACCGAATTCAGAGCAACTT CGACCTGGCAGAAGACGCAAGCTGCAAGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTGCTGGCACAGATCG GAGACCAGTACGCAGACCTGTTCTGGCAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCTGAGAGTCAAC ACAGAAATCACAAAGGCAACCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCACAGGACCTGACACTECTGAA GGCACTGGTCAGACAGCAGCTGCCGGAAGATACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGCAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAAATCTACAAGTTCAT CAAGCCGATCCTGGAAGAGATGGACGGAACAGAAGAACTG CTGGTCAAGCTGAACAGAGAAGACTGCTGAGAAAGCAGA GAACATTCGACAACGGAAGCATCCCGACCAAGATCCACCT GGGGAACTGCACGCAATCTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAACAGAGAAAAGATCGAAAAGA TCCTGACATTGAAATCCCGTACTACGTGCGACCGCTGGC AAGAGGAAAACAGCAGATTGCGATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGGAATTCGAAGAGTCGTGCG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAAATGAC AAATTCGACAAGAACTGCCGAACGAAAAGGTCCTGCCG AAGCACAGCTGCTGTACGAATACTTACAGTCTACAACG AACTGACAAAGGTCAAGTACGTACAGAAGGAATGAGAAA GCCGGCATTCTGAGCGGAGAACAGAAGAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCGTCGAAATCAGCGAGTCGAAGACAGATTCAACGCA ACAAGGACTTCTTGACAACGAAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTGAAGACAGA	29

TABLE 1-continued

Description	Sequence	SEQ ID No
	GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT TCGACGACAAGGT CATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGGAAGACTGAGCAGAAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAACTCTGGACTTCC TGAAGAGCGACGGATTTCGCAACAGAACTTCATCCAGCT GATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAG AAGGCACAGGT CAGCGCAGAGGAGACAGCTGCACGAAC ACATCGCAAACTGGCAGGAAGCCCGCAATCAAGAAGGG AATCCTGCAGACAGT CAAGGTCTGTCGACGAAGTGGTCAAG GTCATGGGAAGACACAAGCCGGAACATCGTCATCGAAA TGGCAAGAGAAAAACAGACAACAGAAAGGGACAGAAGAA CAGCAGAGAAAAGAAATGAAGAGAATCGAAGAAGGAATCAAG GAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAAA ACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTGACACGGAAGTGGAC ATCAACAGACTGAGCGACTACGACGTGACACACATCGTCC CGCAGAGCTTCTTGAAGGACGACAGCATCGACAACAAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAAC GTCCCGAGCGAAGAAGTCTGTCAGAAAGATGAAGAACTACT GGAGACAGCTECTGAACGCAAAAGCTGATCACACAGAGAAA GTTCGACAACCTGACAAGGCAGAGAGAGGAGGACTGAGC GAACTGGACAAGGCAGGATT CATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAAGCAGTTCGCACAGATCTGGGA CAGCAGAATGAACACAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGT CATCACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCTAG AGAAATCAACAAC TACCACCACGCACACGACGCATACCTG AACGCAGTCTGTCGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAAGCGAATTCTGTCACGGAGACTACAAGGTCTA CCAGTCAGAAAGATGATCCCAAGAGCGAACAGGAAATC GGAAGGCAACAGCAAAGTACTTCTTACAGCAACATCA TGAATCTCTTCAAGACAGAAATCACACTGGCAACCGGAGA AATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCTGTCGGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCTGAGCATGCCGAGGTCAACATCTGTCAA GAAGACAGAAAGTCCAGACAGGAGGATTCAGCAAGGAAAGC ATCTTGCCGAAGAGAAAACAGCGACAAGCTGATCGCAAGAA AGAAGGACTGGGACCCGAAGAAGTACGGAGGATTTCGACAG CCCGACAGTCGCATACAGCTCTGCTGTCGCAAGGTCT GAAAAGGGAAGAGCAAGAAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCTGGAAGCAAGGGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCC TGTTCGAACTGGAACCGGAAGAAAGAGAAATGCTGGCAAG CGCAGGAGAACTGCAGAAAGGGAACGAACTGGCACTGCCG AGCAAGTACGTCAACTTCTGTACTTGGCAAGCCACTACG AAAAGCTGAAGGGAAGCCCGGAAGACAACGAACAGAAAGCA GCTGTTCTGTCGAACAGCACAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTCAGCAAGAGAGT CATCTGG CAGACGCAAACTGGACAAGGTCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAAATC ATCCACCTGTTCACACTGACAACCTGGGAGCACCCGCAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCACAGGACTGTACGAAACAAGAAATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGAA GAGAAAGGTCTAGCTAGCCATCACATT TAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATA GCTTATTCATCTCTTTTCTTTTCTGTTGGTGTAAAGCCA ACACCTGTCTAAAAAACATAAATTTCTTTAATCATTTTG CCTCTTTCTCTGTGCTTCAATTAAATAAAAAATGGAAGA ACCAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA GAGAAAGGTCTAGCTAGCCATCACATT TAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATA AAAAAAGAAAAAATAAAAAACAACAAAAAACAACAAA AATAAAAAAAGAAAAAACAACAAAAAATAAAAAA	
Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 19	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT GTGTCTGTCAGGCTTATTTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAACAGCGT CGGATGGGCAGTCATCACAGACGAATACAAGGTCCCAGC AAGAAGTTCAAGGTCTGGGAAACACAGACAGACACAGCA TCAAGAAGAACCTGATCGGAGCACTGCTGTCGACAGCGG AGAAACAGCAGAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAGAAAGAACAGAATCTGCTACCTGC AGGAATCTTCAGCAACGAAATGGCAAGGTGACGACGACG	30

TABLE 1-continued

Description	Sequence	SEQ ID No
	CTTCTTCCACAGACTGGAAGAAAGCTTCTGGTCTGAAGAA GACAAGAAGCACGAAAGACACCCGATCTTCGGAACATCG TCGACGAAGTCGCATACACGAAAAGTACCCGACAATCTA CCACCTGAGAAAGAAGCTGGTCGACAGCACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCC GGACAACAGCGACGCTCGACAAGCTGTTTCATCCAGCTGGTC CAGACATACAACCAGCTGTTCTGAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCCTGAGCGCAAGACT GAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAGCTG CCGGGAGAAAAGAAGACGGACTGTTTCGGAACCTGATCG CACTGAGCCTGGGACTGACACCGAATTCAAGAGCAACTT CGACCTGGCAGAAGACGCAAGCTGCAGCTGAGCAAGGAC ACATACGACGACGACCTGGACAACCTGCTGGCACAGATCG GAGACCGTACGACAGACCTGTTCTGGCAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCTGAGAGTCAAC ACAGAAATCACAAGGCAACCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCAAGGACCTGACACTGCTGAA GGCACTGGTCAGACAGCAGCTGCCGAAAAGTACAAGGAA ATCTTCTTCGACCAGAGCAAGAACGGATACGACAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAAATCTACAAGTTCAT CAAGCCGATCTTGAAAAGATGGACGGAACAGAAGAACTG CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAGCAGA GAACATTCGACAACGGAAGCATCCCGCACCAGATCCACCT GGGAGAAGCTGCACGAATCTTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAACAGAGAAAAGATCGAAAAGA TCCTGACATTCAGAATCCCGTACTACGTGCGACCGCTGGC AAGAGGAAAACAGCAGATTCGCATGGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGGAACTTCGAAGAAGTCGTCTG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAGAATGAC AAACCTCGACAAGAACCTGCCGAACGAAAAGGTCTGCCG AAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTACAGAAGGAATGAGAAA GCCGGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCGTCGAAATCAGCGGAGTCGAAGACAGATTCAACGCA AGCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGG ACAAGGACTTCCTGGACAACGAAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT TCGACGCAAGGTATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAATCCTGGACTTCC TGAAGAGCGACGGATTTCGCAACAGAAACTTCATGCACT GATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAG AAGGCACAGGTCAAGCGACAGGAGACAGCCTGCACGAAC ACATCGCAAACCTGGCAGGAAGCCCGCAATCAAGAAGGG AATCCTGCAGACAGTCAAGGTCGTCGACGAACCTGGTCAAG GTCATGGGAAGACACAAGCCGAAAACATCGTCATCGAAA TGGCAAGAGAAAAACAGACAACAGAAAGGACAGAAGAA CAGCAGAGAAGAAATGAAGAGAATCGAAGAAGGAATCAAG GAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAAA ACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTCGACCAGGAACCTGGAC ATCAACAGACTGAGCGACTACGACGTGCACACATCGTCC CGCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAAC GTCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAACTACT GGAGACAGCTGCTGAACGCAAGCTGATCACACAGAGAAA GTTCGACAACCTGACAAGGCAGAGAGAGGAGGACTGAGC GAACTGGACAAGGCAGGATTATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAGCACGTGCGACAGATCCTGGA CAGCAGAATGAACACAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTATCACACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCAGTTTACAAAGGTCAG AGAAATCAACAATACCACCACGCACACGACGATACCTG AACGCAGTCGTCGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAAGCGAATTCGTCTACGAGACTACAAGGTCTA CGACGTGAGAAAGATGATCGCAAGAGCGAACAGGAAATC GGAAAGGCAACAGCAAAGTACTTCTTACAGCAACATCA TGAACCTCTTCAAGACAGAAATCACACTGGCAACCGGAGA AATCAGAAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCGTCTGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCCTGAGCATGCCGAGGTCAACATCGTCAA GAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAGC	

TABLE 1-continued

Description	Sequence	SEQ ID No
	ATCTGCGGAAGAGAAACAGCGACAAGCTGATCGCAAGAA AGAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAG CCCGACAGTCGCATACAGCGTCCTGGTCGTCGCAAGGTC GAAAAGGGAAAGAGCAAGAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCCTGGAAGCAAAGGGATACAAGGAA GTCAGAAGGACCTGATCATCAAGCTGCCAAGTACAGCC TGTTCGAAGTGGAAAACGGAAGAAAGAGAATGCTGGCAAG CGCAGGAGAACTGCAGAAGGGAAACGAACTGGCACTGCCG AGCAAGTACGTCAACTTCCTGTACCTGGCAAGCCACTACG AAAAGCTGAAGGGGAAGCCCGAAGACAAACGACAGAAGCA GCTGTTTCGTGAAACAGCACAAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTGAGCAAGAGAGTTCATCTGG CAGACGCAAACTGGACAAGTCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAAACATC ATCCACCTGTTCACTGACAAACCTGGGAGCACCGGCAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTGGACGCAACACTGATCCAC CAGAGCATCAGAGACTGTACGAAACAGAATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCGAAGAAGAA GAGAAAAGTCTAGCTAGCCATCACATTAAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATA GCTTATTCATCTCTTTTCTTTTCTGTTGGTGTAAAGCCA ACACCTGTCTAAAAAACATAAATTTCTTTAATCATTTTG CCTCTTTCTCTGTGCTCAATTATAAAAAATGGAAAGA ACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	
Cas9 mRNA with a poly-A NO: 2 tail comprising SEQ ID	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTG GTGTCGTGTCAGGCCTTATTTCGGATCCGCCACCATGGACA AGAAGTACAGCATCGGACTGGACATCGGAACAAACAGCGT CGGATGGGCAGTCATCACAGACGAATACAAGGTCCCGAGC AAGAAGTTCAGGTCTGCGGAACACAGACAGACACAGCA TCAAGAAGAACCCTGATCGGAGCACTGCTGTTGACAGCGG AGAAACAGCAGAGAAGCAACAAGACTGAAGAGAACAGCAAGA AGAAGATACACAAGAAAGAAACAGAAATCTGTACCTGTC AGGAAATCTTCAGCAACGAATGGCAAAGGTGACGACAG CTTCTTCCACAGACTGGAAGAAAGCTTCCTGGTCGAAGAA GACAAGAAGCACGAAGACCCCGATCTTCGGAACATCG TCGACGAAGTCGCATACCACGAAAAGTACCCGACAATCTA CCACCTGAGAAAGAGCTGGTCGACAGCACAGACAAGGCA GACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA AGTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCC GGACAAACAGCGACGTCGACAAGCTGTTTCATCCAGCTGGTC CAGACATACAACAGCTGTTGCAAGAAAACCCGATCAACG CAAGCGGAGTCGACGCAAGGCAATCTGAGCGCAAGACT GAGCAAGAGCAGAAAGACTGGAACCTGATCGCACAGCTG CCGGGAGAAAAGAAAGACGACTGTTGCAAAACCTGATCG CACTGAGCCTGGGACTGACACCGAATTCAGAGCAACTT CGACCTGGCAGAAAGACGCAAGCTGACGCTGAGCAAGGAC ACATACGACGACGACTGGACAACCTGCTGGCACAGATCG GAGACCAGTACGACAGCTGTTCTGCGCAGCAAGAACCT GAGCGACGCAATCTGCTGAGCGACATCCTGAGAGTCAAC ACAGAAATCACAAGGCACCGCTGAGCGCAAGCATGATCA AGAGATACGACGAACACCACGAGACTGACACTGCTGAA GGCATGGTCAGACAGCAGCTGCCGAAAAGTACAAGGAA ATCTTCTTCGACCAGACGAAGACGGATACGCAAGGATACA TCGACGGAGGAGCAAGCCAGGAAGAATTCTACAAGTTCAT CAAGCCGATCCTGGAAGAAGTGGACGGAACAGAAGAAGT CTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAAGCAGA GAACATTCGACAACGGAAGCATCCCGACCCAGATCCACCT GGGAGAACTGCACGCAATCCTGAGAAGACAGGAAGACTTC TACCCGTTCTGAAGGACAAACAGAGAAAGATCGAAAAGA TCCTGACATTGCAATCCCGTACTACGTGCGACCGCTGGC AAGAGGAAACAGCAGATTGCAATGATGACAAGAAAGAGC GAAGAAACAATCACACCGTGAACCTCGAAGAGTCTGTCG ACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAATGAC AAATTCGACAAGAACCTGCCAAGCAAGAAAGTCTGCGG AAGCACAGCCTGCTGTACGAATCTCACAGTCTACAACG AACTGACAAAGGTCAAGTACGTACAGAAGGAATGAGAAA GCCGGCATTCCTGAGCGGAGAAAGAGAAGGCAATCGTC GACCTGCTGTTCAAGACAAACAGAAAGGTACAGTCAAGC AGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA CAGCGTCGAATCAGCGGAGTCGAAGACAGATTCAACGCA AGCTGGGAACATACCACGACCTGCTGAAGATCATCAAGG	31

TABLE 1-continued

Description	Sequence	SEQ ID No
	ACAAGGACTTCCTGGACAACGAAGAAAACGAAGACATCCT GGAAGACATCGTCTGACACTGACACTGTTTCGAAGACAGA GAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGT TCGACGACAAGGTCATGAAGCAGCTGAAGAGAAGAAGATA CACAGGATGGGAAGACTGAGCAGAAAGCTGATCAACGGA ATCAGAGACAAGCAGAGCGGAAAGACAACTCTGGACTTCC TGAAGAGCGACGGATTTCGCAACAGAACTTCATGCAGCT GATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAG AAGGCACAGGTGAGCGGACAGGGAGACAGCCTGCACGAAC ACATCGCAAACCTGGCAGGAAGCCCGGCAATCAAGAAGGG AATCCTGCAGACAGTCAAGGTCGTCGACGAACCTGGTCAAG GTCATGGGAAGACACAAGCCGAAAAACATCGTCATCGAAA TGGCAAGAGAAAAACAGACAACACAGAAGGGACAGAAGAA CAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAATCAAG GAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAAA ACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT GCAGAACGGAAGAGACATGTACGTCGACAGGAACCTGGAC ATCAACAGACTGAGCGACTACGACGTGACACACATCGTCC CGCAGAGCTTCTTGAAGGACGACAGCATCGACAACAGGT CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAAC GTCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAACTACT GGAGACAGCTGCTGAACGCAAAGCTGATCACACAGAGAAA GTTCGACAACCTGACAAGGCGAGAGAGGAGGACTGAGC GAACTGGACAAGGCAGGATTTCATCAAGAGACAGCTGGTCG AAACAAGACAGATCACAAAGCACGTCGCACAGATCCTGGA CAGCAGAATGAACACAAGTACGACGAAAACGACAAGCTG ATCAGAGAAGTCAAGGTCATCACACTGAAGAGCAAGCTGG TCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCAG AGAAATCAACAATAACCAACGACACGACGCATACCTG AACGCAGTCGTCGGAACAGCACTGATCAAGAAGTACCCGA AGCTGGAAAGCGAATTTCGTCTACGGAGACTACAAGGTCTA CGACGTGAGAAAGATGATCGCAAAGAGCGAACAGGAAATC GGAAAGGCAACAGCAAAGTACTTCTTACAGCAACATCA TGAACCTTCTCAAGACAGAAATCACACTGGCAAACGGAGA AATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACA GGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCAACAG TCAGAAAGGTCCTGAGCATGCCGAGGTCAACATCGTCAA GAAGACAGAAGTCCAGACAGGAGGATTTCAGCAAGGAAAGC ATCTTGCCGAAGAGAAAACAGCGACAAGCTGATCGCAAGAA AGAAGGACTGGGACCAGAAAGTACGGAGGATTTCGACAG CCCGACAGTCGCATACAGCGTCTTGGTCGTCGCAAGGTC GAAAAGGGAAGAGCAAGAAGCTGAAGAGCGTCAAGGAAC TGCTGGGAATCACAATCATGGAAGAAGCAGCTTCGAAAA GAACCCGATCGACTTCTTGAAGCAAGGAGATACAAGGAA GTCAAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCC TGTTCGAACTGGAAAAACGGAAGAAAGAGAAATGCTGGCAAG CGCAGGAGAACTGCAGAAAGGAAACGAACTGGCACTGCCG AGCAAGTACGTCAACTTCTGTACTTGGCAAGCCACTACG AAAAGCTGAAGGGAAGCCCGGAAGACAACGAACAGAAGCA GCTGTTCTGTCGAACAGCACAAAGCACTACCTGGACGAAATC ATCGAACAGATCAGCGAATTCAGCAAGAGAGTTCATCCTGG CAGACGCAAACTTGGACAAGGTCCTGAGCGCATACAACAA GCACAGAGACAAGCCGATCAGAGAACAGGCAGAAAAACATC ATCCACCTGTTCACTGACAAACCTGGGAGCACCCGGCAG CATTCAAGTACTTCGACACAACATCGACAGAAAGAGATA CACAAGCACAAAGGAAGTCTTGGACGCAACACTGATCCAC CAGAGCATCACAGGACTGTACGAACAGAAATCGACCTGA GCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGAA GAGAAAGGTCTAGCTAGCCATCACATTTAAAGCATCTCA GCCTACCATGAGAATAAGAGAAAGAAATGAAGATCAATA GCTTATTCATCTCTTTTCTTTTCTGTTGGTGTAAAGCCA ACACCTGTCTAAAAACATAAATTTCTTTAATCATTTTG CCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAGA ACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAA	

Phosphorothioate (PS) linkage or bond refers to a bond where a sulfur is substituted for one nonbridging phosphate oxygen in a phosphodiester linkage, for example in the bonds between nucleotides bases. When phosphorothioates are used to generate oligonucleotides, the modified oligonucleotides may also be referred to as S-oligos.

A “*” may be used to depict a PS modification. In this application, the terms A*, C*, U*, or G* may be used to denote a nucleotide that is linked to the next (e.g., 3') nucleotide with a PS bond.

In this application, the terms “mA*,” “mC*,” “mU*,” or “mG*” may be used to denote a nucleotide that has been substituted with 2'-O-Me and that is linked to the next (e.g., 3') nucleotide with a PS bond.

EXAMPLES

The following examples are provided to illustrate certain disclosed embodiments and are not to be construed as limiting the scope of this disclosure in any way.

Example 1—Design and Stability of Stable Plasmids for Poly-A Coding

Poly-A tails were designed that comprised non-adenine nucleotides. The stability of plasmids encoding these poly-A tails with consecutive adenine nucleotides and non-adenine nucleotides (e.g., interrupting sequences) were compared to poly-A tails composed solely of adenine nucleotides.

The issue of loss of the number of adenosines in an mRNA poly-A tail consisting of only adenosines is highlighted in Table 2. A sequence containing a poly-A tail of 96 adenosines was inserted into a pUC57 plasmid (Genscript) and transformed into *E. coli*. Cells were plated on LB-Amp plates, and incubated overnight at either 30° C. or 37° C. Eight colonies were picked and inoculated into 96-well plates with LB-Amp media and grown overnight at 30° C. or 37° C. (Day 1). Samples from the Day 1 cultures were added to fresh LB-Amp media and grown for two additional days at 30° C. or 37° C. (Day 2). DNA was purified from Day 1 and Day 2 cultures and sequenced to determine poly-A tail length in the plasmids. Exemplary results are shown in Table 2 below and in FIG. 1.

TABLE 2

Poly-A length after plasmid growth in <i>E. Coli</i>				
37° C.			30° C.	
Initial colony size	Day 1 poly-A length	Day 2 poly-A length	Initial colony size	Day 1 poly-A length
Sm	95	18	Reg	80
Reg	95	68	Sm	95
Reg	95	94	Reg	39
Sm	95	N/A	Reg	48
Reg	96	N/A	Sm	95
Sm	36-95 mix	18	Sm	95
Sm	62	61	Reg	47
Reg	69	68	Sm	95

For a number of the colonies each round of growth was associated with a decrease in the number of adenosines within the poly-A tail, with only one colony maintaining over 90 adenosines through two rounds of replication. In addition, the size of bacterial colonies correlated with loss of poly-A tail length from the plasmid (i.e., larger colonies corresponded with loss of poly-A length), suggesting that sequences encoding longer poly-A tails may inhibit bacterial

growth during plasmid production. DNA purified from colonies of *E. coli* represent a population of DNAs from individual *E. coli* harboring plasmid DNA. Thus, the values provided in Table 2 (and similar values described herein) represent average poly-A length of the population. Further, during PCR and sequencing of long repeats such as poly-A, the polymerase may slip, resulting in the appearance that the sequence is slightly shorter than the actual sequence. Thus, for results showing 95 adenosines, it is not certain whether the plasmid has lost one adenosine, or whether it is a PCR artifact. However, significant loss is not an artifact of polymerase slippage during PCR amplification and sequencing.

In a separate experiment, *E. coli* were transformed with a pUC57 plasmid containing a poly-A tail of SEQ ID NO: 1 and plated on LB-Amp plates. Eight clones were cultured through two rounds of growth and tested for maintenance of the sequence encoding the poly-A tail. Representative data on one clone is shown in FIG. 2, where no change in size of the tail was seen with the poly-A tail of SEQ ID NO: 1 over 2 rounds of growth of a plasmid encoding it. Miniprep 1 refers to the first round of growth, while Miniprep 2 refers to the second round of growth. Minipreps were performed using an Invitrogen Purelink Quick Plasmid Miniprep kit.

A plasmid encoding a poly-A tail with an additional non-adenosine pattern (SEQ ID NO: 3) was tested for its ability to withstand replication in *E. coli*. A sequence containing a poly-A tail of SEQ ID NO: 3 was inserted into a pUC19 plasmid (Genscript) and transformed into *E. coli*. Cells were plated on LB-Kan plates, and incubated overnight at either 30° C. or 37° C. Eight colonies were picked and inoculated into 96-well plates with LB-Kan media, and grown overnight at 30° C. or 37° C. (Day 1). Samples from the Day 1 cultures were added to fresh LB-Kan media and grown for two additional days at 30° C. or 37° C. (Day 2). DNA was purified from Day 1 and Day 2 cultures and sequenced to determine poly-A tail length in the plasmids. Of eight Day 1 cultures sequenced, six maintained stretches of 25, 24, 24, and 24 adenosines, and of twelve Day 2 cultures sequenced, nine maintained stretches of 25, 24, 24, and 24 adenosines, demonstrating an improvement of poly-A retention compared to adenosine-only sequences.

These data indicate that DNAs encoding poly-A tails comprising non-adenine nucleotides have improved stability over multiple rounds of plasmid growth and purification in comparison to DNAs encoding poly-A tails containing only adenosines.

Example 2—Activity of Constructs with Poly-A Tails Comprising Non-Adenine Nucleotides

Experiments were performed to determine whether there was a difference in efficacy of mRNA with poly-A tails comprising non-adenine nucleotides (interrupting sequences) versus those with poly-A tails containing only adenosines. A model system was used where mRNA encoding Cas9 protein was transfected by electroporation into HEK-293 cells with a reporter plasmid encoding secreted embryonic alkaline phosphatase (SEAP), as well as a guide RNA targeting SEAP. Successful expression of Cas9 protein from the mRNA results in cleavage of the SEAP target sequence, leading to a color change reflecting decreased production of SEAP. The SEAP HEK-Blue reporter reagents were obtained from Invivogen. A sequence containing a T7 promoter and encoding a Cas9 mRNA with adenosine-only poly-A tail (designed to have 100 adenosine nucleotides, but shown as having 97 adenosine nucleotides by sequencing)

(SEQ ID NO: 6) or a sequence containing a T7 promoter and encoding a Cas9 mRNA with a poly-A tail of SEQ ID NO: 1 (SEQ ID NO: 7) were cloned into pUC57 plasmid (Genscript). mRNA was produced by in vitro transcription from the linearized plasmids encoding each mRNA.

FIG. 3 shows titration of Cas9 mRNA with adenosine-only poly-A or the poly-A of SEQ ID NO: 1 in the HEK-Blue cell assay at concentrations from 0.005-50 nM, and 1 μ M single guide RNA targeting SEAP (SEQ ID NO: 8).

The HEK-Blue results show that the effect of mRNA with either poly-A tail was similar across the dose-response curve. Higher concentrations of mRNA led to a decrease in SEAP reporter gene expression as evidenced by the color change to pink, as the baseline blue color indicates SEAP expression. Thus, the poly-A tail comprising non-adenine nucleotides did not change the efficacy of expression and function of a Cas9 construct compared to a poly-A tail containing only adenines.

The efficacy of editing conferred by expression of a Cas9 mRNA of SEQ ID NO: 6 was also compared to the Cas9 mRNA of SEQ ID NO: 7 (i.e., adenosine-only poly-A tail compared to poly-A tail of SEQ ID NO: 1). For these experiments, HEK-Blue cells were transfected with sgRNA (SEQ ID NO: 8) and the two different mRNAs by electroporation.

FIG. 4 shows percent SEAP inhibition for both constructs after 24-hour incubation. The EC₅₀ for SEAP editing for mRNA with a poly-A tailing containing only adenosine and a poly-A tail comprising non-adenine nucleotides were similar at 0.050 and 0.054, respectively.

FIG. 5 shows percent SEAP inhibition for both constructs after a 48-hour incubation. The EC₅₀ for SEAP editing for mRNA with a poly-A tailing containing only adenosine and a poly-A tail comprising non-adenine nucleotides were similar at 0.086 and 0.082, respectively.

mRNA expression and activity were also confirmed in vivo. The Cas9 mRNAs of SEQ ID NO: 6 (HiCas9 mRNA) and SEQ ID NO: 7 (Disrupted PolyA mRNA) were formulated with single guide RNA of SEQ ID NO: 9 (targeting mouse TTR gene) at a 1:1 weight ratio into lipid nanoparticles (LNPs) and administered to CD-1 female mice (n=5) by intravenous dosing at 1 or 0.5 mg/kg of total RNA. Blood was collected from the animals at 7 days post-dose, and serum levels of TTR protein were measured by ELISA. In short, total TTR serum levels were determined using a Mouse Prealbumin (Transthyretin) ELISA Kit (Aviva Systems Biology, Cat. OKIA00111). Kit reagents and standards were prepared according to the manufacture's protocol. The plate was read on a SpectraMax M5 plate reader at an absorbance of 450 nm. Serum TTR levels were calculated by SoftMax Pro software ver. 6.4.2 using a four parameter logistic curve fit off the standard curve. Final serum values were adjusted for the assay dilution.

FIG. 6 shows comparable levels of serum TTR knockdown (representative of percentage editing of the TTR gene) for both poly-A constructs at 7 days post-dose. Serum TTR knockdown results were confirmed by sequencing of the TTR locus in livers of the mice harvested at 7 days. Mice receiving the adenosine-only poly-A mRNA showed 61.74% and 69.84% editing at 0.5 and 1 mg/kg total RNA, respectively, while mice receiving the poly-A mRNA containing non-adenosine nucleotides showed 63.14% and 70.82% editing at 0.5 and 1 mg/kg total RNA.

Therefore, expression of a Cas9 mRNA with a poly-A tail comprising non-adenine nucleotides produced similar editing efficacy compared to a Cas9 mRNA with a poly-A tail containing only adenines.

Example 3—Activity of Constructs with Poly-A Tails Comprising Additional Interrupting Sequences

Experiments were performed to determine efficacy of mRNA with poly-A tails comprising non-adenine nucleotides versus those with poly-A tails containing only adenosine nucleotides as in Example 2. Sequences containing a T7 promoter and encoding a Cas9 mRNA with an interrupted poly-A tail comprising SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, or SEQ ID NO: 11 were made by PCR amplification using primers to incorporate the poly-A sequences. mRNA was produced by in vitro transcription from these PCR products. mRNA for SEQ ID NO: 18 was produced by in vitro transcription from a linearized plasmid encoding the mRNA.

FIG. 7 shows titration of Cas9 mRNA with adenosine-only poly-A [100PA] or the poly-A of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, or SEQ ID NO: 11 in the HEK-Blue cell assay at concentrations from 0.02-6 nM, and 1 μ M single guide RNA targeting SEAP (SEQ ID NO: 8). Specifically, FIG. 7 shows percent SEAP inhibition for the constructs after a 48-hour incubation, and EC₅₀ values are provided in Table 3, below. All constructs are active.

TABLE 3

EC50 values for SEAP inhibition			
PolyA	Cas9 mRNA Construct	EC50	Standard Error
98 consecutive adenosines	Liv (U- depleted Cas9 N1Me pseudo U)	0.0627	0.0118
97 consecutive adenosines	100 PA	0.0956	0.0041
SEQ ID NO: 4	16 PA	0.0692	0.0087
SEQ ID NO: 5	16 PA long	0.0705	2.237
SEQ ID NO: 3	25 PA	0.0500	0.0213
SEQ ID NO: 2	30 PA	0.0591	0.0086
SEQ ID NO: 10	12 PA	0.0549	0.0296
SEQ ID NO: 11	8 PA	0.04233	0.0295

Example 4—Cloning of Long PolyA with Interrupting Sequences

A 300 nucleotide long polyA tail, SEQ ID NO:18 [300 pa], was designed comprising twelve interrupting sequences from Table 4 (below) and 13 repeats of 12 consecutive adenosines. Anchor Sequences of SEQ ID NO: 18 were designed to minimize hybridization and self-annealing between trinucleotide interrupting sequences within the ~300 nt the poly-A tail. Table 4 below provides interrupting sequences that minimize annealing between interrupting sequences, and include the anchors used in this experiment.

To clone SEQ ID NO: 18, each of sequences PolyA-1 (SEQ ID NO: 12), PolyA-2 (SEQ ID NO: 13), PolyA-3 (SEQ ID NO: 14), and PolyA-4 (SEQ ID NO: 15) are created in the pUC57 mini vector (Genscript). The pA1-2 plasmid is created by amplifying SEQ ID NO:12 with Bcl11a primers, digesting the PCR product with restriction enzymes XhoI and AclI and ligating the restriction fragment into the pA2 plasmid comprising SEQ ID NO: 13 digested with XhoI and BstBI. The pA3-4 plasmid is created in the same manner amplifying SEQ ID NO: 14 and ligating it into the same restriction sites on plasmid pA4. The pA1-4 plasmid (comprising SEQ ID NO:18) is assembled by amplifying the SEQ ID NO: 17 sequence from pA3-4,

57

digesting the PCR fragment with BbsI and XbaI restriction enzymes and cloning the restriction fragment into the polyA 1-2 (SEQ ID NO: 16) construct digested with BbsI and XbaI restriction enzymes. The inserts into pA1-2 and pA3-4 are assessed by Sanger sequencing from both directions using 5 [pUC-M seq2 forward primer and pUC-M seq reverse primer] as primers (SEQ ID Nos: 20 and 21).

The resulting SEQ ID NO: 18 (300PA) polyA sequence is excised by digesting pA1-4 with XhoI and XbaI for cloning into the same sites in a protein encoding vector. All steps are 10 carried out under standard conditions.

TABLE 4

CGG	CGT	CGC
CTG	CTT	CTC

15

58

TABLE 4-continued

CAG	CAT	CAC
CCC	CCG	CCT
GGG	GGT	GGC
GCG	GCT	GCC
GAG	GAT	GAC
GTG	GTT	GTC
TGG	TGT	TGC
TTG	TTT	TTT
TAG	TAT	TAC
TCG	TTC	TCC

SEQUENCE LISTING

Sequence total quantity: 31

SEQ ID NO: 1 moltype = DNA length = 108

FEATURE Location/Qualifiers

misc_feature 1..108

note = mRNA sequence of an exemplary poly-A tail comprising non-adenine nucleotides with 30, 30, and 39 consecutive adenosines and ending with non-adenine nucleotides

source 1..108

mol_type = other DNA
organism = synthetic construct

SEQUENCE: 1

aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	gcgaaaaaa	aaaaaaaaa	aaaaaaaaa	60
-----------	-----------	-----------	-----------	-----------	-----------	----

aaaccgaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaacc		108
------------	-----------	-----------	-----------	---------	--	-----

SEQ ID NO: 2 moltype = DNA length = 104

FEATURE Location/Qualifiers

misc_feature 1..104

note = 30PA - sequence of an exemplary poly-A tail comprising non-adenine nucleotides with 30, 30, and 39 consecutive adenosines

source 1..104

mol_type = other DNA
organism = synthetic construct

SEQUENCE: 2

aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	gcgaaaaaa	aaaaaaaaa	aaaaaaaaa	60
-----------	-----------	-----------	-----------	-----------	-----------	----

aaaccgaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaa		104
------------	-----------	-----------	-----------	-------	--	-----

SEQ ID NO: 3 moltype = DNA length = 109

FEATURE Location/Qualifiers

misc_feature 1..109

note = 25PA - sequence of an exemplary poly-A tail comprising non-adenine nucleotides with four sets of 25 consecutive adenosines

source 1..109

mol_type = other DNA
organism = synthetic construct

SEQUENCE: 3

aaaaaaaaa	aaaaaaaaa	aaaaagcgaa	aaaaaaaaa	aaaaaaaaa	aaaccgaaaa	60
-----------	-----------	------------	-----------	-----------	------------	----

aaaaaaaaa	aaaaaaaaa	agtgaaaaa	aaaaaaaaa	aaaaaaaaa		109
-----------	-----------	-----------	-----------	-----------	--	-----

SEQ ID NO: 4 moltype = DNA length = 101

FEATURE Location/Qualifiers

misc_feature 1..101

note = 16PA - sequence of an exemplary poly-A tail comprising non-adenine nucleotides with six sets of 16 consecutive adenosines

source 1..101

mol_type = other DNA
organism = synthetic construct

SEQUENCE: 4

aaaaaaaaa	aaaaaaagaaa	aaaaaaaaa	aaacaaaaa	aaaaaaaaa	taaaaaaaa	60
-----------	-------------	-----------	-----------	-----------	-----------	----

aaaaaaataa	aaaaaaaaa	aaacaaaaa	aaaaaaaaa	a		101
------------	-----------	-----------	-----------	---	--	-----

SEQ ID NO: 5 moltype = DNA length = 165

FEATURE Location/Qualifiers

misc_feature 1..165

note = 16PA long - sequence of an exemplary poly-A tail

-continued

```

comprising non-adenine nucleotides with six sets of 16
consecutive adenosines and 63 consecutive adenosines
source      1..165
            mol_type = other DNA
            organism = synthetic construct

SEQUENCE: 5
aaaaaaaaaa aaaaaagaaa aaaaaaaaaa aaacaaaaaa aaaaaaaaaa taaaaaaaaa 60
aaaaaaaaaa aaaaaaaaaa aaacaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 120
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 165

SEQ ID NO: 6      moltype = DNA length = 4523
FEATURE          Location/Qualifiers
misc_feature      1..4523
                 note = Cas9 mRNA with a poly-A tail consisting of 97
                 adenosines
source          1..4523
               mol_type = other DNA
               organism = synthetic construct

SEQUENCE: 6
taatacgact cactataggg tccgcagtc ggcgtccagc ggctctgctt gttcgtgtgt 60
gtgtcggttc aggccttatt cggatccatg gataagaagt actcaatcgg gctggatatc 120
ggaactaatt ccgtgggttg ggcagtgatc acggatgaat acaaagtgcc gtccaagaag 180
ttcaagggtcc tggggaacac cgatagacac agcatcaaga aaaatctcat cggagccctg 240
ctgtttgact ccggcgaaac cgacgaagcg acccggtcca aacgtaccgc gaggcgacgc 300
tacacccggc ggaagaatcg catctgctat ctgcaagaga tcttttcgaa cgaaatggca 360
aaggctcagc acagcttctt ccaccgctg gaagaatctt tccctgggga ggaggacaag 420
aagcatgaac ggcacatctat ctttggaac atcgtcgacg aagtggcgta ccacgaaaag 480
taccgcacca tctaccatct gcggaagaag ttggttgact caactgacaa ggccgacctc 540
agattgatct acttggccct cgcccatatg atcaaatctc gcggacactt cctgacgaa 600
ggcgatctga accctgataa ctccgacgtg gataagcttt tcattcaact ggtgcagacc 660
tacaaccaac tgttcgaagc aaaccaatc aatgctagcg gcgtcgatgc caaggccatc 720
ctgtccgccc ggtgtcgaaa gtccgcccgc ctgcaaaacc tgatcgacac gctgccggga 780
gagaaaaaga accgactttt cggcaacttg atcgctctct cactgggact cactcccaat 840
ttcaagtcca attttgacct ggcgaggac gcgaagctgc aactctcaaa ggacacatc 900
gacgacgact tggacaatth gctggcacaa attggcgatc agtacgcgga tctgttctct 960
gcccctaaga acccttcgga cgcaatcttg ctgtccgata tccctgcgct gaacaccgaa 1020
ataaccaaa gcccgtcttg cgctcgatg attaagcggg acgacgagca taccaggat 1080
ctcacgctgc tcaaaagcgt cgtgagacag caactgcctg aaaagtacaa ggagatcttc 1140
ttcgaccagt ccaagaatgg gtacgcaggg tacatcgatg gaggcgctag ccaggaaag 1200
ttctataagt tcatcaagcc aatctggaaa aagatggacg gaaccgaaga actgctggtc 1260
aagctgaaca gggaggactt gctccggaaa cagagaacct ttgacaacgg atccattccc 1320
caccagatcc atctgggtga gctgcacgcc atcttgcggc gccaggagga cttttaccca 1380
ttcctcaagg acaaccggga aaagatcgag aaaattctga cgttccgcat cccgatttac 1440
gtgggcccac tggcgccggc caattcgccg ttcgctgga tgactagaaa atcagaggaa 1500
accatcactc ttggaatth cgaggaaagt gtggataagg gagcttcggc acaaagcttc 1560
atcgaaacga tgcaccaact gcaccaaat ctcccaaacg agaaggtgct tcctaagcac 1620
agcctccctt acgaatactt cactgtctac aacgaactga ctaaagtga atacgttact 1680
gaaggaaatg ggaagccggc ctttctgtcc ggagaacaga agaaagcaat tgcgatctg 1740
ctgttcaaga ccaaccgcga ggtgaccgtc aagcagctta aagaggacta cttcaagaag 1800
atcgagtgtt tcgactcagt ggaatcagc ggggtggagg acagattcaa cgttctgctg 1860
ggaacctatc atgatctcct gaagatcatc aaggacaagg acttctctga caacgaggag 1920
aacagggaca tcttggaaga tatctcctg accctgacct ttttcgagga tcgcgagatg 1980
atcgaggaga ggcttaagac ctacgtctcat ctcttcgacg ataaggtcat gaaacaactc 2040
aagcgccgcc ggtacactgg ttggggccgc ctctcccgca agctgatcaa cggattctgc 2100
gataaacaga gcgtgtaaac tatcctggat ttctcctaat cggatggctt cgctaactcg 2160
aacttcacgc aattgatcca cgacgacagc ctgaccttta agggaggacat ccaaaaagca 2220
caagtgtccg gacagggaga ctcaactccat gaacacatcg cgaatctggc cggttcgccg 2280
gcgattaaag aggggaattc gcaaaactgt aaggtggtcg acgagctggt gaaggtcatg 2340
ggacgggcaca aacccggagaa tatcgtgatt gaaatggccc gagaaaacca gactaccag 2400
aagggccaga aaaactcccg cgaaggatg aagcggatcg aagaaggaa caaggagctg 2460
ggcagccaga tctgaaagag gcaccgggtg gaaaacacgc agctgcagaa cgagaagctc 2520
tacctgtact atttgcaaaa tggacgggac atgtacgtgg accaagagct ggacatcaat 2580
cggttgtctg attacacagt ggaccacatc gttccacagt cctttctgaa ggatgactcg 2640
atcgataaca aggtgttgac tcgcagcgac aagaacagag ggaagtacga taatgtgcc 2700
tcggaggagg tctgaagaa gatgaagaat tactggcgcc agctcctgaa tgcgaagctg 2760
attacccaga gaaagtttga caatctcact aaagccgagc gcggcgagct ctcaagctg 2820
gataaggctg gattatcaca acggcagctg gtcgagactc ggcagattac caagcacgtg 2880
gcgcagatct tggactcccg catgaacact aaatacagcg agaacgataa gctcatcccg 2940
gaagtgaagg tgattaccct gaaaagcaaa cttgtgtcgg actttcgaaa ggaactttcag 3000
ttttacaagg tgagagaaat caacaactac catcacgcgc atgacgcata cctcaacgct 3060
ctggtcggtg ccgccctgat caaaaagtat cctaacttg aatcggagtt tgtgtacgga 3120
gactacaagg tctacgacgt gaggaagatg atagccaagt ccgaacagga aatcgggaaa 3180
gcaactcgca aatactcttt ttactcaaac atcatgaact ttttcaagac tgaattatcg 3240
ctggccaatg gagaactcag gaagaggcca ctgatcgaaa ctaacggaga aacgggagaa 3300
atcgtgtggg acaagggcag ggaactcgca actgttcgca aagtgtcttc tatgccgcaa 3360
gtcaatatgt tgaagaaac cgaagtgcga accggcgat tttcaaggga atcgatcctc 3420
ccaaagagaa atagcgacaa gctcattgca cgcaagaaag actgggaccc gaagaagtac 3480
ggaggattcg attcgccgac tctcgcatat tccgtcctcg tggggcccaa ggtggagaag 3540
ggaaagagca aaaagctcaa atccgtcaaa gagctgctgg ggattaccat catggaacga 3600

```

-continued

```

tcctcggttcg agaagaaccc gattgatttc ctccgagcga aggggttacaa ggaggtgaag 3660
aaggatctga tcatacaact ccccaagtac tcaactgttcg aactggaaaa tggctcggaag 3720
cgcatgcttg cttcgccggg agaactccaa aaaggaaatg agctggcctt gcctagcaag 3780
tacgtcaact tectctatct tgcctcgac tacgaaaaac tcaaagggtc accggaagat 3840
aacgaacaga agcagctttt cgtggagcag cacaagcatt atctggatga aatcatcgaa 3900
caaatctccg agttttcaca gcgcgtgatc ctccgccgacg ccaacctcga caaagtcctg 3960
tcggcctaca ataagcatag agataagccg atcagagaac aggcgcgaga cattatccac 4020
ttgttcaccc tgactaacct gggagcccca gccgccttca agtacttcga tactactatc 4080
gatcgcaaaa gatacacgtc caccaaggaa gttctggacg cgacctgat ccaccaaacg 4140
ataactggac tctacgaaac taggatcgat ctgtcgacg tgggtggcga tggcgggtgga 4200
tctccgaaaa agaagagaaa ggtgtaatga gctagccatc acatttaaaa gcattctcagc 4260
ctaccatgag aataagagaa agaaaatgaa gatcaatagc ttatttcatt cttttttctt 4320
ttcgttgggtg taaagccaac accctgtcta aaaaacataa atttctttaa tcattttgcc 4380
tcttttctct gtgcttcaat taataaaaaa tggaaagAAC ctcgagaaaa aaaaaaaaaa 4440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4500
aaaaaaaaaa aaaaaaaaaa aaa 4523

SEQ ID NO: 7      moltype = DNA length = 4581
FEATURE
misc_feature      Location/Qualifiers
                  1..4581
                  note = T7 promoter and Cas9 mRNA with a poly-A tail
                  comprising SEQ ID NO: 1
source            1..4581
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 7
taatacgact cactataggg tcccgagtc ggcgccagc ggctctgctt gttcgtgtgt 60
gtgtcggtgc aggccttatt cggatctgcc accatggata agaagtactc gatcgggctg 120
gatacgcgaa ctaattccgt ggggttgggca gtgacacgg atgaatacaa agtgcgctcc 180
aagaagtcca aggtcctggg gaacaccgat agacacagca tcaagaagaa tctcatcgga 240
gcctgtgtgt ttgactccgg gaaaccgca gaagcgaccc ggctcaaacg tacgcgaggg 300
cgagctaca cccggcgaaa gaatcgcatc tgctatctgc aagaaatctt ttcgaacgaa 360
atggcaaaag tggacgacag cttcttccac gcctcggaag aatcttctct ggtggaggag 420
gacaagaagc atgaacggca tcttatcttt ggaaacatcg tggacgaagt ggctgaccac 480
gaaaagtacc cgacctata ccatctgcgg aagaagtgg ttgactcaac tgacaaggcc 540
gacctcagat tgatctactt ggcctctgcc catatgatca aatctcggcg acacttctct 600
atcgaaaggc atctgaaccc tgataactcc gacgtggata agctgttcat tcaactggtg 660
cagacctaca accaactggt cgaagaaaa ccaatcaatg ccagcggcgt cgatgccaa 720
gacctcctgt ccgcccgggt gtcgaagtcg cggcgccctc aaacctgat cgacagctg 780
ccgggagaga agaagaacgg acttttcggc aacttgatcg ctctctcact gggactcact 840
cccaatttca agtccaattt tgacctggcc gaggacgcga agctgcaact ctcaaaggac 900
acctacgacg acgacttgga caatttgctg gcacaaattg gcgatcagta cgcggatctg 960
ttccttgccg ctaagaacct ttcggacgca atcttgcgtg ccgatatcct gcgcgtgaac 1020
accgaaataa ccaagcgccc gcttagcgcc tcatgatta agcgggtacg cgagcatcac 1080
caggatctca cgctgctcaa agcgtcgtg agacagcaac tgctgaaaa gtacaaggag 1140
attttcttcg accagtccaa gaatgggtac gcagggtaca tcatggaggg cgccagccag 1200
gaagagtctc ataagttcat caagccaatc ctggaaaaa tggacggaa cgaagaactg 1260
ctggtcaagc tgaacaggga ggaatctgtc cgcaaacaga gaacctttga caacggaa 1320
attccacacc agatccatct ggttgagctg cacgccatct tgcggcgcca ggaggactt 1380
taccatttcc tcaaggacaa ccgggaaaa atcgagaaaa ttctgacgtt ccgcatccc 1440
tattacgtgg gccactggc gcgcggcaat tgcgccttcg cgtggatgac tagaaaaatc 1500
gaggaaacca tcaactcctg gaatttcgag gaagttgtgg ataaggaggc ttcggcaca 1560
tcttcatcga aacgaatgac caacttcgac aagaatctcc caaacgaaa ggtgcttct 1620
aagcacagcc tcttttaca atacttcact gtctacaacg aactgactaa agtgaataac 1680
gttactgaag gaatgaggaa gccggccctt ctgagcggag aacagaagaa agcgaattgt 1740
gatctgctgt tcaagaccaa ccgcaagggt accgtcaagc agcttaaaag ggactacttc 1800
aagaagatcg agtggttcga ctcagtggaa atcagcggag tggaggacag attcaacgct 1860
tcgctgggaa cctatcatga tctcctgaag atcatcaagg acaaggactt ccttgacaac 1920
gaggagaaag aggcacatct ggaagatata gtctgacct tgacctttt cgaggatcgc 1980
gagatgatcg aggagaggct taagacctac gctcatctct tcgacgataa ggtcatgaaa 2040
caactcaagc gccgcgggta cactggttgg ggccgcctct ccgcgaagct gatcaacggt 2100
attcgcgata aacagagcgg taaaactatc ctggatttcc tcaaatcgga tggcttcgct 2160
aatcgtaact tcatgcagtt gatccacgac gacagcctga cctttaagga ggacatccag 2220
aaagcacaag tgagcggaca gggagactca ctccatgaac acatcgcgaa tctggccggt 2280
tcgcccggca ttaagaaggg aatcctgcaa actgtgaagg tgggtggcga gctggtgaag 2340
gtcatgggac ggcacaaacc ggagaatata gtgattgaaa tggcccgaga aaaccagact 2400
acccagaagg gccagaagaa ctcccgcgaa aggatgaagc ggatcgaaga agaatcaag 2460
gagctgggca gccagatcct gaaagagcac ccggtggaaa acacgcagct gcagaacgag 2520
aagctctacc tgtactatct gcaaaatgga cgggacatgt acgtggacca agagctggac 2580
atcaatcggt tgtctgatta cgacgtggac cacatcgctc cacagtcctt tctgaaggat 2640
gactccatcg ataacaaggt gttgactcgc agcgacaaga acagagggaa gtcagataat 2700
gtgccatcgg aggaggtcgt gaagaagatg aagaattact ggccgcagct cctgaatgcg 2760
aagctgatta cccagagaaa gtttgacaat ctactaaag ccgagcgcgg cggaacttca 2820
gagctggata aggtctgatt catcaaacgg cagctggtcg agactcggca gattaccaag 2880
cacgtggcgc agatcctgga ctcccgcagt aacactaaat acgacgagaa cgataagctc 2940
atccgggaag tgaagggtgat tacctgaaa agcaaaacttg tgcggactt tcggaaggac 3000
tttcagtttt acaaaagtga agaaatcaac aactaccatc acgctgatga cgcatacctc 3060
aacgtctgtg tcggcacccg cctgatcaag aagtaacctc aacttgaatc ggagtttgtg 3120
tacggagact acaaggtcta cgacgtgagg aagatgatag ccaagtcgca acaggaaatc 3180

```

-continued

```

gggaaagcaa ctgcgaaata cttcttttac tcaaacatca tgaacttctt caagactgaa 3240
attacgctgg ccaatggaga aatcagggaag aggcactga tcgaaactaa cggagaaacg 3300
ggcgaaatcg tgtgggacaa gggcaggagac ttgcgaactg ttgcgaaagt gctctctatg 3360
ccgcaagtca atattgtgaa gaaaaccgaa gtgcaaacgg gcggattttc aaaggaatcg 3420
atcctcccaa agagaaatag cgacaagctc attgcacgca agaaagactg ggaccggaag 3480
aagtacggag gattcgattc gccgactgtc gcatactccg tcctcgtggt ggccaaggtg 3540
gagaagggaa agagcaagaa gctcaaattc gtcaaagagc tgctggggat taccatcatg 3600
gaacgatcct cgttcgagaa gaaccgattt gatttctggt aggcgaaggg ttacaaggag 3660
gtgaagaagg atctgatcat caaactgccc aagtactcac tggtcgaact ggaatatggt 3720
cggaagcgca tgctggcttc ggcggagaaa ctccagagaa gaaatgagct ggccttgctt 3780
agcaagtacg tcaacttctt ctatcttgct tcgcactacg agaaactcaa agggtcaccg 3840
gaagataacg aacagaagca gcttttcgtg gacgacgaca agcattatct ggatgaaatc 3900
atcgaaacaa tctccgagtt ttcaaagcgc gtgatcctcg ccgacgcca cctcgacaaa 3960
gtcctgtcgg cctacaataa gcatagagat aagccgatca gagaacggc cgagaacatt 4020
atccacttgt tcaccctgac taacctggga gctccagccg ccttcaagta cttcgatact 4080
actatcgacc gcaaaagata cagctccacc aaggaagttc tggacgcgac cctgatccac 4140
caaaagcatc ctggactcta cgaactaggt atcgatctgt cgcagctggg tggcgatggt 4200
ggcgtggtgat cctaccataa cgacgtgcct gactacgcct ccggaggtgg tggccccaag 4260
aagaaacgga aggtgtgata gctagccatc acatttaaaa gcattctcagc ctaccatgag 4320
aataagagaa agaaaatgaa gatcaatagc ttattcatct ctttttcttt ttcgttggtg 4380
taaagccaac accctgtcta aaaaacataa atttctttaa tcattttgcc tcttttctct 4440
gtgcttcaat taataaaaaa tggaaagaac ctcgagaaaa aaaaaaaaaa aaaaaaaaaa 4500
aaaaaaaacg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa cgaaaaaaaaaa aaaaaaaaaa 4560
aaaaaaaaaa aaaaaaaaaa a aaaaaaaaaa 4581

```

```

SEQ ID NO: 8          moltype = RNA length = 100
FEATURE              Location/Qualifiers
misc_feature          1..100
                      note = Single guide RNA targeting SEAP
modified_base         1..3
                      mod_base = OTHER
                      note = Each nucleotide modified with 2'-O-Me and is linked
                      to the next nucleotide with a Phosphorothioate (PS)
                      linkage or bond
modified_base         29..39
                      mod_base = OTHER
                      note = 2'-O-Me
modified_base         68..96
                      mod_base = OTHER
                      note = 2'-O-Me
modified_base         97..99
                      mod_base = OTHER
                      note = Each nucleotide modified with 2'-O-Me and is linked
                      to the next nucleotide with a Phosphorothioate (PS)
                      linkage or bond
modified_base         100
                      mod_base = OTHER
                      note = 2'-O-Me
source                1..100
                      mol_type = other RNA
                      organism = synthetic construct

SEQUENCE: 8
ctccctgatg gagatgacag gtttttagagc tagaaatagc aagttaaaaa aaggctagtc 60
cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt 100

```

```

SEQ ID NO: 9          moltype = RNA length = 100
FEATURE              Location/Qualifiers
misc_feature          1..100
                      note = Single guide RNA targeting mouse TTR
modified_base         1..3
                      mod_base = OTHER
                      note = Each nucleotide modified with 2'-O-Me and is linked
                      to the next nucleotide with a Phosphorothioate (PS)
                      linkage or bond
modified_base         29..39
                      mod_base = OTHER
                      note = 2'-O-Me
modified_base         68..96
                      mod_base = OTHER
                      note = 2'-O-Me
modified_base         97..99
                      mod_base = OTHER
                      note = Each nucleotide modified with 2'-O-Me and is linked
                      to the next nucleotide with a Phosphorothioate (PS)
                      linkage or bond
modified_base         100
                      mod_base = OTHER
                      note = 2'-O-Me
source                1..100

```


-continued

```

mol_type = other RNA
organism = synthetic construct

SEQUENCE: 9
ttacagccac gtctacagca gtttttagagc tagaaatagc aagttaaaat aaggctagtc 60
cgttatcaac ttgaaaaagt ggcaccgagt cgggtctttt 100

SEQ ID NO: 10      moltype = DNA length = 116
FEATURE           Location/Qualifiers
misc_feature       1..116
                   note = 12PA - mRNA sequence of an exemplary poly-A tail
                   comprising non-adenine nucleotides with nine sets of 12
                   consecutive adenosines and mononucleotide interrupting
                   sequences
source             1..116
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 10
aaaaaaaaa aataaaaaa aaaaaataaaa aaaaaaaaca aaaaaaaaaa aataaaaaa 60
aaaacaaaa aaaaaaaagaa aaaaaaaaaa caaaaaaaa aaataaaaaa aaaaaa 116

SEQ ID NO: 11      moltype = DNA length = 115
FEATURE           Location/Qualifiers
misc_feature       1..115
                   note = 8PA - mRNA sequence of an exemplary poly-A tail
                   comprising non-adenine nucleotides with twelve sets of 8
                   consecutive adenosines and mononucleotide interrupting
                   sequences
source             1..115
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 11
aaaaaaaaata aaaaaataaa aaaaaacaaa aaaaaaaaaa aaagaaaaaa aataaaaaaa 60
acaaaaaaa caaaaaaaat aaaaaaaaga aaaaaaacaa aaaaaataaa aaaaaa 115

SEQ ID NO: 12      moltype = DNA length = 159
FEATURE           Location/Qualifiers
misc_feature       1..159
                   note = PolyA-1, Bcl11a primer annealing sites flanking
                   sequence comprising five interrupting sequences separating
                   six repeats of 12 consecutive adenosines
source             1..159
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 12
tcttccttca gtctgtaaac ctcagctcga gaaaaaaaa aaatggaaaa aaaaaaaacg 60
gaaaaaaaaa aaaggtaaaa aaaaaaaata taaaaaaaaa aaacataaaa aaaaaaaacg 120
ttcatatcgg ttctagacca cacttcttac tgagggtccc 159

SEQ ID NO: 13      moltype = DNA length = 188
FEATURE           Location/Qualifiers
misc_feature       1..188
                   note = PolyA-2, Bcl11a primer annealing sites flanking
                   sequence comprising five interrupting sequences separating
                   six sets of 12 consecutive adenosines
source             1..188
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 13
tcttccttca gtctgtaaac ctcagaattc atctagctcg agaaaaaatt cgaaaaaaa 60
aaaacgtaaa aaaaaaaaac tcaaaaaaaa aaagataaaa aaaaaaaaac ctaaaaaaa 120
aaaatgtaaa aaaaaaaaag ggaaagtctt ccatatcggg ttagaccac acttcttact 180
gagggtccc 188

SEQ ID NO: 14      moltype = DNA length = 170
FEATURE           Location/Qualifiers
misc_feature       1..170
                   note = PolyA-3, Bcl11a primer annealing sites flanking
                   sequence comprising five interrupting sequences separating
                   six sets of 12 consecutive adenosines
source             1..170
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 14
tcttccttca gtctgtaaac ctcagctcga ggaagacaag gaaaaaaaa aaaacgcaaa 60
aaaaaaaaac caaaaaaaa aaatgcaaa aaaaaaaaat cgaaaaaaaa aaatctaaa 120
aaaaaaaaac gttcatatcg gttctagacc acacttctta ctgagggtccc 170

SEQ ID NO: 15      moltype = DNA length = 171
FEATURE           Location/Qualifiers

```

-continued

```

misc_feature      1..171
                  note = PolyA-4, Bcl11a primer annealing sites flanking
                  sequence comprising six interrupting sequences separating
                  seven sets of 12 consecutive adenosines
source            1..171
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 15
tcttccttca gtctgtaaac ctcagctcga gaaaaaatc gaaaaaaaa aaacccaaaa 60
aaaaaaaaa caaaaaaaaa aaatagaaaa aaaaaaaagt taaaaaaaa aaactgaaaa 120
aaaaaaaatt taaaaaaaaa aaatctagac cacacttctt actgaggtcc c 171

SEQ ID NO: 16      moltype = DNA length = 267
FEATURE            Location/Qualifiers
misc_feature        1..267
                  note = PolyA 1-2, Bcl11a primer annealing sites flanking
                  sequence comprising 11 interrupting sequences separating
                  12 sets of 12 consecutive adenosines
source              1..267
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 16
tcttccttca gtctgtaaac ctcagaattc atctagctcg agaaaaaaaa aaatgggaaa 60
aaaaaaaaac ggaaaaaaaa aaagggtaaa aaaaaaaaaa ataaaaaaaa aaacataaaa 120
aaaaaaaaac gaaaaaaaaa aaacgtaaaa aaaaaaaact caaaaaaaaa aaagataaaa 180
aaaaaaaaacc taaaaaaaaa aaatgtaaaa aaaaaaaagg gaaagtcttc catatcggtt 240
ctagaccaca cttcttactg aggtccc 267

SEQ ID NO: 17      moltype = DNA length = 261
FEATURE            Location/Qualifiers
misc_feature        1..261
                  note = PolyA 3-4, Bcl11a primer annealing sites flanking
                  sequence comprising 12 interrupting sequences separating
                  13 sets of 12 consecutive adenosines
source              1..261
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 17
tcttccttca gtctgtaaac ctcagctcga ggaagacaag ggaaaaaaaa aaacgcaaaa 60
aaaaaaaaac caaaaaaaaa aaatgcacaa aaaaaaaaaa cgaaaaaaaa aaatctaaa 120
aaaaaaaaac gaaaaaaaaa aaacccaaaa aaaaaaaaga caaaaaaaaa aaatagaaaa 180
aaaaaaaagt taaaaaaaaa aaactgaaaa aaaaaaaatt taaaaaaaaa aaatctagac 240
cacacttctt actgaggtcc c 261

SEQ ID NO: 18      moltype = DNA length = 370
FEATURE            Location/Qualifiers
misc_feature        1..370
                  note = 300pa, mRNA sequence of an exemplary poly-A tail
                  comprising 24 interrupting sequences separating 13 repeats
                  of 12 consecutive adenosines
source              1..370
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 18
aaaaaaaaaa aatggaaaaa aaaaaaacgg aaaaaaaaaa aaggtaaaaa aaaaaaatat 60
aaaaaaaaaa aacataaaaa aaaaaaacga aaaaaaaaaa acgtaaaaaa aaaaaactca 120
aaaaaaaaaa agataaaaaa aaaaaaccta aaaaaaaaaa atgtaaaaaa aaaaaaggga 180
aaaaaaaaaa acgcaaaaaa aaaaaacaca aaaaaaaaaa atgcaaaaaa aaaaaatcga 240
aaaaaaaaaa atctaaaaaa aaaaaacgaa aaaaaaaaaa cccaaaaaa aaaaagacaa 300
aaaaaaaaaa tagaaaaaaa aaaaagttaa aaaaaaaaaa ctgaaaaaaa aaaaatttaa 360
aaaaaaaaaa 370

SEQ ID NO: 19      moltype = DNA length = 97
FEATURE            Location/Qualifiers
misc_feature        1..97
                  note = 100PA - sequence of an exemplary poly-A tail
                  comprising 97 adenine nucleotide homopolymer
source              1..97
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 19
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 97

SEQ ID NO: 20      moltype = DNA length = 20
FEATURE            Location/Qualifiers
misc_feature        1..20
                  note = pUC-M seq2 forward primer
source              1..20

```

-continued

```

mol_type = other DNA
organism = synthetic construct

SEQUENCE: 20
gggttattgt ctcattgagcg 20

SEQ ID NO: 21      moltype = DNA length = 20
FEATURE           Location/Qualifiers
misc_feature       1..20
                   note = pUC-M seq reverse primer
source            1..20
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 21
ttttgtgatg ctcgtcaggg 20

SEQ ID NO: 22      moltype = DNA length = 25
FEATURE           Location/Qualifiers
misc_feature       1..25
                   note = RN-Bcl11a for
source            1..25
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 22
tcttccttca gtctgtaaac ctcag 25

SEQ ID NO: 23      moltype = DNA length = 22
FEATURE           Location/Qualifiers
misc_feature       1..22
                   note = RN-Bcl11a rev
source            1..22
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 23
gggacctcag taagaagtgt gg 22

SEQ ID NO: 24      moltype = DNA length = 4506
FEATURE           Location/Qualifiers
misc_feature       1..4506
                   note = Liv-Udepleted: Cas9 mRNA with a poly-A tail
                   consisting of 98 consecutive adenosines
source            1..4506
                   mol_type = other DNA
                   organism = synthetic construct

SEQUENCE: 24
tcccgcagtc ggcgccagc ggctctgctt gtctcgtgtg gtgtcgttgc aggccttatt 60
cggatccgcc accatggaca agaagtacag catcggactg gacatcggaa caaacagcgt 120
cggatgggca gtcattcacag acgaatacaa ggtcccgagc aagaagttca aggtcctggg 180
aaacacagac agacacagca tcaagaagaa cctgatcgga gcaactgtgt tcgacagcgg 240
agaaacagca gaagcaacaa gactgaagag aacagcaaga agaagatata caagaagaaa 300
gaacagaatc tgctacctgc aggaaatctt cagcaacgaa atggcaaaagg tcgacgacag 360
cttcttccac agactggaag aaagcttcct ggtcgaagaa gacaagaagc acgaaagaca 420
cccgatcttc ggaaacatcg tcgacgaagt cgcataccac gaaaagtacc cgacaatcta 480
ccacctgaga aagaagctgg tcgacagcac agacaaggca gacctgagac tgatctacct 540
ggcactggca cacatgatca agttcagagg acacttcctg atcgaaggag acctgaacct 600
ggacaacagc gacgtcgaca agctgttcat ccagctgggtc cagacatata accagctggt 660
cgaagaaaaa ccgatcaacg caagcggagt cgacgcaaa gcaatcctga gcgcaagact 720
gagcaagagc agaagactgg aaaacctgat cgcacagctg ccgggagaaa agaagaacgg 780
actgttcgga aacctgatcg cactgagcct gggactgaca cgaacttca agagcaactt 840
cgacctggca gaagacgcaa agctgcagct gagcaaggac acatacgacg acgacctgga 900
caacctgctg gcacagatcg gagaccagta cgcagacctg ttctctggcg caaagaacct 960
gagcgacgca atcctgctga gcgacatcct gagagtcaac acagaaatca caaaggcacc 1020
gctgagcgca agcatgatca agagatacga cgaacaccac caggacctga cactgctgaa 1080
ggcactggtc agacagcagc tgccggaaaa gtacaaggaa atcttcttcg accagagcaa 1140
gaacggatag ctaggataca tcgacggagg agcaagccag gaagaattct acaagttcat 1200
caagccgata ctggaaaaga tggacggaac agaagaactg ctggtcaagc tgaacagaga 1260
agacctgctg agaaagcaga gaacattcga caacggaagc atcccgacc agatccacct 1320
gggagaactg cagcaatcc tgagaagaca ggaagacttc taccggttcc tgaaggacaa 1380
cagagaaaag atcgaaaaga tcttgacatt cagaatcccg tactacgtcg gaccgctggc 1440
aagaggaaac agcagattcg catggatgac aagaagagc gaagaaacaa tcacaccgtg 1500
gaacttcgaa gaagtctgag acaaggaggc aagcgcacag agcttcatcg aaagaatgac 1560
aaacttcgac aagaacctgc cgaacgaaaa ggtcctgcgc aagcacagcc tgctgtacga 1620
atacttcaca gtctacaacg aactgacaaa ggtcaagtac gtcacagaag gaatgagaaa 1680
gccgcatctc ctgagcggag aacagaagaa ggcaatcgtc gacctgtgtg tcaagacaaa 1740
cagaagggtc acgtcaaagc agctgaagga agactacttc aagaagatcg aatgcttcga 1800
cagcgtcgaa atcagcggag tcgaagacag attcaacgca agcctgggaa cataccacga 1860
cctgctgaag atcatcaagg acaaggactt cctggacaac gaagaaaacg aagacacct 1920
ggaagacatc gtctgacac tgacactgtt cgaagacaga gaaatgatcg aagaaagact 1980
gaagacatag gcacacctgt tcgacgacaa ggtcatgaag cagctgaaga gaagaagata 2040
cacaggatgg ggaagactga gcagaaagct gatcaacgga atcagagaca agcagagcgg 2100

```

-continued

```

aaagacaatc ctggacttcc tgaagagcga cggattcgca aacagaaact tcatgcagct 2160
gatccacgac gacagctcga cattcaagga agacatccag aaggcacagg tcagcggaca 2220
gggagacagc ctgcacgaac acatcgcaaa cctggcagga agcccgccaa tcaagaaggg 2280
aatcctgcag acagtcaagg tctgcgacga actggtcaag gtcatgggaa gacacaagcc 2340
ggaaaacatc gtcacgaaa tggcaagaga aaaccagaca acacagaagg gacagaagaa 2400
cagcagagaa agaatagaaga gaatcgaaga aggaatcaag gaactgggaa gccagatcct 2460
gaaggaacac ccggtcgaaa acacacagct gcagaacgaa aagctgtacc tgtactacct 2520
gcagaacgga agagacatgt acgtcgacca ggaactggac atcaacagac tgagcgacta 2580
cgacgtcgac cacatcgtcc cgcagagctt cctgaaggac gacagcatcg acaacaaggt 2640
cctgacaaga agcgacaaga acagaggaaa gagcgacaac gtcccgagcg aagaagtcgt 2700
caagaagatg aagaactact ggagacagct gctgaacgca aagctgatca cacagagaaa 2760
gttcgacaac ctgacaaagg cagagagagg aggactgagc gaactggaca aggcaggatt 2820
catcaagaga cagctggctg aaacaagaca gatcacaaag cactgcgac agatcctgga 2880
cagcagaatg aacacaaagt acgacgaaaa cgacaagctg atcagagaaag tcaaggtcat 2940
cacactgaag agcaagctgg tcagcgactt cagaaaggac ttccagttct acaaggtcag 3000
agaaatcaac aactaccacc acgcacacga cgcatacctg aacgcagtcg tcggaacagc 3060
actgatcaag aagttaccga agctggaaaag cgaattcgtc tacggagact acaaggtcta 3120
cgacgtcaga aagatgatcg caaagagcga acaggaaaac ggaaaggcaa cagcaaaagt 3180
cttcttttac agcaacatca tgaacttctt caagacagaa atcacactgg caaacggaga 3240
aatcagaaaag agacogctga tcgaaaacaaa cggagaaaaca ggagaaatcg tctgggacaa 3300
gggaagagac ttgcacaacg tcagaaaggt cctgagcatg ccgagggtca acatcgtcaa 3360
gaagacagaa gtccagacag gaggattcag caaggaaagc atcctgccga agagaacacg 3420
cgacaagctg atcgcaagaa agaaggactg ggaccggaag aagtcaggag gattcgacag 3480
cccgacagtc gcatacagcg tctctgtcgt cgcaaaagtc gaaaagggaa agagcaagaa 3540
gctgaagagc gtcaaggaaac tgctgggaat cacaatcatg gaaagaagca gcttcgaaaa 3600
gaaccgcatc gacttctctg aagcaaaagg atacaaggaa gtcaagaagg acctgatcat 3660
caagctgccg aagtacagcc tgttcgaact ggaaaaacgga agaaagagaa tgctggcaag 3720
cgcaggagaa ctgcagaagg gaaacgaact ggcactgccg agcaagtacg tcaacttcct 3780
gtactctgga atcgactacg aaaagctgaa gggaaagccg gaagacacag aacagaagca 3840
gctgttcgtc gaacagcaca agcactacct ggacgaaatc atcgaaacga tcagcgaatt 3900
cagcaagaga gtcatcctgg cagacgcaaa cctggacaag gtctcgagcg catacaacaa 3960
gcacagagac aagcogcatc gagaaacagg agaaaaacatc atccacctgt tcacactgac 4020
aaactctggg gcaccggcgc cattcaagta cttcgacaca acaatcgaca gaaagagata 4080
cacaagcaca aaggaaagtc tggacgcaac actgatccac cagagcatca caggactgta 4140
cgaaaacaaga atcgacttga gccagctggg agggagcggg ggagggaagc cgaagaagaa 4200
gagaaaggtc tagctagcca tcacatttaa aagcatctca gcctaccatg agaataagag 4260
aaagaaaatg aagatcaata gcttattcat ctctttttct tttctgttgg tgtaaagcca 4320
acacctgttc taaaaaacat aaattttctt aatcattttg cctcttttct ctgtgttcca 4380
attaataaaa aatggaaaga acctcgagaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4500
aaaaaa 4506

```

```

SEQ ID NO: 25      moltype = DNA length = 4512
FEATURE           Location/Qualifiers
misc_feature       1..4512
                  note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 3
source            1..4512
                  mol_type = other DNA
                  organism = synthetic construct

```

```

SEQUENCE: 25
tccccgagtc ggcgtccagc ggctctgtgt gtctgtgtgt gtgtcgttgc aggccttatt 60
cggatccgcc accatggaga aagaatcacg catcggactg gacatcggaa caaacagcgt 120
cggatgggga gtcacacagc acgaatacaa ggtcccgagc aagaagtcca aggtcctggg 180
aaacacagac agacacagca tcaagaagaa cctgatcgga gcaactgtgt tcgacagcgg 240
agaaacagca gaagcaacaa gactgaagag aacagcaaga agaagatata caagaagaaa 300
gaacagaaac tgctacctgc aggaaatctt cagcaacgaa atggcaaaag tcgacgacag 360
cttcttccac agactggaag aaagcttctt ggtcgaaaga gacaagaagc acgaaagaca 420
cccgatcttc ggaacacatc tcgacgaagt cgcataccac gaaaagtacc cgacaatcta 480
ccacctgaga aagaagctgg tcgacagcac agacaaggca gacctgagac tgatctacct 540
ggcactggca cacatgatca agttcagagg acacttctct atcgaaaggag acctgaacct 600
ggacaacagc gacgtcgata agctgttcat ccagctgggtc cagacatata accagctggt 660
cgaagaaaaa ccgatcaacg caagcggagt cgcgcgcaag gcaatcctga ggcgaagact 720
gagcaagagc agaagactgg aaaacctgat cgcacagctg ccgggagaaa agaagaacgg 780
actgttcgga aactgtatc cactgagcct gggactgaca cgaacttca agagcaactt 840
cgacctggca gaagacgcaa agctgcagct gagcaaggac acatacgacg acgacctgga 900
aaactctgct gcacagatcg gagaccagta cgcagacctg ttcttggcag caaagaacct 960
gagcgagcga atcctgttga gcgacatcct gagagtcaac acagaaatca caaaggcacc 1020
gctgagcgca agcatgatca agagatagca cgaacaccac caggacctga cactgctgaa 1080
ggcactgggt agacagcagc tgccggaaaa gtacaaggaa atcttcttcc accagagcaa 1140
gaacggatag ctaggataca tcgacggagg agcaagccag gaagaattct acaagttcat 1200
caagccgcat ctagaaaaga tggacggaaac agaagaactg ctggtcgaag tgaacagaga 1260
agacctgctg agaaagcaga gaacattcga caacggaagc atcccgacc agatccacct 1320
gggagaactg cagcaatcc tgagaagaca ggaagacttc taccgttcc tgaaggacaa 1380
cagagaaaag atcgaaaaga tctgtacatt cagaatcccg tactacgtcg gaccgctggc 1440
aagaggaaac agcagattcg catggatgac aagaagagc gaagaaacaa tcacaccgtg 1500
gaacttcgaa gaagtctctg acaaggagagc aagcgcacag agcttcatcg aaagaatgac 1560
aaacttcgac aagaacctgc cgaacgaaaa ggtcctgccg aagcacagcc tgctgtacga 1620
atacttcaca gttacaaag aactgacaaa ggtcaagtag gtcacagaag gaatgagaaa 1680
gccggcattc ctgagcggag aacagaagaa ggcaatcgtc gacctgtgtg tcaagacaaa 1740

```

-continued

```

cagaaagggtc acagtcaagc agctgaagga agactacttc aagaagatcg aatgcttcga 1800
cagcgtcgaa atcagcggag tcgaagacag attcaacgca agcctgggaa cataccacga 1860
cctgctgaag atcatcaagg acaaggactt cctggacaac gaagaaaacg aagacatcct 1920
ggaagacatc gtctctgacac tgacactgtt cgaagacaga gaaatgatcg aagaaagact 1980
gaagacatc gcacacctgt tcgacgacaa ggtcatgaag cagctgaaga gaagaagata 2040
cacaggatgg ggaagactga gcagaaagct gatcaacgga atcagagaca agcagagcgg 2100
aaagacaatc ctggacttcc tgaagagcga cggattcgca aacagaaact tcatgcagct 2160
gatccacgac gacagctga cattcaagga agacatccag aaggcacagg tcagcggaca 2220
gggagacagc ctgcacgaac acatcgcaaa cctggcagga agcccgcaaa tcaagaaggg 2280
aatcctgcag acagtcaagg tcgtcgacga actggtcaag gtcatgggaa gacacaagcc 2340
ggaaaacatc gtcatcgaaa tggcaagaga aaaccagaca acacagaagg gacagaagaa 2400
cagcagagaa agaatagaaga gaatcgaaga aggaatcaag gaactgggaa gccagatcct 2460
gaaggaacac ccggtcgaaa acacacagct gcagaacgaa aagctgtacc tgtactacct 2520
gcagaacgga acgctcgacca acgtcgacga ggaactggac atcaacagac tgagcgacta 2580
cgacgtcgac cacatcgtcc cgcagagctt cctgaaggac gacagcatcg acaacaaggt 2640
cctgacaaga agcgacaaga acagagggaaa gagcgacaac gtcccgagcg aagaagtctg 2700
caagaagatg aagaactga ggagacagct gctgaacgca aagctgatca cacagagaaa 2760
gttcgacaac ctgacaagg cagagagagg aggactgagc gaactggaca aggcaggatt 2820
catcaagaga cagctggtcg aaacaagaca gatcacaagg cactgcgac agatcctgga 2880
cagcagaatg aacacaaagt acgacgaaaa cgacaagctg atcagagaag tcaaggtcat 2940
cacactgaag agcaagctgg tcagcgactt cagaaaggac ttccagtctt acaaggtcag 3000
agaaatcaac aactaccacc acgcacacga cgcatacctg aacgcagtcg tcggaacagc 3060
actgatcaag aagtaaccga agctggaaa agctgtctgc tacggagact acaaggtcta 3120
cgacgtcaga aagatgatcg caaagagcga acaggaaatc ggaaaggcaa cagcaaaagt 3180
cttcttttac agcaacatca tgaacttctt caagacagaa atccactgg caaacggaga 3240
aatcagaaag agaccgtgta tcgaaaacaa cggagaaaac ggagaaatcg tctgggacaa 3300
gggaagagac ttcgcaacag tcagaaaggt cctgagcatg ccgaggtgca acatcgtcaa 3360
gaagacagaa gtcacagacg gaggttcag caagaaaagc atcctgccga agagaacacg 3420
cgacaagctg atcgcaagaa agaaggactg ggaccggaag aagtaacggg gattcgacag 3480
cccgacagtc gcatacagcg tcctggtcgt cgcaaaagtc gaaaagggaa agagcaagaa 3540
gctgaagagc gtcaaggaac tgctgggaat cacaatcatg gaaagaagca gcttcgaaa 3600
gaaccgagtc gacttctctg aagcaaaagg atacaaggaa gtcaagaagg acctgatcat 3660
caagctgccg aagtacagcc tgttcgaact ggaaaaacgga agaaagagaa tgctggcaag 3720
cgcaggagaa tcgcagaagg gaaacgaact ggcactgccg agcaagtacg tcaacttcct 3780
gtactggca agccactacg aaaagctgaa gggaagcccg gaagacaacg aacagaagca 3840
gctgttcgtc gaacagacac agcactacct ggacgaaatc atcgaaacga tcagcgaatt 3900
cagcaagaga gtcactctgg cagacgcaaa cctggacaag gtcctgagcg catacaaca 3960
gcacagagac aagccgatca gagaacagcg agaaaaatc atccactgt tcacactgac 4020
aaacctggga gccacggcgc cattcaagta cttcgacaca acaatcgaca gaaagagata 4080
cacaagcaca aaggaagtcc tggacgcaac actgatccac cagagcatca caggactgta 4140
cgaaaacaaga atcgactgta gccagctggg agggagacgga ggagggaagc cgaagaagaa 4200
gagaaaggct tagctagcca tcacatttaa aagcatctca gcctaccatg agaataagag 4260
aaagaaaatg aagatcaata gcttattcat ctctttttct tttctgttgg tgtaaagcca 4320
acacctgttc taaaaaacat aaattttctt aatcattttt cctcttttct ctgtgcttca 4380
attaataaaa aatgggaaga accaaaaaaa aaaaaaaaaa aaaaaaaagc gaaaaaaaaa 4440
aaaaaaaaaa aaaaaaccga aaaaaaaaaa aaaaaaaaaa aaaaagtga aaaaaaaaaa 4500
aaaaaaaaaa aa 4512

```

```

SEQ ID NO: 26      moltype = DNA length = 4504
FEATURE            Location/Qualifiers
misc_feature       1..4504
                    note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 4
source             1..4504
                    mol_type = other DNA
                    organism = synthetic construct

```

```

SEQUENCE: 26
tcccgcagtc ggcgtccagc ggctctgctt gttcgtgtgt gtgtcgttgc aggccttatt 60
cggatccgcc accatggaca agaagtacag catcggactg gacatcgga caaacagcgt 120
cggatgggca gtcacacagc acgaatacaa ggtcccgagc aagaagttca aggtcctggg 180
aaacacagac agacacagca tcaagaagaa cctgatcgga gcactgtgtg tcgacagcgg 240
agaaacagca gaagcaacaa gactgaagag aacagcaaga agaagatata caagaagaaa 300
gaacagaatc tgctacctgc aggaaatctt cagcaacgaa atggcaaaag tcgacgacag 360
cttcttccac agactggaag aaagcttcct ggtcgaagaa gacaagaagc acgaaagaca 420
ccgactcttc ggaaacatcg tcgacgaagt cgcataccac gaaaagtacc cgacaatcta 480
ccacctgaga aagaagctgg tcgacagcac agacaaggca gacctgagac tgatctacct 540
ggcactggca cacatgatca agttcagagg acacttctct atcgaaaggag acctgaacct 600
ggacaacagc cagctcgaca agctgttcat ccagctggtc cagacatata accagctgtt 660
cgaaagaaac ccgatcaacg caagcggagt cgacgcaaa gcaatcctga gcgcaagact 720
gagcaagagc agaagactgg aaaacctgat cgcacagctg ccgggagaaa agaagaacgg 780
actgttcgga aacctgatcg cactgagcct gggactgaca ccgaacttca agagcaactt 840
cgactggca gaagacgcaa agctgagct gagcaaggac acatacagcg acgacctgga 900
caacctgctg gcacagatcg gagaccagta cgcagacctg ttctggcgag caaagaacct 960
gagcgacgca atcctgttga gcgacatcct gagagtcaac acagaaatca caaaggcacc 1020
gctgagcgca agcatgatca agagatacga cgaacaccac caggacctga cactgctgaa 1080
ggcactggtc agacagcagc tgccggaaaa gtacaaggaa atcttcttctg accagagcaa 1140
gaacggatag gcaggatata tcgacggagg agcaagccag gaagaattct acaagttcat 1200
caagccgata ctggaaaaa tggacggaac agaagaactg ctggtcaagc tgaacagaga 1260
agactgctg ctgaagcaga gaacattcga caacggaagc atcccgacc agatccacct 1320
gggagactg cagcgaatcc tgagaagaca ggaagacttc taccggttcc tgaaggacaa 1380

```

-continued

```

cagagaaaag atcgaaaaga tcttgacatt cagaatcccc tactacgtcg gaccgctggc 1440
aagaggaaaac agcagatttcg catggatgac aagaaaagagc gaagaaaacaa tcacaccgtg 1500
gaacttcgaa gaagtcgtcg acaaggaggc aagcgcacag agcttcacg aaagaatgac 1560
aaacttcgac aagaacctgc cgaacgaaaa ggtcctgcgc aagcacagcc tgcgtgacga 1620
atacttcaca gtctacaacg aactgacaaa ggtcaagtac gtcacagaag gaatgagaaa 1680
gccggtcatc ctgagcggag aacagaagaa ggcaatcgtc gacctgtgt tcaagacaaa 1740
cagaaaaggtc acagtcaagc agctgaagga agactacttc aagaagatcg aatgcttoga 1800
cagcgtcgaa atcagcggag tcgaagacag attcaacgca agcctgggaa cataccacga 1860
cctgtctgaag atcatcaagg acaaggactt cctggacac gaagaaaacg aagacatcct 1920
ggaagacatc gtcttgacac tgacactgtt cgaagacaga gaaatgatcg aagaaagact 1980
gaagacatc gcacacgtgt tcgacgacaa ggtcatgaag cagctgaaga gaagaagata 2040
cacaggatgg ggaagactga gcagaagct gatcaacgga atcagagaca agcagagcgg 2100
aaagacaatc ctggacttcc tgaagagcga cggattcgca aacagaaact tcatgcagct 2160
gatccacgac cagacgtga cattcaagga agacatccag aaggcacagg tcagcggaca 2220
gggagacagc ctgacagaac acatcgcaaa cctggcagga agcccgcaa tcaagaaggg 2280
aatcctgcag acagtcaagg tcgtcgacga actggtcaa gtcattggaa gacacaagcc 2340
ggaaaacatc gtcatcgaaa tggcaagaga aaaccagaca acacagaagg gacagaagaa 2400
cagcagagaa agaataaga gaatcgaaga aggaatcaag gaactgggaa gccagatcct 2460
gaaggaacac ccggtcgaaa acacacagct gcagaacgaa aagctgtacc tgtactacct 2520
gcagaacgga agagactgt acgtcgacca ggaactggac atcaacagac tgagcacta 2580
cgacgtcgac cacatcgtcc cgcagagctt cctgaaggac gacagcatcg acaacaaggt 2640
cctgacaaga agcgaagaac acagaggaaa gagcgacaac gtcccgagcg aagaagtcgt 2700
caagaagatg aagaactact ggagacagct gctgaacgca aagctgatca cacagagaaa 2760
gttcgacaac ctgacaagg cagagagagg aggactgagc gaactggaca aggcaggatt 2820
catcaagaga cagctggtcg aaacaagaca gatcacaagg cactgcgac agatcctgga 2880
cagcagaatg aacacaaagt acgacgaaaa cgacaagctg atcagagaaa tcaaggtcat 2940
cacactgaag agcaagctgg tcagcgactt cagaaaggac ttccagtctt acaaggtcag 3000
agaaatcaac aactaccacc acgcacacga cgcatacctg aacgcagtc tcggaacagc 3060
actgatcaag aagtagccga agctggaaa gcaattcgtc tacggagact acaaggtcta 3120
cgacgtcaga aagatgatcg caaagagcga acaggaaaac ggaaaggcaa cagcaaaatg 3180
cttctttcac agcaacctca tgaactttt caagacagaa atcacactgg caaacggaga 3240
aatcagaaa agaccgtgta tcgaaaacaaa cggagaaaac ggagaaatcg tctgggacaa 3300
gggaagagac ttgcgaacag tcagaaaggt cctgagcatg ccgcaggatc acatcgtcaa 3360
gaagacagaa gtccagacag gaggattcag caaggaaagc atcctgccga agagaacacg 3420
cgacaagctg atcgcaagaa agaaggactg ggaccggaag aagtagcgag gattcgacag 3480
cccgacagtc gcatacagcg tctgtgtcgt cgcaaaagtc gaaaagggaa agagcaagaa 3540
gctgaagagc gtcaaggaa gcttggaat cactggaatg gaaagaagca gcttcgaaaa 3600
gaacccgacg gacttctctg aagcaaaagg atacaaggaa gtcaagaagg acctgatcat 3660
caagctgccg aagtacagcc tgttcgaact ggaaaaacgga agaaagagaa tgctggcaag 3720
cgaggagaaa ctgcagaagg gaaacgaact ggcactgccg agcaagtacg tcaacttctt 3780
gtacctggca agccactacg aaaagctgaa gggaagcccg gaagacaacg aacagaagca 3840
cgtgttcgtc gaacagacac agcactacct ggacgaaatc atcgaaacga tcagcgaatt 3900
cagcaagaga gtcatcctgg cagacgcaaa cctggacaag gtctgagcg catacaacaa 3960
gcacagagac aagccgatca gagaacagcg agaaaaatc atccactgt tcacactgac 4020
aaacctggga gccaccgagc cattcaagta cttcgacaca acaatcgaca gaaagagata 4080
cacaagcaca aaggaagtc gccagcgaac actgatccac cagagcatca caggactgta 4140
cgaaaacaaga atcgactgta gccagctggg aggagacgga ggagggaagc cgaagaagaa 4200
gagaaaggtc tagctagcca tcacatttaa aagcatctca gcctaccatg agaataagag 4260
aaagaaaatg aagatcaata gcttattcat ctctttttct tttctgttgg tgtaaagcca 4320
acacctgttc taaaaaacat aaattttttt aatcattttt cctcttttct ctgtgttcca 4380
attaataaaa aatggaaaga accaaaaaaa aaaaaaaaag aaaaaaaaac aaaaaacaaa 4440
aaaaaaaaaa aaataaaaaa aaaaaaaaaa taaaaaaaaa aaaaaaacaa aaaaaaaa 4500
aaaa 4504

```

```

SEQ ID NO: 27      moltype = DNA length = 4568
FEATURE           Location/Qualifiers
misc_feature       1..4568
note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 5
source            1..4568
mol_type = other DNA
organism = synthetic construct

```

```

SEQUENCE: 27
tcccgcagtc ggcgtccagc ggctctgtgt gtctgtgtgc aggccttatt 60
cggatccgcc accatggaca agaagtacag catcggactg gacatcggaa caaacagcgt 120
cggatgggca gtcacacag acgaatacaa ggtcccgagc aagaagtcca aggtcctggg 180
aaacacagac agacacagca tcaagaagaa cctgatcgga gactgtgtgt tcgacagcgg 240
agaaacagca gaagcaacaa gactgaagag aacagcaaga agaagataca caagaagaaa 300
gaacagaatc tgcctacgtc aggaatatct cagcaacgaa atggcaagg tcgacgacag 360
cttcttccac agactggaag aaagcttctt ggtcgaagaa gacaagaagc acgaaagaca 420
cccgatcttc ggaacatcgt tcgacgaagt cgcataccac gaaaagtacc cgacaatcta 480
ccactgaga aagaagctgg tcgacagcac agacaaggca gacctgagac tgatctacct 540
ggcactggca cacatgatca agttcagagg acacttctgt atcgaaggag acctgaacct 600
ggacaacagc cagctgcaga agctgttcat ccagctgttc cagacatata accagctgtt 660
cgaagaaaaa ccgcatcaac caagcggagt cgacgcaaa gcaatcctga gcgcaagact 720
gagcaagagc agaagactgg aaaaacctgt cgcacagctg ccgggagaaa agaagaacgg 780
actgttcgga aacctgatcg cactgagcct gggactgaca ccgaacttca agagcaactt 840
cgacctggca gaagacgcaa agctgcagct gagcaaggac acatacgagc acgacctgga 900
caacctgctg gcacagatcg gagaccagta cgcagacctg ttctgtggcg caaagaacct 960
gagcgacgca atcctgctga gcgacatcct gagagtcaac acagaaatca caaaggcacc 1020

```

-continued

```

gctgagcgca agcatgatca agagatagca cgaacaccac caggacctga cactgctgaa 1080
ggcactggctc agacagcagc tgcgggaaaa gtacaaggaa atcttcttcg accagagcaa 1140
gaacggatcac gcaggatata tcgacggagg agcaagccag gaagaattct acaagttcat 1200
caagccgatc ctggaaaaa tggacggaac agaagaactg ctggtcaagc tgaacagaga 1260
agacctgctg agaaagcaga gaacattcga caacggaagc atcccgacc agatccacct 1320
gggagaactg cagcaatcc tgagaagaca ggaagacttc taccgttcc tgaaggacaa 1380
cagagaaaa atcgaaaaa tcttgacatt cagaatcccg tactacgtcg gaccgctggc 1440
aagaggaaa agcagattcg catggatgac aagaaagagc gaagaaacaa tcacaccgtg 1500
gaacttcgaa gaagtctgag acaaggagag aagcgacagc agcttcatcg aaagaatgac 1560
aaacttcgac aagaacctgc cgaacgaaaa ggtcctgccc aagcacagcc tgctgtacga 1620
atacttcaca gtctacaacg aactgacaaa ggtcaagtac gtcacagaag gaatgagaaa 1680
gccggcatto ctgagcggag aacagaagaa ggcaatctgc gacctgtgt tcaagacaaa 1740
cagaaaggtc acagtcaagc agctgaagga agactacttc aagaagatcg aatgcttga 1800
cagcgtcgaa atcagcggag tcgaagacag attcaacgca agcctgggaa cataccacga 1860
cctgctgaag atcatcaagg acaaggactt cctggacaac gaagaaaaacg aagacatcct 1920
ggaagacatc gtcttgacac tgacactgtt cgaagacaga gaaatgatcg aagaaagact 1980
gaagacatc gcacacattgt tcgacgacaa ggtcatgaag cagctgaaga gaagaagata 2040
cacaggatgg ggaagactga gcagaagct gatcaacgga atcagagaca agcagagcgg 2100
aaagacaatc ctggacttcc tgaagagcga cggattcgca aacagaaact tcatgacgtc 2160
gatccacgac gacagcctga cattcaagga agacatccag aaggcacagg tcagcggaca 2220
gggagacagc ctgacagaac acatcgcaaa cctggcagga agcccgcaa tcagaaggg 2280
aatcctgcag acagtcaagg tcgtcgaca actggtcaag gtcattggga gacacaagcc 2340
ggaaaaatc gtcatcgaaa tggcaagaga aaaccagaca acacagaagg gacagaagaa 2400
cagcagagaa agaataaga gaatcgaaga aggaatcaag gaactgggaa gccagatcct 2460
gaaggaacac ccggtcgaaa acacacagct gcagaacgaa aagctgtacc tgtactacct 2520
gcagaacgga agagacatgt acgtcgacca ggaactggac atcaacagac tgagcgacta 2580
cgactcgac cacatcgtcc cgcagagctt cctgaaggac gacagcatcg acaacaaggt 2640
cctgacaaga agcgaagaac acagaggaaa gagcgacaac gtcccgagcg aagaagtcgt 2700
caagaagatg aagaactact ggagacagct gctgaacgca aagctgatca cacagagaaa 2760
gttcgacaac ctgacaaagg cagagagagg aggactgagc gaactggaca aggcaggatt 2820
catcaagaga cagctggctg aaacaagaca gatcacaaag cactcgac agatcctgga 2880
cagcagaatg aacacaaagt acgacgaaaa cgacaagctg atcagagaaa tcagggtcat 2940
cacactgaag agcaagctgg tcagcgactt cagaaaggac ttccagtctt acaaggctcag 3000
agaaatcaac aactaccacc agcgcacaga cgcatacctg aacgcagtcg tcggaacagc 3060
actgatcaag aagtaaccga agctggaaa gcaattctgc tacggagact acaaggctta 3120
cgactgcaga aagatgatcg caaagagcga acaggaaaac ggaaaggcaa cagcaaaagta 3180
cttcttctac agcaacatca tgaacttctt caagacagaa atcacactgg caaacggaga 3240
aatcagaagg agaccgctga tcgaaacaaa cggagaaaaa ggagaaatcg tctgggacaa 3300
gggaagagac ttgcgaacag tcagaaggt cctgagcatg ccgaggtca acatcgtcaa 3360
gaagacagaa gtccagacag gaggtttcag caaggaaaag atcctgccga agagaacag 3420
cgacaagctg atcgaagaa agaaggactg ggaccggaag aagtacggag gattcgacag 3480
cccgacagtc gcatacagcg tcttggtcgt cgcaaaagtc gaaaagggaa agagcaagaa 3540
gctgaagagc gtcaaggaa gctgggaat cacaatcatg gaaagaagca gcttcgaaaa 3600
gaaccgagtc gacttctctg aagcaaaagg atacaaggaa gtcaagaagg acctgatcat 3660
caagctgccg aagtacagcc tgttcgaact ggaaaacgga agaaagagaa tgctggcaag 3720
cgcaggagaa ctgcagaagg gaaacgaact ggcactgccc agcaagtacg tcaacttctt 3780
gtactgggca agccactacg aaaagctgaa ggggaagccc gaagacaacg aacagaagca 3840
ctgtttctgc gaacagcaca agcactacct ggacgaaatc atcgaaacaga tcagcgaatt 3900
cagcaagaga gtcatcctgg cagacgcaaa cctggacaag gtcctgagcg catacaacaa 3960
gcacagagac aagccgatca gagaacaggg agaaaaatc atccactgt tcacactgac 4020
aaactgggga gccccggcgc cattcaagta cttcgacaca acaatcgaca gaaagagata 4080
cacaagcaca aaggatccac actgacgaac cagagcatca caggactgta 4140
cgaaacaaga atcgactgga gccagctggg aggagacgga ggaggaagcc cgaagaagaa 4200
gagaaaggtc tagctagcca tcacatttaa aagcatctca gcctaccatg agaataagag 4260
aaagaaaaatg aagatcaata gcttattcat ctctttttct ttttgggttg tgaagaagca 4320
acacctgttc taaaaaacat aaattttctt aatcattttt cctcttttct ctgtgttca 4380
attaataaaa aatggaaaga accaaaaaaa aaaaaaaaag aaaaaaaaac aaaaaacaaa 4440
aaaaaaaaaa aatataaaaa aaaaaaaaac aaaaaaaaac aaaaaaaaac aaaaaaaaac 4500
aaaaacaaaa aaaaaaaaac aaaaaaaaac aaaaaaaaac aaaaaaaaac aaaaaaaaac 4560
aaaaaaaaaa 4568

```

```

SEQ ID NO: 28      moltype = DNA length = 4519
FEATURE           Location/Qualifiers
misc_feature       1..4519
                   note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 10
source             1..4519
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 28
tcccgcagtc ggcgtccagc ggcctctgctt gttcgtgtgt gtgtcgttgc aggccttatt 60
cggatccgcc accatggaca agaagtacag catcggactg gacatcggaa caaacacgct 120
cggatgggca gtcacacag acgaatacaa ggtcccagc aagaagttca aggtcctggg 180
aaacacagac agacacagca tcaagaagaa cctgatcgga gactgtgtg tcgacagcgg 240
agaacacgca gaagcaacaa gactgaagag aacagcaaga agaagatata caagaagaaa 300
gaacagaatc tgctacctgc aggaatctt cagcaacgaa atggcaaaag tcgacgacag 360
cttcttccac agactggaag aaagcttcct ggtcgaaaga gacaagaagc acgaaagaca 420
cccgatcttc ggaacatcgt tcgacgaagt cgcataccac gaaaagtacc cgacaatcta 480
ccactgaga aagaagctgg tcgacagcac agacaaggca gacctgagac tgatctacct 540
ggcactggca cacatgatca agttcagagg acacttctctg atcgaaggag acctgaaccc 600

```

-continued

```

ggacaacagc gacgtcgaca agctgttcat ccagctggtc cagacatata accagctgtt 660
cgaagaaaac ccgatcaacg caagcggagt cgacgcaaa gcaatcctga gcgcaagact 720
gagcaagagc agaagactgg aaacactgat cgcacagctg ccgggagaaa agaagaacgg 780
actgttcgga aacctgatcg cactgagcct gggactgaca ccgaacttca agagcaactt 840
cgacctggga gaagacgcaa agctgcagct gagcaaggac acatacgacg acgacctgga 900
caacctgctg gcacagatcg gagaccagta cgcagacctg ttcttggcag caaagaacct 960
gagcgagcga atcctgtctg gcgacatcct gagagtcaac acagaaatca caaaggcacc 1020
gctgagcgca agcatgatca agagatacga cgaacaccac caggacctga cactgctgaa 1080
ggcactggtc agacagcagc tgcgggaaaa gtacaaggaa atcttcttcg accagagcaa 1140
gaacggatag gcaggatata tcgacggagg agcaagccag gaagaattct acaagttcat 1200
caagccgata ctggaaaaga tggacgggaa agaagaactg ctggtcaagc tgaacagaga 1260
agacctgctg agaagcaga gaacattcga caacggaaag atcccgcacc agatccacct 1320
gggagaactg cagcgaatcg tgagaagaca ggaagacttc taccogttcc tgaaggacaa 1380
cagagaaaag atcgaaaaga tctgacatt cagaatcccg tactactgctg gacctgtggc 1440
aagagggaaa agcagattcg catggatgac aagaagagc gaagaaaaca tcacaccgtg 1500
gaacttcgaa gaagtctgtg acaaggggagc aagcgcacag agcttcatcg aaagaatgac 1560
aaacttcgac aagaacctgc cgaacgaaaa ggtcctgccc aagcacagcg tgctgtacga 1620
atacttcaca gtctacacag aactgacaaa ggtcaagtag gtcacagaag gaatgagaaa 1680
gccggcattc ctgagcggag aacagaagaa ggcaatcgct gacctgtgtt tcaagacaaa 1740
cagaagagtc acagtcaagc agctgaagga agactacttc aagaagatcg aatgcttcga 1800
cagcgtcgaa atcagcggag tcgaagacag attcaacgca agcctgggaa cataccacga 1860
cctgtgaaag atcatcaagg acaaggactt cctggacaac gaagaaaacg aagacatcct 1920
ggagagacat ctcctgacac tgacactgtt cgaagacaga gaaatgatcg aagaaagact 1980
gaagacatag gcacacctgt tcgacgacaa ggtcatgaag cagctgaaga gaagaagata 2040
cacaggatgg ggaagactga gcagaaagct gatcaacgga atcagagaca agcagagcgg 2100
aaagacaatc ctggacttcc tgaaagcgca cggatttcga aacagaaact tcactgagct 2160
gatccacgac gacagcctga catcaagga agacatccag aaggcacagg tcagcggaca 2220
gggagacagc ctgcacgaac acatcgcaaa cctggcagga agcccgcaa tcaagaaggg 2280
aatcctgcag atcgataagg tctgtagcga actggtcaag gtcattggga gacacaagcc 2340
ggaaaacatc gtcattcgaa tggcaagaga aaaccagaca acacagaagg gacagaagaa 2400
cagcagagaa agaataagaa gaatacgaag aggaatcaag gaactgggaa gccagatcct 2460
gaaggaacac ccggtcgaaa acacacagct gcagaacgaa aagctgtacc tgtactacct 2520
gcagaacgga agagacatgt acgtcgacca ggaactggac atcaacagac tgagcgacta 2580
cgagtcgac cacatcgctc cgcagagctt cctgaaggac gacagcatcg acaacaagggt 2640
cctgacaaga agcagacaga acagaggaaa gagcgacaac gtcccagcgg aagaagtctg 2700
caagaagatg aagaactact ggagacagct gctgaacgca aagctgatca cacagagaaa 2760
gttcgacaa ctgacaaaag cagagagagg aggaactgagc gaactggaca aggcaggatt 2820
catcaagaga cagctgtgtg aaacaagaca gatcacaaag cacgtgcgac agatcctgga 2880
cagcagaatg aacacaaagt agcagcaaaa cgacaagctg atcagagaag tcaaggtcat 2940
cacactgaag agcaagctgg tcagcgactt cagaaggagc ttccagttct acaaggtcag 3000
agaaatcaac aactaccacc acgcacacga cgcatacctg aacgcagtcg tcggaacagc 3060
actgatcaag aagtaccoga agctggaaag cgaattctgt tacggagact acaaggtcta 3120
cgagtcgaga aagatgacg caaagagcga acaggaatc ggaaaggcaa cagcaaatga 3180
cttctttcac agcaacatca tgaactttct caagacagaa atcacactgg caaacggaga 3240
aatcagaaag agaccgctga tcgaaacaaa cggagaaaaca ggagaaatcg tctgggacaa 3300
gggaagagac ttcgcaacag ctgaaaagggt cctgagcatg ccgcaaggtca acatcgtcaa 3360
gaagacagaa gtccagacag gaggattcag caaggaaaag atcctgcccga agagaaaacg 3420
gcacaagctg atcgcaagaa agaaggactg ggacccgaag aagtaaggag gattcgacag 3480
cccagacgtc gcatacagcg tctgtgtcgt cgcaaaaggtc gaaaagggaa agagcaagaa 3540
gctgaagagc gtcaaggaa tcgtgggaat cacaatcatg gaaagaagca gcttcgaaaa 3600
gaacccgatg gacttctctg aagcaaaagg atacaaggaa gtcaagaagg acctgatcat 3660
caagctgccc aagtacaggc gtgtcgaaat ggaaaacgga agaagagaaa tgctggcaag 3720
cgcaggagaa ctgcagaaag gaaacgaact ggcactgccc agcaagtacg tcaacttctc 3780
gtacctggca agccactacg aaaagctgaa gggaaagccc gaagacaaag aacagaagca 3840
gctgttctgc gaacagcaca agcactacct ggacgaaatc atcgaaacaga tcagcgaatt 3900
cagcaagaga gtcatcctgg cagacgcaaa cctggcaag gtctgtgagc catacaacaa 3960
gcacagagac aagccgatga gagaacaggg agaaaacatc atccacctgt tcacactgac 4020
aaacctggga gcacggcgag cattcaagta cttcgacaca acaatcgaca gaaagagata 4080
cacaagcaca aggaaggtcc tggacgcaac actgatccac cagagcatca caggactgta 4140
cgaacaagaa atcgacctga gccagctggg aggagacgga ggaggaagcc cgaagaagaa 4200
gagaaaggtc tagctagcca aagcatctca gctaccatg agaatagag 4260
aaagaaaaatg aagatcaata gcttattcat ctctttttct ttttctgttg tgtaaagcca 4320
acaccctgtc taaaaaacat aaatttcttt aatcattttg cctcttttct ctgtgtctca 4380
attaataaaa aatggaaaag accaaaaaaa aaaaaataaa aaaaaaataa aaaaaaaa 4440
acaaaaaaa aaaaaaaa aaaaaaacaa aaaaaaaa gaaaaaaa aaacaaaa 4500
aaaaataaa aaaaaaaa 4518

```

```

SEQ ID NO: 29      moltype = DNA   length = 4518
FEATURE           Location/Qualifiers
misc_feature       1..4518
                  note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 11
source            1..4518
                  mol_type = other DNA
                  organism = synthetic construct

```

```

SEQUENCE: 29
tcccgcagtc ggcgtccagc ggctctgctt gtctgtgtgt gtgtcgttgc aggccttatt 60
cggatccgcc accatggaca agaagtacag catcggactg gacatcgga ccaacagcgt 120
cggatgggca gtcacacagc agcaatacaa ggtcccagc aagaagtcca aggtcctggg 180
aaacacagac agacacagca tcaagaagaa cctgatcgga gcaactgtgt tcgacagcgg 240

```


agaaacagca	gaagcaacaa	gactgaagag	aacagcaaga	agaagataca	caagaagaaa	300
gaacacgaat	tgctactcgc	aggaatatct	cagcaacgaa	atggcgaag	tcgcagacag	360
ctctctccac	agctgggaag	aaagcttctc	ggtcgaagaa	gacaagaagc	acgaagacaga	420
cccgatcttc	ggaacacttc	tcgcaggaag	cgcataccac	gaagaagtacc	cgacaatcta	480
ccactctgaga	aagaagactgg	tcgcagcacac	agacaaagca	gacctgagac	tgactctacct	540
ggcacttgcca	cacatgatcta	agtttcagagg	acacttctct	atcgaaggag	acctgaacc	600
ggcaacacagc	gacgtcgaca	agctgtttact	ccagctggctc	cagacataca	accagctgtt	660
cgaagaaaaa	ccgatcaacy	caagcggagt	cgacgcgaag	gcaatcctga	gcgcgaagct	720
gactgaagagc	agaagactgg	aaaactctgat	cgacagactg	ccggggagaaa	agaagaacgg	780
agctgttcgga	aaactctgat	cactgagcct	gggactgaca	ccgaacttca	agagcaactt	840
cgactctggca	gaagcagcga	agctgcagct	gagcaaggac	acatcacgag	acgcactgga	900
caacctcgtg	gcacagatcg	gagaccagta	cgacagctct	ttctgtcgag	caaaagactc	960
gagcgacgca	atctctgtga	gcgacatcct	gagagctcaac	acagaaaatc	caaaggcacc	1020
gctgacatgca	agcatgatca	agagatcaga	gcacaccacc	caggacatgca	cactgctgaa	1080
ggcactggtc	agacacagc	tcgcggaaaa	gtacaaggaa	atcttctctg	accagacaga	1140
gaacgggatac	gcaggatata	tcgcaggagg	agcaaggccag	gaagaattct	acaagttcat	1200
caacccgctac	ctggaaaaag	tgagcggaac	aagaagactc	ctgtgcgaag	tgaaacagag	1260
agactctgctg	agaaagcaga	gaactctcga	caagcgaagc	atccccgac	agatccacct	1320
gggagaactg	cacgcaatcc	tgagaagaca	ggaagacttc	taccctgttc	tgaaggacaa	1380
caagaaaaaa	atcgaaaaag	ttctgatctc	cgaaatcccg	tactacgtcg	gaccgtggcg	1440
agagaggaaa	agcagatctg	ctgagctgac	aagaagaagc	gaactaaaac	tcacacctgt	1500
gaacttcgaa	gaagtctgtc	acaaggggag	aagcgcacag	agcttcacgt	aaagaatgac	1560
aaactctcgac	agaactacgc	cgacacgaaa	ggtctgtccg	atgcacagcc	tgctgtcaga	1620
atacttcaca	gtctacaagc	aactcgaaaa	ggtcaagtac	gtccagaaag	gaatgaaaaa	1680
gccggcatct	ctgagcggag	aaacagaagaa	ggcaatcgtc	gacctgtgtg	tcagacaaaa	1740
cgaaaaggtc	acagtcaagg	agctgaagga	agactacttc	aagaagatcg	aatgctcga	1800
cagcgtcgaa	atcagcggag	tcgtacagag	atctcaacgc	agctcgggaa	cataccacga	1860
cctgctgaag	atcatcaagg	acaaggactt	cctggacaa	gaagaaaacg	aagacatcct	1920
ggaagcatct	gtctctgacac	tgacactgtt	cggaagacga	gaaatgatcg	agaaaagact	1980
gaagacatca	gcacactcgt	tcgcagcaca	ggtctgaag	cagctgaaga	gaagaagata	2040
cacaggatgg	ggaagactga	gcagaaaagt	gatcaacgga	atcagagaca	agcagagcgg	2100
aaagacaatct	ctggactctc	tgaaagcgca	cggatctcga	acaagaaact	tcatgcagct	2160
gattccagac	gacagctcga	catctcaagg	agacatccga	aagccacagg	tcgcggcaga	2220
gggagacagc	ctgcacgaac	acatcgaaaa	cctggcagga	agcccgccga	tcagaagggg	2280
aatctctgcag	acagtgcga	ttcgtcgaga	actggtcaga	tgactgggaa	gacacaagcc	2340
ggaaaaactg	gtcatcgaaa	tgggcaagga	aaacagacga	acacagagag	gacagaagaa	2400
cagcagagaa	agaatgaaga	gaatcgaaag	aggaatcaag	gaactgggaa	gccagatcct	2460
gaaggaacac	ccggtcgaaa	acacacagct	cgagaacgaa	aatctgtac	tgtactacct	2520
cgaaacactg	agagacatct	acgtcgacca	ggaactggac	agagcgtcta	tgagcagata	2580
cgagctcgac	cacatctgtc	cgcagagctt	cctgaaggac	gacagcatcg	acaacaaggt	2640
ctcgacaaga	agcgacaaga	acagaggaaa	gagcgacac	gtcccagagc	aagaagctcg	2700
caagaagatg	aagaactact	gctgcaacga	agctgatcga	cagctgatac	cagacagaaa	2760
gttcgacaac	ctgacaaaag	cagagagagg	aggaactgag	gaactggaca	agggcagatt	2820
catcaagaga	cagctgtgtg	aaaaacagaca	gattacaaaag	cacgtcgcac	agatcctgga	2880
cagcagaatg	aaacaaaagt	acgcagcaaaa	cgacacagct	atcagagaaa	taaaaggtcat	2940
cacactgaag	agcaagctgt	tcagcgaact	cagaaaaggac	ttcagttct	acaaggtcag	3000
agaaatcaac	aaactaccac	acgcacagca	cgcataactg	aacgcgagct	tcggaagaca	3060
actgtcatca	aagttaccga	agctgggaag	cgaaatctgt	tcaggagact	acaaggtcta	3120
cgagctcaga	aagatgatcg	caaaagcgca	acaggaaatc	ggaaaggcca	cagcaaaagt	3180
ctcttctctac	agcaaatcata	tgaacttctt	caagacagaa	atcacactgg	caaacgggaa	3240
aatcagaaaa	agaccgtgta	tcgaaaacaa	ccggaagaaa	ggagaaatcg	tcctgggaca	3300
gggaagagagc	ttcgcaaac	tcagaaaggt	cctgagcatg	ccgcaagtca	acatcgtcaa	3360
gaagacagaa	gtccagacag	gaggatttcag	caaggaaaagc	atcctgcgga	agagaacag	3420
cgacaagctg	atcgacagaa	agaaaggtcg	ggacccggaag	aagtcaggag	tgctgcagac	3480
cccgacagtc	gcatacagcg	ttctggtcgt	cgcaaaagtg	gaaaagggaa	agagcaagaa	3540
gtcgaagagc	gtcaaggaac	tgctgggaat	caacaatcat	gaaaagagca	gcttcgaaaa	3600
gaaccctgat	gacttctcgg	aagcaaaaagg	atacaaggaa	gtcagaagaa	acctgatcat	3660
caagctgccg	aagtcacag					

```

SEQ ID NO: 30      multype = DNA  length = 4500
FEATURE
misc_feature       1..4500
                    note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 19
source             1..4500
                    mol type = other DNA

```

-continued

organism = synthetic construct

SEQUENCE: 30

tcccgcagtc	ggcgctccagc	ggctctgctt	gttcgtgtgt	gtgtcgttgc	aggccttatt	60
cggatccgcc	accatggaca	agaagtacag	catcggactg	gacatcggaa	caaacagegt	120
cggatgggca	gtcatcacag	acgaatacaa	ggtcccgagc	aagaagttca	aggctcctggg	180
aaacacagac	agacacagca	tcaagaagaa	cctgatcggg	gcactgtgtg	tcgacagcgg	240
agaaacagca	gaagcaacaa	gactgaagag	aacagcaaga	agaagatata	caagaagaaa	300
gaacagaatc	tgctacctgc	aggaaatctt	cagcaacgaa	atggcaaaag	tcgacgacag	360
cttcttccac	agactggaag	aaagcttcct	ggtcgaaaga	gacaagaagc	acgaaagaca	420
cccgatcttc	ggaacatcgc	tcgacgaagt	cgcataccac	gaaaagtacc	cgacaatcta	480
ccacctgaga	aagaagctgg	tcgacagcac	agacaaggca	gacctgagac	tgatctacct	540
ggcactggca	cacatgatca	agttcagagg	acacttcctg	atcgaaaggag	acctgaaccc	600
ggacaacagc	gacgtcgaca	agctgttcat	ccagctggtc	cagacatata	accagctgtt	660
cgaagaaaaa	ccgaatcaacg	caagcggagt	cgacgcaaa	gcaatcctga	gcgcaagact	720
gagcaagagc	agaagactgg	aaaacctgat	cgcacagctg	ccgggagaaa	agaagaacgg	780
actgttcgga	aaactgatcg	cactgagcct	gggactgaca	ccgaacttca	agagcaactt	840
cgacctggca	gaagacgcaa	agctgcagct	gagcaaggac	acatacagag	acgacctgga	900
caacctgctg	gcacagatcg	gagaccagta	cgcagacctg	ttctcggcag	caaagaacct	960
gagcgagcca	atcctgctga	gcgacatcct	gagagtcaac	acagaaatca	caaaggcacc	1020
gctgagcgca	agcatgatca	agagatacga	cgaacaccac	caggacctga	cactgctgaa	1080
ggcactggtc	agacagcagc	tgccggaaaa	gtacaaggaa	atcttcttcg	accagagcaa	1140
gaacggatag	cagggatata	tcgacggagg	agcaagccag	gaagaattct	acaagttcat	1200
caagccgatac	ctggaaaaaga	tggaacggaac	agaagaactg	ctgggtcaagc	tgaacagaga	1260
agacctgctg	agaagcaga	gaacattcga	caacgggaagc	atcccgacc	agatccacct	1320
gggagaaactg	cacgcaatcc	tgagaagaca	ggaagacttc	taccogtctc	tgaaggacaa	1380
cagagaaaaag	atcgaaaaaga	tcctgacatt	cagaatcccg	tactacgtcg	gacctgtggc	1440
aagagggaaa	agcagattcg	catggatgac	aagaaagagc	gaagaaacaa	tcacaccgtg	1500
gaacttcgaa	gaagtgcgtc	caaggggagc	aagcgcacag	agcttcacgc	aaagaatgac	1560
aaacttcgac	aagaacctgc	cgaacgaaaa	ggtcctgccc	aagcacagcc	tgctgtacga	1620
atacttcaca	gtctacaacg	aactgacaaa	ggtcaagtac	gtcacagaag	gaatgagaaa	1680
gccggcattc	ctgagcggag	aacagaagaa	ggcaatcgct	gacctgctgt	tcaagacaaa	1740
cagaaaggctc	acagtgaagc	agctgaagga	agactacttc	aagaagatcg	aatgcttcga	1800
cagcgtcgaa	atcagcggag	tcaagacag	attcaacgca	agcctgggaa	cataccacga	1860
cctgctgaag	atcatcaaag	acaaggactt	cctggacaac	gaagaaaaacg	aagacatcct	1920
ggaagacatc	gtcctgacac	tgacactgtt	cgaagacaga	gaaatgatcg	aagaaagact	1980
gaagacatag	gcacacctgt	tcgacgacaa	ggtcatgaag	cagctgaaga	gaagaagata	2040
cacaggatgg	ggaagactga	gcagaaagct	gatcaacgga	atcagagaca	agcagagcgg	2100
aaagacaatc	ctggacttcc	tgaaagagcga	cggattcgca	aacagaaact	tcagtcagct	2160
gatccacgac	gacagcctga	catccaagga	agacatccag	aaggcacagg	tcagcggaca	2220
gggagacagc	ctgcacgaac	acatcgcaaa	cctggcagga	agcccgcaaa	tcaagaagggg	2280
aatcctgcag	acagtcaagg	tcgtcgacga	actgggtcaag	gtcatgggaa	gacacaagcc	2340
ggaaaaatc	gtcatcgaaa	tggaagagga	aaaccagaca	acacagaagg	gacagaagaa	2400
cagcagagaa	agaatgaaga	gaatcgaa	aggaatcaag	gaactgggaa	gccagatcct	2460
gaaggaaacac	ccggtcgaaa	acacacagct	gcagaacgaa	aagctgtacc	tgtactacct	2520
gcagaacgga	agagacatgt	acgtcgacca	ggaactggac	atcaacagac	tgagcgacta	2580
cgacgtcgac	cacatcgctc	cgagagctt	cctgaaggac	gacagcatcg	acaacaagggt	2640
cctgacaaga	agcgcagaaga	acagaggaaa	gagcgacaac	gtcccagagc	aagaagtcgt	2700
aaagaagatg	aagaactact	ggagacagct	gctgaacgca	aagctgatca	cacagagaaa	2760
gttcgacaac	ctgacaaaag	cagagagagg	aggactgagc	gaactggaca	aggcaggatt	2820
catcaagaga	cagctggtcg	aaacaagaca	gatcacaaag	cacgtcgac	agatcctgga	2880
cagcagaatg	aacacaaggt	acagcgaaaa	cgacaagctg	atcagagaag	tcaaggctcat	2940
cacactgaag	aagatgacgc	caagaagctt	cagaagggac	ttccagttct	acaaggctcg	3000
agaaatcaac	aactaccacc	acgcacacga	cgcatacctg	aacgcagctg	tcggaacagc	3060
actgatcaag	aagtaccoga	agctggaaag	cgaattcgct	tacggagact	acaaggctta	3120
cgagctcaga	aagatgatcg	caaaagcgca	acaggaaatc	ggaaaggcaa	cagcaaaagta	3180
cttcttctac	agcaacatca	tgaacttctt	caagacagaa	atcacactgg	caaacggaga	3240
aatcagaaaag	agaccgctga	tcgaaacaaa	cggagaaaaa	ggagaaatcg	tctgggacaa	3300
gggaagagac	ttcgcaacag	tcagaaaagg	cctgagcatg	ccgagggtca	acatcgtcaa	3360
gaagacagaa	gtccagacag	gaggattcag	caaggaaaagc	atcctgccga	agagaaaacag	3420
gcacaagctg	atcgcaagaa	agaaggactg	ggacccggaag	aagtaaggag	gattcgacag	3480
cccgcagctc	gcatacagcg	tctgtgctgt	cgcaaaaggtc	gaaaagggaa	agagcaagaa	3540
gctgaagagc	gtcaaggaac	tgctgggaat	cacaatcatg	gaaagaaagca	gcttcgaaaa	3600
gaacccgatc	gacttctctg	aagcaaaagg	atacaaggaa	gtcaagaagg	acctgatcat	3660
caagctgccg	aagtacagcc	gttctgaact	ggaaaaacgga	agaaagagaa	tgctggcaag	3720
cgcaggagaa	ctgcagaagg	gaaacgaact	ggcactgccg	agcaagtacg	tcaacttctc	3780
gtacctggca	agccactacg	aaaagctgaa	gggaagcccg	gaagacaaag	aacagaagca	3840
gctgttcgtc	gaacagcaca	agcactacct	ggacgaaatc	atcgaaacga	tcagcgaatt	3900
cagcaagaga	gtcatcctgg	cagacgcaaa	cctggacaa	gtcctgagcg	catacaacaa	3960
gcacagagac	aagccgatca	gagaacaggc	agaaaaacatc	atccacctgt	tcacactgac	4020
aaacctggga	gcacccggcg	cattcaagta	cttcgacaca	acaatcgaca	gaaagagata	4080
cacaagcaca	aagggaagtc	tggaacgcaac	actgatccac	cagagcatca	caggactgta	4140
cgaacaagaa	atcgacctga	gccagctggg	aggagacgga	ggagggaagc	cgaagaagaa	4200
gagaaaggctc	tagctagcca	tcacatttaa	aagcatctca	gcctaccatg	agaataaagag	4260
aaagaaaaatg	aagatcaata	gcttattcat	ctctttttct	tttctggttg	tgtaaaagcca	4320
acaccctgtc	taaaaaacat	aaattttctt	aatcattttg	cctcttttct	ctgtgcttca	4380
attaataaaa	aattggaaaga	accaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4440
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4500

-continued

FEATURE	Location/Qualifiers
misc_feature	1..4500
	note = Cas9 mRNA with a poly-A tail comprising SEQ ID NO: 2
source	1..4500
	mol_type = other DNA
	organism = synthetic construct

SEQUENCE: 31

tcccgcagtc	ggcgctccagc	ggctctgtgct	gttcgtgtgt	gtgtcgttgc	aggccttatt	60
cggatccgcc	accatggaca	agaagtacag	catcggactg	gacatcggaa	caaacagcgt	120
cggatgggca	gtcatcacag	acgaatacaa	ggccccgagc	aagaagtcca	aggtcctggg	180
aaacacagac	agacacagca	tcagaagaa	cctgatcgga	gcaactgctgt	tcgacagcgg	240
agaaacagca	gaagcaacaa	gactgaagag	aacagcaaga	agaagatata	caagaagaaa	300
gaacagaatc	tgctacctgc	aggaaatctt	cagcaacgaa	atggcaaaag	tcgacgacag	360
cttcttccac	agactggaa	aaagcttcct	ggcgaagaa	gacaagaagc	acgaaagaca	420
cccgatcttc	ggaaacatcg	tcgacgaagt	cgcataccac	gaaaagtacc	cgacaatcta	480
ccacctgaga	aagaagctgg	tcgacagcac	agacaaggca	gacctgagac	tgatctacct	540
ggcactggca	cacatgatca	agttcagagg	acacttcctg	atcgaaggag	acctgaaccc	600
ggacaacagc	gacgtcgaca	agctgttcat	ccagctggtc	cagacatata	accagctggt	660
cgaagaaaac	cgatcaacg	caagcggagt	cgacgcaaa	gcaatcctga	gcgcaagact	720
gagcaagagc	agaagctgg	aaaacctgat	cgcacagctg	ccgggagaaa	agaagaacgg	780
actgttcgga	aacctgatcg	cactgagcct	gggactgaca	ccgaacttca	agagcaactt	840
cgactggca	gaagcgaac	agctgcagct	gagcaaggac	acatacgacg	acgacctgga	900
caacctgctg	gcacagatcg	gagaccagta	cgcagacctg	ttctctggcag	caaagaacct	960
gagcgacgca	atctctgtga	gcgacatcct	gagagtcaac	acagaaatca	caaaggcacc	1020
gctgagcgca	agcatgatca	agagatacga	cgaacaccac	caggacctga	cactgtgtaa	1080
ggcactgtgc	agacagcagc	tgccggaaaa	gtacaaggaa	atcttcttcg	accagagcaa	1140
gaacggatag	gcaggatata	tcgacggagg	agcaagccag	gaagaattct	acaagttcat	1200
caagccgagc	ctggaaaaga	tggaaggaa	agaagaactg	ctggtcaagc	tgaacagaga	1260
agactgtgct	agaaagcaga	gaacattcga	caacggaagc	atcccgaccc	agatccacct	1320
gggagaactg	cacgcaatcc	tgagaagaca	ggaagacttc	taccogtccc	tgaaggacaa	1380
cagagaaaag	atcgaaaaga	ctctgacatt	cagaatcccg	tactacgtcg	gaccgctggc	1440
aagaggaaaac	agcagattcg	catggatgac	aagaaaagagc	gaagaaaaca	tcacaccgtg	1500
gaacttcgaa	gaagtctgtg	acaaggggagc	aagcgacagc	agcttcatcg	aaagaatgac	1560
aaacttcgac	agaacactgc	gaacgaaaa	ggctcctgcc	aagcacagcc	tgctgtacga	1620
atacttcaca	gtctacaacg	aactgacaaa	ggtcaagtac	gtcacagaag	gaatgagaaa	1680
gcccgcatct	ctgagcggag	aacagaagaa	ggcaatcgct	gacctgtgtg	tcaagacaaa	1740
cagaaaaggct	acagtcaaag	agactacttc	aagaagatcg	aatgcttcga	1800	
cagcgtcgaa	atcagcggag	tcgaagacag	attcaacgca	agcctgggaa	cataccacga	1860
cctgtctgaag	atcatcaagg	acaaggactt	cctggacaac	gaagaaaaacg	aagacatcct	1920
ggaagacatc	gtcctgacac	tgacactggt	cgaagacaga	gaaatgatcg	aagaaagact	1980
gaagacatac	gcacacctgt	tcgacgacaa	ggtcatgaag	cagctgaaga	gaagaagata	2040
cacaggatgg	ggaagactga	gcagaagct	gatcaacgga	atcagagaca	agcagagcgg	2100
aaagacaatc	ctggacttcc	tgaagagcga	cggatttcga	aacagaaaact	tcatgcagct	2160
gatccacgac	gacagcctga	cattcaagga	agacatccag	aaggcacagg	tcagcggaca	2220
gggagacagc	ctgcacgaac	acatcgcaaa	cctggcagga	agcccgccaa	tcaagaaggg	2280
aatcctcgag	acagtcaaag	actgtcgaca	actgggtcaag	gtcatgggaa	gacacaagcc	2340
ggaaaacatc	gtcatcgaaa	tggtcaagaga	aaaccagaca	acacagaagg	gacagaagaa	2400
cagcagagaa	agaatgaaga	gaatcgaa	aggaatcaag	gaactgggaa	gccagatcct	2460
gaaggaaacac	ccggtcgaaa	acacacagct	gcagaacgaa	aagctgtacc	tgtactacct	2520
gcagaacgga	agagacatgt	acgtcgacca	ggaactggac	atcaacagac	tgagcgacta	2580
gcagctcgac	cacatcgctc	cgcagagctt	cctgaaggac	gacagcatcg	acaacaaggt	2640
cctgacaaga	agcgaaga	acagaggaaa	gagcgacaac	gtcccagcgg	aagaagtcgt	2700
caagaagatg	aagaactact	ggagacagct	gctgaacgca	aagctgatca	cacagagaaa	2760
gttcgacaac	ctgcacaagg	cagagagagg	aggactgagc	gaactggaca	aggcaggatt	2820
catcaagaga	cagctggtcg	aaacaagaca	gatcacaaag	cacgtcgcac	agatcctgga	2880
cagcagaatg	aacacaaagt	acgacgaaaa	cgacaagctg	atcagagaag	tcaaggtcat	2940
cacactgaag	agcaagctgg	tcagcgactt	cagaaaaggac	ttccagttct	acaaggtcag	3000
agaaatcaac	aactaccacc	acgcacacga	cgcataacctg	aacgcagtcg	tcggaacagc	3060
actgatcaag	aagtacccca	agctggaaa	cgaattctgtc	tacggagact	acaaggtcta	3120
cgacgtcaga	aagatgatcg	caaagagcga	acaggaaaac	ggaaaggcaa	cagcaaaagta	3180
cttctttctac	agcaaacatca	tgaacttctt	caagacagaa	atcacactgg	caaacggaga	3240
aatcagaaag	agaccgctga	tcgaaacaaa	cggagaaaaca	ggagaaatcg	tctgggacaa	3300
gggaagagag	ttcgcaacag	tcagaaaggt	cctgagcatg	ccgaggtcca	acatcgctcaa	3360
gaagacagaa	gtccagacag	gaggatttcag	caaggaaaagc	atcctgcccga	agagaacacag	3420
cgacaagctg	atcgcaagaa	agaaggactg	ggaccccaag	aagtacggag	gatttcgacag	3480
cccgacagtc	gcatacagcg	tcttggtcgt	cgcaaaagtc	gaaaagggaa	agagcaagaa	3540
gctgaagagc	gtcaaggaa	tgctgggaat	cacaatcatg	gaaagaagca	gcttcgaaaa	3600
gaaccgcatc	gacttctctg	aagcaaaagg	atacaaggaa	gtcaagaagg	acctgatcat	3660
caagctgccg	aagtacagcc	tgttcgaact	ggaaaaacgga	agaaagagaa	tgctggcaag	3720
cgcaggagaa	ctgcagaa	gaaacgaact	ggcactgccg	agcaagtacg	tcaacttctct	3780
gtacctggca	agccactacg	aaaagctgaa	gggaagcccg	gaagacaacg	aacagaagca	3840
gctgttcgtc	gaacagcaca	agcactacct	ggacgaaatc	atcgaaacaga	tcagcgaatt	3900
cagcaagaga	gtcatctcgg	cagacgcaaa	cctggacaag	gtcctgagcg	catacaacaa	3960
gcacagagac	aagccgatca	gagaaacaggc	agaaaacatc	atccacctgt	tcacactgac	4020
aaacctggga	gcacggcgag	cattcaagta	cttcgacaca	acaatcgaca	gaaagagata	4080
cacaagcaca	aaggaaagtc	tggaacgcaac	actgatccac	cagagcatca	caggactgta	4140
cgaaacaaga	atcgacactga	gccagctggg	aggagacgga	ggagggaagcc	cgaagaagaa	4200
gagaaaggtc	tagctagcca	tcacatttaa	aagcatctca	gcctaccatg	agaataagag	4260
aaagaaaatg	aagatcaata	gcttattcat	ctctttttct	ttttcgttgg	tgtaaagcca	4320

-continued

```

acaccctgtc taaaaaacat aaatttcttt aatcattttg cctcttttct ctgtgettca 4380
attaataaaa aatggaaaga accaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4500

```

I claim:

1. A DNA comprising nucleotides encoding a poly-adenylated (poly-A) tail located 3' to nucleotides encoding a protein of interest, wherein the poly-A tail comprises:

- (a) a plurality of homopolymer sequences of 8, 9, 10, 11, and/or 12 consecutive adenine (A) nucleotides; and
- (b) an interrupting sequence between each homopolymer sequence, wherein the interrupting sequence comprises:
 - (i) a dinucleotide comprising two consecutive non-adenine nucleotides; or
 - (ii) a trinucleotide that does not include a terminal adenine (A).

2. The DNA of claim 1, wherein the interrupting sequence prevents the loss of one or more adenine nucleotides during DNA replication as compared to the loss that occurs in a DNA comprising a 3' tail of a similar or same length that contains only adenine nucleotides.

3. The DNA of claim 1, wherein the interrupting sequence is positioned to interrupt the consecutive adenine nucleotides so that a poly (A) binding protein can bind to a stretch of consecutive adenine nucleotides.

4. The DNA of claim 1, wherein the poly-A tail comprises twenty-five homopolymer sequences of 11 or 12 consecutive adenine (A) nucleotides.

5. The DNA of claim 1, wherein the poly-A tail comprises at least 50 total adenine nucleotides.

6. The DNA of claim 1, wherein the poly-A tail comprises 40-1000, 40-900, 40-800, 40-700, 40-600, 40-500, 40-400, 40-300, 40-200, or 40-100 total adenine nucleotides.

7. The DNA of claim 1, wherein the poly-A tail comprises 300-310 total adenine nucleotides.

8. The DNA of claim 1, wherein the interrupting sequence is located after every 11 or 12 consecutive adenine nucleotides.

9. The DNA of claim 1, wherein the non-adenine nucleotide is guanine, cytosine, or thymine.

10. The DNA of claim 1, wherein the adenine nucleotides are adenosine monophosphate.

11. The DNA of claim 1, wherein the interrupting sequence comprises a trinucleotide chosen from TGG, CGG, GGT, TAT, CAT, CGT, CTC, GAT, CCT, TGT, CGC, CAC, TGC, TCG, TCT, CCC, GAC, TAG, GTT, CTG, and TTT.

12. The DNA of claim 1, wherein the interrupting sequence comprises a dinucleotide chosen from CG, GC, CC, GG, TT, CT, TC, GT, and TG.

13. The DNA of claim 1, wherein the dinucleotide interrupting sequence is CG.

14. The DNA of claim 1, wherein the interrupting sequence is chosen from TGG, CGG, GGT, TAT, CAT, CGT, CTC, GAT, CCT, TGT, CGC, CAC, TGC, TCG, TCT, CCC, GAC, TAG, GTT, CTG, TTT, and CG.

15. The DNA of claim 1, wherein the poly-A tail comprises a sequence of SEQ ID NO: 18.

16. The DNA of claim 1, wherein the protein is a therapeutic protein.

17. The DNA of claim 16, wherein the protein is a cytokine, chemokine, growth factor, RNA-guided nuclease, class 2 CRISPR-associated Cas endonuclease, chimeric Cas protein, Cas9, or modified Cas9.

18. An mRNA encoded by the DNA of claim 1.

19. An mRNA comprising a poly-adenylated (poly-A) tail located 3' to nucleotides encoding a protein of interest, wherein the poly-A tail comprises:

- (a) a plurality of homopolymer sequences of 11 or 12 consecutive adenine (A) nucleotides; and
- (b) an interrupting sequence between each homopolymer sequence, wherein the interrupting sequence comprises:
 - (i) a dinucleotide comprising two consecutive non-adenine nucleotides; or
 - (ii) a trinucleotide that does not include a terminal adenine (A).

20. A host cell comprising the DNA of claim 1.

21. The DNA of claim 1, wherein the DNA is within a vector.

22. The DNA of claim 21, wherein the interrupting sequence prevents loss of nucleotides encoding the poly-A tail within the vector during growth of the host cell as compared to the loss that occurs in a DNA comprising nucleotides encoding a poly-A tail of a similar or same length that contains only adenine nucleotides.

23. A method of producing mRNA from the DNA vector of claim 21, comprising:

- a. linearizing the vector downstream of the poly-A tail;
- b. denaturing the linearized vector; and
- c. contacting the denaturated DNA with an RNA polymerase in the presence of guanine, cytosine, uracil, and adenine nucleotides.

* * * * *